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Summary
Human adipose  tissue  is  known to  be  an  attractive  and readily  available  source  of 
mesenchymal stem cells (MSCs). In the last fifteen years the isolated adipose-derived stem 
cells  (ASCs)  have  experienced  a  great  scientific  interest  and  have  become  increasingly 
popular for application in regenerative medicine. The aim of this study was to analyse growth 
properties, various marker expression, and differentiation ability of human ASCs that have 
been cultured in the medium supplemented with autologous serum (AS). 
The obtained results showed that ASCs can be easily and effectively propagated in the 
medium containing AS and such culture conditions does not alter their characteristic spindle-
shaped morphology throughout the eight tested passages (P). The aggregation of ASCs into 
four  different  types  of  bodies  was  observed  under  various  stress  conditions.  The  ASC 
assembly into adherent bodies was triggered by slight changes in the growth environment or 
the use of different growth surface, such as uncoated glass. Altered composition of a culture 
medium induced generation of individual floating ASC bodies. Another type of floating cell 
bodies  were  detected  in  early  passages  that  subsequently  formed  compact  and  large 
aggregates  of  interconnected  ASC  bodies.  The  exact  reason  provoking  this  type  of  cell 
clustering is unknown. Furthermore, single floating ASC bodies of both types were capable of 
adhering to the surface and converting back to functional monolayer culture, when transferred 
onto new plastic tissue culture flask.  Few ASCs in the monolayer culture showed alkaline 
phosphatase (AP) activity, thus representing more mature cells. Floating ASC bodies, after 
their transfer to a new flasks, were AP negative, but a large fraction of cells migrating out of 
the ASC bodies after their attachment to the surface exhibited AP activity. These observations 
suggest that spontaneously formed floating ASC bodies may represent more primitive cell 
subpopulation within the individual ASC culture.
The 8-color flow cytometry analysis at cell passages 2, 3, 4, 5, and 8 showed that ASCs 
represent highly homogeneous cell population by expressing typical MSC surface markers 
CD29,  CD44,  CD73,  CD90,  CD105  simultaneously,  but  lacking  the  expression  of  such 
markers  as HLA-DR, CD34, CD14, CD19,  and CD45. Furthermore,  median fluorescence 
intensity of positive cell surface markers increased with each subsequent passage indicating 
the overall accumulation of protein expression. The complementary real-time RT-PCR data on 
positive MSC surface marker genes revealed the increase of gene expression until P4 or P5, 
except for  CD105 where the peak expression was observed at P2.  The investigation of the 
expression of pluripotency markers in ASCs showed that these cells express such pluripotency 
markers as OCT4 isoform A and SOX2, but the presence of NANOG was inconclusive. At the 
same time, the expression of  NANOG pseudogene 8 (NANOGP8) was discovered in ASCs. 
The immunocytochemistry data lead to possibility that in the ASCs of the investigated donor 
the NANOGP8 is not only transcribed, but also translated into protein. 
The ASC differentiation into cells of mesodermal lineage showed that these cells can be 
differentiated into adipocytes, osteocytes, and chondrocytes not only at P3, but also at P6. 
However, their differentiation into cells of endodermal origin or insulin-positive cells was not 
successful. In total, nine various differentiation protocols were employed on ASCs of four 
donors  to  test  their  ability  to  give  rise  to  the  cells  of  endodermal  lineage.  Data  from 
immunocytochemistry or real-time RT-PCR methods showed no solid evidence to suggest the 
expression of insulin  or other  markers characteristic  to  pancreatic  cells  or  cells  from any 
transition state, along the pancreatic differentiation, after ASCs have been subjected to any of 
investigated protocols.
Kopsavilkums
Ir zināms, ka cilvēka taukaudi ir vērtīgs un viegli pieejams mezenhimālo cilmes šūnu 
avots (MCŠ). Pēdējo piecpadsmit gadu laikā no taukaudiem iegūtās cilmes šūnas (TCŠ) ir 
piedzīvojušas ievērojamu zinātnisko interesi, un to popularitāte pielietojumam reģeneratīvajā 
medicīnā ir kļuvusi arvien lielāka. Šī darba mērķis bija analizēt augšanas īpatnības,  dažādu 
marķieru ekspresiju un diferencēšanās spējas cilvēka TCŠ, kas audzētas barotnē ar autologo 
serumu (AS).
Iegūtie rezultāti parādīja, ka TCŠ var viegli un efektīvi pavairot barotnē, kas satur AS, 
un  šādi  audzēšanas  apstākļi  nemaina  tām  raksturīgo  vārpstveida  morfoloģiju  astoņu 
pārbaudīto šūnu pasāžu (P) laikā. Dažādos stresa apstākļos tika novērota TCŠ agregācija četru 
dažādu  veidu  sakopojumos.  TCŠ  apvienošanos  adherentos  sakopojumos  izraisīja  nelielas 
izmaiņas  augšanas  vidē  vai  arī  citas  augšanas  virsmas,  piemēram,  neapstrādāta  stikla, 
izmantošana.  Izmainīts  šūnu  kultivēšanas  barotnes  sastāvs  veicināja  individuālu,  peldošu 
TCŠ  sakopojumu  veidošanos.  Agrās  šūnu  pasāžās  tika  detektēti  cita  veida  peldoši  šūnu 
sakopojumi,  kas  vēlāk  izveidoja  blīvus  un  lielus  savstarpēji  saistītu  TCŠ  sakopojumu 
agregātus. Precīzs iemesls, kas izraisīja šāda veida šūnu apvienošanos, nav zināms. Papildus 
tam,  abu  veidu  atsevišķi  peldošie  TCŠ  sakopojumi  spēja  piestiprināties  pie  virsmas  un 
pārveidoties atpakaļ par funkcionālu monoslāņa kultūru pēc tam, kad tika pārnesti uz jaunu 
plastmasas šūnu kultivēšanas flakonu. Atsevišķas TCŠ monoslāņa kultūrā uzrādīja sārmainās 
fosfatāzes  (SF)  aktivitāti,  tādējādi  reprezentējot  nobriedušākas  šūnas.  Peldošie  TCŠ 
sakopojumi pēc to  pārnešanas uz jaunu flakonu nebija SF pozitīvi, bet liela daļa no šūnām, 
kas migrēja ārā no TCŠ sakopojumiem pēc to piestiprināšanās pie virsmas, demonstrēja SF 
aktivitāti.  Šie  novērojumi  liek  domāt,  ka  spontāni  veidojušies  peldošie  TCŠ  sakopojumi 
varētu reprezentēt primitīvāku šūnu subpopulāciju individuālā TCŠ kultūrā.
Astoņu krāsu plūsmas citometrijas analīze šūnām no 2., 3., 4., 5. un 8. pasāžas parādīja, 
ka TCŠ reprezentē ļoti homogēnu šūnu populāciju, vienlaicīgi ekspresējot MCŠ raksturīgos 
virsmas marķierus CD29, CD44, CD73, CD90, CD105, bet neuzrādot tādu marķieru kā HLA-
DR,  CD34,  CD14,  CD19  un  CD45  ekspresiju.  Turklāt,  šūnu  pozitīvo  virsmas  marķieru 
vidējās  fluorescences  intensitāte  pieauga  ar  katru  nākamo  pasāžu,  norādot  uz  vispārējo 
proteīna ekspresijas  uzkrāšanos.  Dati  par  pozitīvajiem MCŠ virsmas marķieru gēniem, no 
papildus veiktās reālā laika RT-PĶR, atklāja šo gēnu ekspresijas pieaugumu līdz P4 vai P5, 
izņemot CD105 gadījumā, kur augstākais ekspresijas līmenis tika detektēts P2. Pluripotences 
marķieru  ekspresijas  pētījumi  TCŠ  parādīja,  ka  šīs  šūnas  ekspresē  tādus  pluripotences 
marķierus kā  OCT4 izoforma A un  SOX2, bet  NANOG klātbūtne nebija viennozīmīga. Tajā 
pašā laikā, TCŠ tika atklāta NANOG pseidogēna 8 (NANOGP8) ekspresija. Imunocitoķīmijas 
dati norādīja uz iespēju, ka pētītā donora TCŠ notiek ne tikai NANOGP8 transkripcija, bet arī 
tā translācija proteīnā.
TCŠ  diferenciācija  par  mezodermālās  līnijas  šūnām  parādīja,  ka  šīs  šūnas  var  tikt 
diferencētas par adipocītiem, osteocītiem un hondrocītiem ne tikai P3, bet arī P6. Taču to 
diferenciācija  par  endodermālas  izcelsmes  šūnām  vai  insulīna  pozitīvām  šūnām  nebija 
veiksmīga. Kopumā tika izmēģināti deviņi dažādi diferenciācijas protokoli, izmantojot četru 
donoru  TCŠ,  lai  pārbaudītu  to  spēju  pārveidoties  par  endodermālās  līnijas  šūnām. 
Imunocitoķīmijas  un  reālā  laika  RT-PĶR rezultāti  nedeva  pārliecinošus  pierādījumus,  kas 
liktu domāt par insulīna vai citu raksturīgu marķieru, kas atrodami aizkuņģa dziedzera šūnās 
vai šūnās no jebkura aizkuņģa dziedzera diferenciācijas laikā novērojamā pārejas stāvokļa, 
ekspresiju TCŠ pēc tam, kad tās tikušas pakļautas jebkuram no šajā darbā izmēģinātajiem 
protokoliem.
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Appendix
Abbreviations
3D three-dimensional
aa  amino acid
AP  alkaline phosphatase
AS  autologous serum
ASCs adipose-derived stem cells
BAT  brown adipose tissue
bFGF  basic fibroblast growth factor
BM bone marrow
BSA  bovine serum albumin
CD  cluster of differentiation
cDNA complementary deoxyribonucleic acid
C-PEPT  C-peptide
DAPI 4',6-diamidino-2-phenylindole
DAPT  N-[N-(3,5-difluorophenacetyl)-1-alanyl]-S-phenylglycine t-butyl ester
DE  definitive endoderm
DEPC  diethylpyrocarbonate
DMEM  Dulbecco's Modified Eagle Medium
DNA deoxyribonucleic acid
DNase I deoxyribonuclease I
EBs  embryoid bodies
ESCs  embryonic stem cells
FBS  fetal bovine serum
FSCs fetal stem cells
GCG glucagon
GLP-1 glucagon-like peptide-1
GSK3β  glycogen synthase kinase 3 β
GVHD graft-versus-host disease
HCl  hydrochloric acid
HIF-1α hypoxia-inducible factor 1α
HLA human leukocyte antigen
HSCs  haematopoietic stem cells
INS  insulin
iPSCs induced pluripotent stem cells 
ISCT International Society for Cellular Therapy
MHC  major histocompatibility complex
mRNA  messenger ribonucleic acid
MSCs mesenchymal stem cells
NANOGP1, NANOGP2... NANOG pseudogene 1, NANOG pseudogene 2
NGN3 neurogenin 3
OCT4P1, OCT4P2...  OCT4 pseudogene 1, OCT4 pseudogene 2
ORF  open reading frame
P1, P2... cell passage 1, cell passage 2 
PBS  phosphate-buffered saline
PCR  polymerase chain reaction
PI3K phosphatidylinositol 3-kinase
RNA  ribonucleic acid
rpm revolutions per minute
RT room temperature
RT-PCR reverse transcription polymerase chain reaction
SCs  stem cells
SST somatostatin
SVF stromal vascular fraction
T1D  type 1 diabetes
T2D type 2 diabetes
TA cells  transit-amplifying cells
TBS Tris-buffered saline
TGFβ transforming growth factor β
TNAP  tissue-nonspecific alkaline phosphatase
UC  umbilical cord
WAT  white adipose tissue
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Introduction
Stem cells (SCs) are undifferentiated cells that can self-renew and give rise to diverse 
types of cells. Most adult tissues or organs can serve as a source of somatic, i.e., adult SCs, as 
they exist in specialized niches within those organs and play an important role in tissue repair 
and regeneration through our life (Mimeault, Batra 2006). P. Zuk and her colleagues showed 
that mesenchymal stem cells (MSCs) can be obtained not only from adult bone marrow (BM), 
but also from adipose tissue (Zuk et al. 2001). Since then the potential use of adipose-derived 
stem cells (ASCs) has experienced a great increase of scientific interest.
The attraction of MSCs has been furthered by the observations that adult SCs express 
OCT4 and other pluripotency markers, usually detected in embryonic SCs (ESCs) (Tai et al. 
2005, Izadpanah et al. 2006, Ambady et al. 2010). This has led to discussions regarding actual 
potency of somatic SCs. It is tempting to speculate that adult SCs share greater degree of 
similarities with ESCs than anticipated. However, the actual characteristics of routinely tested 
pluripotency  markers  OCT4  and  NANOG  are  highly  confusing.  Overlooking  these 
particularities  can  result  into  misleading  conclusions  regarding  the  expression  of  those 
markers in somatic SCs.
Even though it is generally believed that adult SCs possess lower differentiation ability 
than pluripotent SCs, their potential use in the development of cell-based therapies is growing 
rapidly (Mimeault, Batra 2006). The potential of MSC in treating bone disorders, neurological 
diseases, liver diseases, heart damages, diabetes, graft-versus-host disease, as well as healing 
chronic wounds has been intensely explored (Lindroos et al. 2011, Catacchio et al. 2013). One 
of those diseases - type 1  diabetes - has gained particular interest, since it can be cured by 
replacing destroyed pancreatic β cells, thus restoring insulin secretion. A lot of effort has been 
made to differentiate both ESCs and somatic SCs into insulin-producing cells. This is still 
hampered by problems, such as the lack of efficient standard method for functional insulin-
secreting cell generation, inability to consistently produce clinically significant amounts of 
insulin, and differentiation on a large scale. These are yet to be overcome before SCs can be 
used for the treatment of diabetes (Wong 2011). 
Furthermore,  to ensure the safety of the SCs intended for the clinical use, all possible 
threats must be eliminated. Although the danger of prion diseases and zoonoses from the fetal 
bovine serum (FBS), that is used to supplement most of the cell culture media, is considered 
to be minimal  (Doerr et al. 2003), it has been shown that 108 MSCs grown in the medium 
supplemented with 20% FBS would carry 7-30 mg of FBS proteins.  It  could lead to the 
possible autoimmune reaction against patient's own SCs  (Spees et al.  2004). To avoid this 
risk, the FBS can be substituted with an autologous serum (AS).
The  aim of  this  doctoral  study was  to  determine  characteristics  of  human adipose-
derived stem cells, cultured in the medium containing autologous serum, with respect to their 
growth  properties,  various  marker  expression,  and  differentiation  potential  into  cells  of 
mesodermal, as well as endodermal origin. In order to achieve this goal the following tasks 
were set:
• to obtain human ASCs, propagate them in a medium supplemented with autologous 
serum, and evaluate their growth characteristics;
• to detect the expression of such surface markers as CD14, CD19, CD29, CD34, CD44, 
CD45, CD73, CD90, CD105, and HLA-DR on human ASCs at different passages using 
flow cytometry, real-time RT-PCR, and immunocytochemistry methods;
• to determine the expression of pluripotency markers OCT4, NANOG, and SOX2 in 
human ASCs by means of RT-PCR, sequencing, and immunocytochemistry methods;
• to analyse alkaline phosphatase activity in ASC culture;
• to differentiate human ASCs into adipocytes, osteocytes, and chondrocytes in vitro and 
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assess this differentiation capacity at passages 3 and 6;
• to  test  the ability  of  human ASCs to differentiate  into insulin-producing cells  using 
various differentiation protocols.
Unless  noted  otherwise,  the  author  of  all  the  figures  presented  under  “Results  and 
discussion” and “Appendix” is A. Bogdanova-Jātniece.
Part of the main results described in the doctoral thesis is published in three original 
papers. The list of publications and the author's contributions to each of them are as follows:
Original paper I
Bogdanova A.,  Berzins  U.,  Bruvere R.,  Eivazova G.,  Kozlovska T. Adipose-derived 
stem cells cultured in autologous serum maintain the characteristics of mesenchymal stem 
cells. Proceedings of the Latvian Academy of Sciences, Section B 2010, 64(3/4): 106-113.
Contributions: performed and optimised the immunocytochemistry method and in vitro 
differentiation of ASCs; wrote the manuscript.
Original paper II
Bogdanova  A.,  Berzins  U.,  Nikulshin  S.,  Skrastina  D.,  Ezerta  A.,  Legzdina  D., 
Kozlovska T. Characterization of human adipose-derived stem cells cultured in autologous 
serum after  subsequent  passaging  and  long  term cryopreservation.  Journal  of  Stem Cells 
2014, 9(3): 135-148.
Contributions: participated in the  in vitro differentiation of ASCs and gene expression 
analysis by real-time RT-PCR; collected and analysed the data; prepared the graphical and 
visual information; wrote the manuscript.
Original paper III
Bogdanova-Jatniece A., Berzins U., Kozlovska T. Growth properties and pluripotency 
marker expression of spontaneously formed three-dimensional aggregates of human adipose-
derived stem cells. International Journal of Stem Cells 2014, 7(2): 143-152.
Contributions:  carried  out  the  methods  of  alkaline  phosphatase  detection  and 
immunocytochemistry; collected and analysed the data; wrote the manuscript.
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1. Literature overview
1.1. Stem cells
Stem cells play a major role in the development of multicellular organisms as they can 
create a new life from only one fertilized oocyte and SCs are indispensable during an adult 
lifespan since they can regenerate certain tissues undergoing a natural physiological turnover 
or an injury (Fuchs et al. 2004). SCs are defined as undifferentiated cells that can self-renew 
(generate precise copies of themselves upon division) and differentiate into diverse cell types 
(produce specialized cell types) (Mimeault, Batra 2006). They can be classified according to 
their  origin  (see  Chapter  1.2.),  as  well  as  potency. Potency  of  SCs  is  regarded  as  their  
potential to differentiate into various cell types (Bindu, Srilatha 2011). Three major types are 
commonly  discriminated:  totipotent,  pluripotent,  and multipotent  SCs.  Totipotent  SCs  are 
referred to as cells that can differentiate into embryonic and extra-embryonic cell types giving 
rise to a new and complete organism on their own. The only totipotent cells are a fertilized 
egg and early blastomeres up to the 8 cell stage (Pera, Dottori 2005). Pluripotent SCs can 
differentiate into every cell type of the body, including germ cells. The embryonic stem cells, 
isolated  from the  inner  cell  mass  (ICM) of  a  blastocyst,  are  the  best  known example  of 
pluripotent SCs (Mimeault, Batra 2006). Multipotent SCs can give rise to several types of 
mature cells. One such example is haematopoietic SCs (HSCs) that can differentiate into all 
types of blood cells. Sometimes bipotent (giving rise to two types of differentiated cells) and 
unipotent (producing only one cell type) SCs are also discriminated (Pera, Dottori 2005).
In order to sustain a population of undifferentiated SCs and produce differentiated cells 
as well, SCs employ two cell division strategies: asymmetric and symmetric (Figure 1.1.1.).
Figure  1.1.1. Figure  and  caption  from  Morrison  and  Kimble  2006:  “Stem  cell  division 
strategies.  (A)  Stem  cells  (orange)  must  accomplish  the  dual  task  of  self-renewal  and 
generation  of  differentiated  cells  (green).  (B)  Asymmetric  cell  division:  each  stem  cell 
generates one daughter stem cell and one daughter destined to differentiate. (C) Symmetric 
cell division: each stem cell can divide symmetrically to generate either two daughter stem 
cells or two differentiated cells. (D) Combination of cell divisions: each stem cell can divide 
either symmetrically or asymmetrically. C and D represent population strategies that provide 
dynamic control over the balance between stem cells and differentiated cells.”
Asymmetric  cell  division  is  defined  as  a  process  where  each  stem  cell  divides  to 
produce one daughter cell that differentiates and another daughter stem cell to sustain self-
renewal (Morrison, Kimble 2006). This strategy helps to maintain the population of SCs at a 
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steady level, but it does not allow a dynamic control of SCs in case of injury. Therefore SCs 
also use symmetric  cell  division creating two stem cells  or  two more differentiated  cells 
(Shahriyari,  Komarova  2013).  The  more  differentiated  cells  produced  during  both  cell 
division  strategies  are  termed  transit-amplifying  (TA)  or  intermediate  cells.  The TA cells 
possess high proliferative index and migratory properties.  These cells  can further produce 
other intermediate cell progenitors and more mature cells within tissues or organs of their 
origin or other, more distant tissues (Mimeault, Batra 2006). It has been recently shown that 
TA cells  also play a  regulatory role  by activating quiescent  stem cells,  thus orchestrating 
tissue regeneration (Hsu et al. 2014). It is believed that most SCs can divide by either division 
strategies,  switching  between  the  modes  of  asymmetric  and  symmetric  division,  and  the 
balance between those two is under control of numerous developmental and environmental 
signals  (Morrison,  Kimble  2006)  coming  from  the  surrounding  tissues  and  the  SCs 
themselves (Shahriyari, Komarova 2013). A stem cell niche is also thought to participate in 
the regulation of this balance by precisely orienting the divisions to sustain a correct flow and 
directionality of the cells (Fuchs et al. 2004).
The stem cell  niche  is  described as  a  local  tissue microenvironment  that  hosts  and 
influences the actions or characteristics of SCs (Hsu, Fuchs 2012). The niches are composed 
of the SCs themselves  and surrounding differentiated cell  types that  secrete  and organize 
fertile environment of extracellular matrix and other factors (Fuchs et al. 2004). The functions 
of  SCs  depend  on  cooperation  between  their  intrinsic  genetic  programmes  and  extrinsic 
regulatory signals from the niche (Dzierzak, Enver 2008), as well as feedback mechanisms 
from differentiated progeny (Hsu et  al.  2014).  It  is  thought that  inside the niche SCs are 
usually dormant. There are two possible ways how to activate SCs in the niche. First, SCs are 
slowly, but constantly, dividing and filling up the niche until excess SCs lose a direct contact  
with it. When these cells encounter a new environment outside the niche, they progress to 
differentiate. It seems, that this mechanism is more used during development. Second, SCs 
stay quiescent within the niche until  environmental changes,  e.g.,  from the tissue  injury, 
signal to the niche and SCs become activated in return. This model is believed to function 
more often in adult tissues (Fuchs et al. 2004). However, a great difference in proliferative 
abilities of SCs from different tissues and organs have been observed, and not all somatic 
tissues even contain the SC reserves, and not all cell types can be efficiently regenerated from 
SCs in vivo (Naveiras, Daley 2006). Few of the best-characterised SC niches are hair follicles 
of  mammalian  skin,  endothelial  gut  crypts,  bone  marrow  (BM),  and  mammalian  and 
invertebrate testes (González-Reyes 2003).
The potential  therapeutic  applications of  different  types of  SCs include their  use as 
adjuvant  immunotherapy  for  diverse  cancer  types,  Parkinson's  and  Alzheimer's  diseases, 
muscular degenerative disorders, chronic liver and heart failures, diabetes, as well as skin, 
eye, kidney, and haematopoietic  disorders (Mimeault, Batra 2006). Similarly, SCs could be 
used  to  prevent  graft-versus-host  disease  (GVHD),  correct  inborn  metabolic  errors,  and 
deliver a variety of therapeutic genes into the cells (Tocci, Forte 2003).
1.2. Types of stem cells
According to their origin, three main types of SCs are distinguished: embryonic, fetal, 
and adult, i.e., somatic SCs. All of them possess ability to self-renew and differentiate under 
appropriate conditions in vitro and after transplantation in the host in vivo (Mimeault, Batra 
2006) (Figure 1.2.1.).
Embryonic SCs are derived from the inner cell mass of a blastocyst. Firstly they were 
isolated from mice (Martin 1981) and only later from humans (Thomson et al. 1998). The 
main  characteristics  of  ESCs  are  as  follows:  they  are  obtained  from  a  pluripotent  cell 
population;  they  are  firmly  diploid  and  maintain  normal  karyotype  in  vitro;  they  can  be
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Figure 1.2.1. The source of different types of stem cells. Embryonic stem cells are derived 
from the inner cell mass of a blastocyst and possess the ability to differentiate into every cell 
type of all three germ layers under appropriate conditions. Different tissues from fetuses and 
adults contain somatic stem cells that can differentiate into various cell types from the organ 
from which they originate, but their extent to differentiate into cell types from other lineages 
is  still  being explored.  Figure  created from Mimeault,  Batra  2006 and O'Connor, Crystal 
2006.
propagated  indefinitely  while  preserving a  primitive  embryonic state;  they are capable to 
spontaneously differentiate into all derivatives of three primary germ layers, both in teratomas 
after grafting and in vitro under specific conditions; they can give rise to every cell type of a 
body when introduced into a host blastocyst (Pera et al. 2000). Although human ESCs have a 
great capacity for forming the basis of future therapies, their ability to form teratomas (benign 
tumors composed of different somatic cell types usually representing all three germ layers), 
when injected into immunodeficient mice (Thomson et al. 1998), is a major safety concern in 
their potential use (Goldring et al. 2011). Another obstacle hampering an extensive use of 
ESCs in  clinical  applications  is  ethical  issues.  Since  they  are  obtained  from human  pre-
implantation embryos which are destroyed during the process, it rises the debate regarding 
ontological and moral status of the pre-implantation embryos. This discussion is still ongoing 
and each country has its own political laws regulating the field of ESC research (de Wert, 
Mummery 2003). Nevertheless, the latest clinical study from United States of America (USA) 
shows the long-term safety of human ESC transplants to treat forms of macular degeneration. 
In this study the ESCs were firstly differentiated into retinal pigment epithelial cells and then 
transplanted into patients. No evidence of adverse proliferation, rejection, or serious ocular or 
systemic safety issues related to the transplanted tissue was found after a median follow-up of 
22 months (Schwartz et al. 2015).
During the past decade another type of SCs that in many ways resembles ESCs and is 
called induced pluripotent  stem cells  (iPSCs) has revolutionized the field of SC research. 
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They were discovered in 2006 by showing that simultaneously enforced expression of four 
transcription factors: Oct4, Sox2, Klf4, and c-Myc can generate SCs with similar properties to 
those of ESCs from mouse fibroblasts (Takahashi, Yamanaka 2006). A year later this finding 
was replicated using human somatic cells and above-mentioned factors (Takashi et al. 2007), 
as well as combination of OCT4, SOX2, NANOG, and LIN28 (Yu et al. 2007). This work was 
awarded the Nobel Prize in Physiology or Medicine in 2012 shared by Sir John B. Gurdon 
and Shinya Yamanaka “for the discovery that mature cells can be reprogrammed to become 
pluripotent”  (nobelprize.org).  The  published  observations  suggesting  similarities  between 
ESCs and iPSCs are just as many as those which show their differences (Narsinh et al. 2011, 
Puri, Nagy 2012). It seems that this controversy arises from variations among ESC and iPSC 
clones that are being analysed in every given study. This degree of variation emerges from 
different  technical  variables  and,  in  the  case  of  iPSCs,  stochastic  events  during 
reprogramming (Yamanaka 2012).  Although iPSCs promise availability  of  patient-specific 
pluripotent  SC therapy,  in  vitro disease modeling,  drug development,  and disease-specific 
pharmacological treatment testing without the need of creation of human embryos (Puri, Nagy 
2012), a great scientific effort is still needed to understand the mechanism of reprogramming 
to pluripotency in order to improve the efficiency of the current methodology (at the moment, 
maximum  10%  of  cells  undergo  complete  reprogramming)  and  facilitate  their  medical 
applications (Plath, Lowry 2011). Recently the first clinical study on humans using iPSCs has 
been  launched  in  Japan.  The  patient's  skin  cells  were  used  to  produce  iPSCs  that  were 
afterwards differentiated into retinal pigment epithelium cells. Then a sheet of retinal pigment 
epithelium  cells  was  transplanted  into  an  eye  of  a  woman  to  treat  age-related  macular 
degeneration (Cyranoski 2014).
Fetal  stem cells  (FSCs)  can  be  isolated  from fetal  tissues  obtained  from cadaveric 
fetuses after elective abortion, spontaneous abortion, stillbirth, and ectopic pregnancy (Ishii, 
Eto 2014).  They can be isolated from such fetal  tissues as  liver, bone marrow, pancreas, 
spleen, kidney, and blood (Abdulrazzak et al. 2010), as well as such extra-embryonic tissues 
as  placenta,  amniotic  membrane,  amniotic  fluid,  and  Wharton's  jelly  (Marcus,  Woodbury 
2008). It is generally thought that a differentiation potential of FSCs is somewhere between 
ESCs and adult SCs (Abdulrazzak et al. 2010). Unlike ESCs, FSCs do not form teratomas in  
vivo and have low rejection reactions after transplanting, when obtained from fetuses up to 12 
weeks old (Mimeault, Batra 2006). While only few ethical reservations exist over the use of 
extra-embryonic tissues as a source of FSCs, the exploitation of cadaveric fetal tissues is a 
subject of significant public and political debate (Ishii, Eto 2014). Yet, clinical trials using 
FSCs are  actively  conducted,  mostly  in  USA and United  Kingdom,  and show promising 
results.  However,  full  caution  must  be  taken since  a  brain  tumor  of  non-host  origin  was 
detected in a patient four years after the fetal neural SC therapy. The analysis showed that the 
tumor is derived from at least two donors emerging from the transplanted SCs (Amariglio et 
al.  2009).  FSC transplantation  has  been  used  to  treat  neurological  diseases  (amyotrophic 
lateral sclerosis, cerebral palsy, cerebral atrophy, Huntington's disease, Parkinson's disease), 
central  nervous  system  injuries,  heart  failure,  diabetes,  skin  wounds,  and  osteogenesis  
imperfecta (Ishii, Eto 2014).
An umbilical cord (UC) could also serve as a very attractive source of SCs and its use is 
not limited by ethical issues, as the UC is discarded as biowaste after a childbirth. Not only 
Wharton's jelly within the UC, but also endothelial/subendothelial layer of umbilical vein, UC 
blood, and UC amniotic membrane (cord lining) contain SCs (Lim, Phan 2014). Cord lining 
can be used to obtain mesenchymal cells (Kita et al. 2010) and epithelial cells (Huang et al. 
2011)  that can differentiate into mesenchymal tissues, such as bone, cartilage, muscle, and 
epithelial tissues, such as skin and cornea, respectively. Both types of cord lining SCs can 
resist  rejection  after  transplantation  and  have  been  proved  effective  in  different  clinical 
applications (Lim, Phan 2014). Since 1989 when the first successful UC blood transplantation 
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in a child with Fanconi anemia has been performed (Gluckman et al. 1989), the use of UC 
blood as a source of HSCs has remarkably increased leading to more than 20 000 cord blood 
transplants worldwide (Gluckman 2009). Currently there are at least 635 000 UC blood units 
stored in more than 100 UC blood banks (bmdw.org). The main advantage of UC blood over 
bone marrow or mobilized peripheral blood transplantation is a higher acceptable degree of 
human leukocyte antigen (HLA) mismatch between a donor and a recipient, as UC blood only 
require to be matched at four of six HLA class I and II molecules in order to keep a risk of 
developing severe GVHD at minimum. This benefit is likely caused by the low amount of T 
cells  and  immunologically  naïve  state  of  lymphocytes  in  UC  blood  (Rao  et  al.  2012). 
Additionally, UC blood SC superiorities include the ability to form more colonies in culture, 
higher  cell  cycle  rate,  autocrine  production  of  growth  factors,  and  longer  telomeres 
(Gluckman et al. 1997). Furthermore, few studies have reported capacity of UC blood SCs 
under special  culture conditions  in vitro and  in vivo to differentiate not only into cells of 
haematopoietic  lineage,  but  also  into  dendritic  cells,  neural  cell  progenitors,  hepatocytes, 
pancreatic cells, and endothelium (Mimeault, Batra 2006), but these controversial findings are 
not widely accepted (Gupta 2012). However, the biggest obstacle to the UC blood transplants 
is relatively small number of haematopoietic progenitor cells and haematopoietic SCs in UC 
blood leading  to  delayed engraftment,  increased  transplant  related  mortality, and reduced 
survival (Rocha, Gluckman 2006). This is the reason why UC blood transplants have been 
mostly performed in children, as recipients with weight higher than 50 kg need UC blood 
from more than one donor to ensure prompt engraftment (Rao et al. 2012).
Adult SCs are isolated from mature tissues where they exist in specialized niches within 
the greater part  of adult  tissues or organs and play an important role in tissue repair  and 
regeneration (Mimeault, Batra 2006). They show lower differentiation ability when compared 
to ESCs or FSCs and are usually referred to by their tissue origin, e.g., adipose-derived SCs,  
dental  pulp  SCs  (Bindu,  Srilatha  2011).  Although  most  somatic  SCs  are  believed  to  be 
lineage-restricted, compiling evidence shows their capacity to give rise to another cell types 
of unrelated tissue (Catacchio et al. 2013). The examples of adult SCs of endodermal origin 
include lung epithelial SCs (Volckaert,  De Langhe 2014), gastrointestinal tract SCs (Mills, 
Shivdasani  2011),  pancreatic  SCs (Zulewski  et  al.  2001),  and liver  SCs (Matthews,  Yeoh 
2005). Bone marrow SCs (Pittenger et al. 1999), cardiac SCs (Beltrami et al. 2003), adipose 
tissue SCs (Zuk et al. 2001), and muscle SCs (Shi, Garry 2006) are of mesodermal origin. 
And such somatic SCs as neural SCs (Watts et  al.  2005), epidermal and hair follicle SCs 
(Blanpain, Fuchs 2006), corneal (Takács et al. 2009) and retinal SCs (Tropepe et al. 2000) are 
of ectodermal origin.
1.3. Mesenchymal stem cells
In 1976 Friedenstein and colleagues discovered that BM contains fibroblast-like cells 
that  adhere  to  plastic  culture  plates  and  form discrete  colonies  initiated  by  a  single  cell 
(colony-forming  unit  fibroblast)  (Friedenstein  et  al.  1976 after  Chamberlain  et  al.  2007). 
Following work revealed that progeny of these cells can give rise to bone, cartilage, adipose 
tissue,  and fibrous tissue after transplantation (Friedenstein et  al.  1990 after  Bianco et  al. 
2008),  but  a  worldwide  interest  was  risen  only  later  when  similar  work  was  published 
describing  isolation,  expansion  and  tri-lineage  differentiation  potential  of  human  BM 
mesenchymal  stem  cells  (MSCs)  (Pittenger  et  al.  1999).  Since  then,  cells  exhibiting 
characteristics of MSCs have been isolated not only from BM, but also from many other adult 
tissues,  e.g.,  adipose  tissue,  muscle,  bone,  cartilage,  tendon,  skin,  dental  tissues,  salivary 
gland, foreskin, synovial fluid, synovial membrane, endometrium, amniotic fluid, amniotic 
membrane, menstrual blood, peripheral blood, and from different fetal tissues, such as spleen, 
lung, pancreas, kidneys, as well as from UC blood, placenta, UC, Wharton's jelly (Taléns-
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Visconti et al. 2006, Lin et al. 2007, Secco et al. 2008, Ullah et al. 2015). 
Initially these cells were termed osteogenic SCs or bone marrow stromal SCs (Bianco et 
al. 2008), but a term “mesenchymal stem cells” was introduced in 1991 to name hypothetical 
multipotent  and self-renewing precursor  cells  derived from embryonic MSCs which  were 
involved in maintaining homeostasis of skeletal tissues and repairing them during adulthood 
(Caplan 1991). The cells described by Friedenstein were promptly referred to as a prototype 
of MSCs, even though there were no experimental data regarding these cells that could strictly 
meet all the characteristics conveyed in the original term of MSCs. The analysis of biological 
properties of these multipotent progenitors has been done on  in vitro expanded populations 
that  may  not  reveal  actual  in  vivo situation,  and  the  existence  of  a  common  post-natal 
mesenchymal progenitor has been an issue of debate, since bone and muscle have different 
progenitors during embryogenesis and the ability of these progenitor cells to differentiate into 
muscle  cells  in  vivo has  not  yet  been convincingly  demonstrated  (Nombela-Arrieta  et  al. 
2011).  Nonetheless,  the term  “mesenchymal  stem cells” has  gained huge global  usage  to 
describe stromal precursors with the ability to differentiate  into cell  types of mesodermal 
origin (Bianco et al. 2008). Although  the International Society for Cellular Therapy (ISCT) 
has recommended the use of the name “multipotent mesenchymal stromal cells” to refer to in  
vitro cultured fibroblast-like plastic-adherent cells, regardless of the tissue source from which 
they have been isolated, and the term “mesenchymal stem cells” should be used to designate 
cells that meet specified stem cell criteria (long-term self-renewing cells that can differentiate 
into multiple cell types in vivo) (Horwitz et al. 2005), investigators all over the world continue 
to use historical term “mesenchymal stem cells” or alternatively - “mesenchymal stem/stromal 
cells” (Phinney, Prockop 2007, Keating 2012).
To define MSCs, the ISCT has proposed following minimal criteria: firstly, these cells 
must be plastic-adherent when maintained in standard culture conditions, secondly, they must 
express such surface markers as CD105, CD73, and CD90, but must lack the expression of 
CD45, CD34, CD14 or CD11b, CD19 or CD79α, and HLA-DR markers, thirdly, they must be 
able to differentiate into adipocytes, osteoblasts, and chondroblasts  in vitro (Dominici et al. 
2006). The main issue regarding identification of MSCs according to their surface markers is 
a lack of one unique MSC marker that would allow to distinguish these cells. Therefore,  a 
panel of positive and negative markers must be verified to identify MSCs. Additional positive 
markers: CD13, CD29, CD44, CD71, CD106, CD166, CD271, CD146, ICAM-1, Stro-1, and 
negative markers: CD31, CD117, CD80, CD86, CD40, CD18, CD56 have been reported for 
MSCs (Chamberlain et al. 2007, Kolf et al. 2007, Lv et al. 2014), but, unfortunately, MSCs 
obtained from various tissues show dissimilar expression pattern of above-mentioned markers 
(Chamberlain et al. 2007). Moreover, isolation procedure, culture conditions, cell confluence, 
certain growth factors, as well as disease conditions of a donor may influence phenotype of 
MSCs (Lv et  al.  2014).  Although MSCs are  defined by their  in  vitro differentiation  into 
adipocytes, osteoblasts, and chondroblasts, the experimental evidence shows their ability to 
differentiate into other cell types as well, e.g., myocytes (Gang et al. 2004), cardiomyocytes 
(Xu  et  al.  2004),  neurons  (Woodbury  et  al.  2000),  endothelial  cells  (Cao  et  al.  2005), 
hepatocytes (Lee et al. 2004), and pancreatic cells (Gao et al. 2008).
Historically BM has been regarded as the main source of MSCs for experimental and 
clinical use. And, undoubtedly, most of the knowledge we have about MSCs has come from 
extensive studies of BM (Secco et al. 2008). However, the number, differentiation potential, 
and maximal life span of BM MSCs decrease significantly with age (D'Ippolito et al. 1999, 
Nishida et al. 1999, Mueller, Glowacki 2001). Moreover, the harvest of BM itself is highly 
invasive procedure that can cause infection, bleeding, and chronic pain (Secco et al. 2008) and 
frequently requires general or spinal anaesthesia (Zuk et al. 2001). It has been estimated that 
only 0,001 to 0,01% of all nucleated cells of BM are MSCs (Pittenger et al. 1999), but it has 
not hampered their broad applications. 
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The  potential  clinical  use  of  MSCs  includes  treating  bone  disorders  (osteogenesis  
imperfecta,  bone  healing,  bone  defect  repairing),  liver  diseases,  neurological  diseases 
(traumatic brain injuries, spinal cord injuries, Parkinson's disease, multiple sclerosis), heart 
damages, as well as healing chronic wounds. Currently, the only type of SCs being routinely 
used in clinics is HSCs (Catacchio et al.  2013). They are able to give rise to all types of 
functional blood cells (Mimeault, Batra 2006) and are mostly employed for the treatment of 
haematological malignancies (Catacchio et al. 2013). At the moment there are 526 registered 
clinical trials throughout the world in different clinical phases evaluating the potential of MSC 
based therapy (Figure 1.3.1.). The biggest part of these trials are Phase I/II studies and only 
few of  them are  in  Phase  III/IV (clinicaltrials.gov).  A considerable  part  of  these  trials  is 
devoted to treat cardiovascular disorders followed by autoimmune disease, osteoarthritis, liver 
disorders and GVHD (Figure 1.3.2.) (Ullah et al. 2015).
Figure 1.3.1. Registered clinical trials of mesenchymal stem cell-based therapy worldwide. 
Actual as of October 2015. Figure from clinicaltrials.gov.
Figure 1.3.2. Number of various diseases registered for clinical trials of mesenchymal stem 
cell-based therapy. Figure from Ullah et al. 2015.
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In the setting of allogeneic transplantation and prevention or treatment of GVHD MSCs 
may  have  a  significant  therapeutic  potential since  they  do  not  induce  considerable 
alloreactivity. It is known that MSCs express low levels of major histocompatibility complex 
(MHC) class I antigens and do not express MHC class II and co-stimulatory molecules, e.g., 
CD40,  CD80,  CD86.  Therefore,  MSCs are  protected  from alloreactive  natural  killer  cell-
mediated  lysis  (Sensebé et  al.  2010).  Furthermore,  MSC  populations  display 
immunomodulatory  capacities  and their  inhibitory  effect  on  T cell  proliferation  has  been 
studied extensively (Bartholomew et al. 2002, Di Nicola et al. 2002, Le Blanc et al. 2003, Tse 
et  al.  2003).  Although  little  is  known  about  the  molecular  mechanisms  underlying  this 
phenomena, there is evidence of various factors such as transforming growth factor-β and 
hepatocyte growth factor (Di Nicola et al. 2002), prostaglandin E2 (Aggarwal, Pittenger 2005, 
Cui  et  al.  2007),  indoleamine  2,3-deoxygenase  (Meisel  et  al.  2004),  heme  oxygenase-1 
(Chabannes  et  al.  2007),  nitric  oxide  (Sato  et  al.  2007),  interleukins  -  6  and 10,  human 
leukocyte antigen-G5 and matrix metalloproteinases (for reviews, see Abumaree et al. 2012, 
De Miguel  et  al.  2012)  produced by MSCs that  could  mediate  the suppression of  T cell 
proliferation. In addition, MSCs express HLA-G antigen (non-classical MHC class I antigen 
with  strong  immune-inhibitory  properties)  that  could  contribute  to  inhibition  of  immune 
response (Nasef et al. 2007). It has been shown that MSCs can also inhibit the proliferation of 
T  cells  by  blocking  cyclin  D2  expression  and  up-regulating  p27Kip1  expression,  thus 
arresting cells in the G1 phase of the cell cycle (Glennie et al. 2005). Other approaches that 
may be responsible for the ability of MSCs to modulate immune response is induction of 
CD8+ regulatory T cells (Djouad et al. 2003) or regulatory antigen-presenting cells (Beyth et 
al.  2005),  as  well  as  interference  with  dendritic  cells  (Aggarwal,  Pittenger  2005)  and 
inhibition of the formation of cytotoxic T cells (Rasmusson et al. 2003). In addition, human 
MSCs can also  inhibit  proliferation,  differentiation,  and chemotaxis  of  B cells  (Corcione 
2006).
1.4. Adipose-derived stem cells
Adipose tissue, like BM, is derived from mesoderm and serves as an excellent source of 
MSCs named adipose-derived stem/stromal cells. Other terms attributed to these cells can also 
be found in a scientific literature: adipose-derived adult stem (ADAS) cells, adipose-derived 
adult stromal cells (ADSCs), adipose stromal cells (ASCs), adipose mesenchymal stem cells 
(AdMSCs), processed lipoaspirate (PLA) cells. In order to minimize a confusion between all 
the existing names, the International Fat Applied Technology Society has suggested to use the 
term “adipose-derived stem cells” (ASCs) to identify the plastic-adherent, multipotent cell 
population isolated from adipose tissue (Gimble et al. 2007). 
There are mainly two major types of adipose tissue – brown and white – that differ both 
morphologically  and functionally  (Tsuji  et  al.  2014).  The brown adipose  tissue  (BAT) in 
humans  is  present  and  active  in  infants  where  it  generates  heat  to  sustain  optimal  body 
temperature without shivering (Nedergaard et al. 2007). This thermogenesis is sustained by 
uncoupling protein 1 (so named because it uncouples respiration from ATP synthesis leading 
to  heat  production,  according  to  Enerbäck  2009),  expressed  in  the  inner  membrane  of 
mitochondria,  and regulated by adrenergic  signalling through sympathetic  nervous system 
(Tsuji et al. 2014). Brown adipocytes have many small lipid vacuoles and large amount of 
mitochondria (Enerbäck 2009). This abundance of mitochondria together with a very high 
vascularization give the BAT its brown colour (Tsuji et al. 2014). It was generally accepted 
that BAT disappears within the first years of life and is absent in adults. However, since the 
year  2002 (although some evidence has  been detected much earlier, but  has been mostly 
ignored) this dogma has been challenged. BAT has been found in adults (Figure 1.4.1.) and is 
shown to be active. Still, not all adults have BAT, and estimated prevalence is in the range of 
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some  dozens  of  percent  (Nedergaard  et  al.  2007).  Even  though  somatic  SCs  have  been 
isolated from BAT (Silva et al. 2014), the low amount of BAT within a body does not make it 
a suitable source of ASCs.
Figure 1.4.1. Figure and caption from Gesta et al. 2007: “Depots of white adipose tissue in 
humans are found in areas all over the body, with subcutaneous and intra-abdominal depots 
representing the main compartments for fat storage. Brown adipose tissue is abundant at birth 
and still present in adulthood but to a lesser extent.”
The white adipose tissue (WAT), on the other hand, is found throughout a body (Figure 
1.4.1.) (Gesta et al. 2007). It serves to store excess energy in the form of triglycerides and 
provides insulation. The colour of WAT is yellow or ivory (Tsuji et al. 2014). In contrast to 
brown adipocytes,  the white  adipocytes have few mitochondria  and a  single lipid droplet 
(Enerbäck  2009).  ASCs  are  routinely  isolated  from  stromal  vascular  fraction  (SVF)  of 
subcutaneous and intra-abdominal WAT and growing numbers of obese people around the 
world  make  WAT abundant  and  readily  accessible  source  of  ASCs.  It  is  estimated  that 
approximately 400 000 liposuction surgeries are performed every year in the USA alone and 
each of these procedures produce from 100 ml up to 3 l of lipoaspirate tissue that is regarded 
as medical waste (Gimble et al. 2007). Furthermore, 1 ml of adipose tissue holds 500-fold 
greater amount of stem cells than the same amount of BM (Fraser et al. 2006), but in contrast 
to BM MSCs, ASCs are easier to obtain and display lower donor site morbidity (Kakudo et al. 
2007). One argument against the use of WAT could be its low amount in some patients, but 
even very small depots of fat might be sufficient for the isolation of ASCs due to their high 
frequency (Kern et al. 2006). Recent evidence shows that 1 g of WAT contains approximately 
1-2x106 SVF cells from which 10% are ASCs (Pham 2014). It is known that SVF of adipose 
tissue contains a heterogeneous stromal cell population that includes not only ASCs, but also 
cells  of  haematopoietic  lineage,  e.g.,  granulocytes,  monocytes,  lymphocytes,  erythrocytes, 
mast cells, as well as endothelial cells, fibroblasts, pericytes, and pre-adipocytes (Zuk et al. 
2001, Bourin et al. 2013). Nevertheless, subsequent passaging of the initial SVF selects for a 
relatively homogeneous ASC population (Zuk et al. 2001).
Like  MSCs  from  BM  and  other  sources,  ASCs  are  spindle-shaped  cells  with 
fibroblastoid morphology and normal karyotype that can be easily propagated in vitro (Zuk et 
al.  2001).  It  has been shown that ASCs bear high proliferative capacity  and can undergo 
multilineage  in  vitro  differentiation into adipocytes,  osteoblasts,  chondroblasts  (Zuk et  al. 
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2001, Kern et al. 2006), smooth muscle cells (Jeon et al. 2006), skeletal muscle cells (Zuk et 
al. 2002, Lee, Kemp 2006), cardiomyocytes (Planat-Bénard et al. 2004), neurons (Jang et al. 
2010),  endothelial  cells  (Cao et  al.  2005),  hepatocytes  (Taléns-Visconti  et  al.  2006),  and 
pancreatic cells (Chandra et al. 2011). Furthermore, their multi-lineage potential is not altered 
by freezing/thawing procedure (Rodriguez et al. 2005). ASCs are positive or negative for most 
of the cell surface markers defined for all types of MSCs, but recently the ISCT together with 
the International Federation for Adipose Therapeutics and Science have established minimal 
panel of surface markers to define ASCs. According to their statement, ASCs must be positive 
for such markers as CD13, CD29, CD44, CD73, CD90, CD105, (CD34 can also be present at 
variable levels and generally at  early phase of culture),  and negative for such markers as 
CD31, CD45, and CD235a. Additional positive: CD10, CD26, CD36, CD49d, CD49e, and 
negative: CD3, CD11b, CD49f, CD106, PODXL markers can be used for the characterization 
of ASCs (Bourin et  al.  2013).  This list  can be extended with CD9, CD54, CD55, CD59, 
CD146, CD166 as positive and CD14, CD19, CD79α, CD80, CD117, CD133, CD144, c-kit 
as negative markers (Schäffler and Büchler 2007). In contrast to BM MSCs, ASCs express 
CD49d and CD36, but lack the expression of CD49f, CD104, and CD106 (Bourin et al. 2013,  
Ong,  Sugii  2013).  However,  the  expression  of  above-mentioned  markers  is  not  always 
consistent across scientific reports. This may be due to donor heterogeneity, methods and 
quality of ASC isolation, antibody sources, sensitivity of detection methods, and cell culture 
conditions (media composition, oxygen supply, cell confluency, passage number) (Ong, Sugii 
2013). Additionally, there are differences in marker expression between cells of whole SVF 
and cultured ASCs that need to be taken into consideration (Cawthorn et al. 2012).
ASCs, similarly to BM MSCs, are immunoprivileged and suppress the proliferation of 
lymphocytes  in a dose dependent manner (Yañez et al. 2006,  Cui et al. 2007) making them 
effective donor cells in allogeneic setting, as well as reducing GVHD (Fraser et al. 2006). 
Likewise BM MSCs, ASCs also secrete various soluble factors, such as angiogenic factors 
(hepatocyte growth factor, vascular endothelial growth factor), haematopoietic factors (colony 
stimulating factors, interleukins-7, -12), proinflammatory factors (interleukins-1α, -6, -8, -11, 
tumor necrosis factor α), and anti-apoptotic factors (insulin-like growth factor 1) that promote 
tissue regeneration at the site of injury (Kilroy et al. 2007, Salgado et al. 2010). Additionally, 
ASCs can be effectively reprogrammed into iPSCs without a requirement for feeder cells 
(Sugii  et  al.  2010).  All  these characteristics make ASCs suitable  for a broad spectrum of 
applications  (Figure 1.4.2.)  and there are  currently 72 registered clinical trials  around the
Figure  1.4.2. Figure  and  caption  from  Ong  and  Sugii  2013:  “Biological  properties  and 
therapeutic potentials of ASCs. The right side summarizes secretome of the ASCs, and the left 
side summarizes multi-lineage differentiation capacity and immunobiology of the ASCs.”
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world exploring their potential (clinicaltrials.gov). Their efficacy in treating such conditions 
as  type  I  and  type  II  diabetes,  liver  cirrhosis,  fistulas,  GVHD,  cardiovascular  diseases, 
rheumatoid  arthritis,  Crohn’s  disease,  ulcerous  colitis,  limb  ischemia,  multiple  sclerosis, 
amyotrophic  lateral  sclerosis,  bone  repair,  soft  tissue  augmentation,  and  lipodystrophy  is 
being examined (Lindroos et al. 2011).
1.5. What is the difference between MSCs, fibroblasts, and pericytes?
In the past few years there has been a lot of discussion about a true identity of MSCs 
and  their  relation  to  fibroblasts  and  pericytes.  Fibroblasts  are  widely  considered  to  be 
terminally differentiated mesenchymal cells (Cappellesso-Fleury et al. 2010) that produce and 
remodel extracellular matrix and play a critical role in tissue development, differentiation, 
maintenance, and repair (Flavell et al. 2008). Since they are the most abundant cells of stroma 
(Flavell et al. 2008), they are considered to be the most frequent contaminating cell phenotype 
present in many cell cultures and, naturally, MSCs, that are localized in the stroma of tissue or 
organs, are no exception (Blasi et al. 2011). However, it is believed that successive passaging 
of the obtained cells serves as a purification of MSC culture (Horwitz et al. 2006).
Nevertheless, some researchers question the general assumption that MSCs are unique 
type of cells distinct from fibroblasts (Haniffa et al. 2009, Hematti 2012). Similarly to MSCs, 
fibroblasts exhibit spindle-shaped morphology, display comparable proliferation capability in  
vitro (Alt et al. 2011), and adhere to plastic (Flavell et al. 2008). Both MSCs and fibroblasts 
are positive for CD13, CD29, CD44, CD49e, CD71, CD73, CD90, CD105, CD166, STRO-1, 
and HLA class I markers and negative for CD14, CD31, CD34, CD45, CD80, CD86, CD133, 
glycophorin A, cadherin 5, and HLA class II markers (Jones et al. 2007, Covas et al. 2008, 
Lorenz et al. 2008, Alt et al. 2011, Blasi et al. 2011). 
It is broadly accepted that a multipotent differentiation potential of the cells is one of the 
main criteria to define the identity of MSCs (Dominici et al. 2006). Therefore, it is no wonder 
that a true identity of MSCs is challenged when ability of fibroblasts to convert into other 
types of cells has been also shown. The dermal fibroblasts have been able to differentiate into 
adipocytes, osteocytes, chondrocytes (Lorenz et al. 2008,  Alt et al. 2011, Blasi et al. 2011, 
Jääger et al. 2012), cardiomyocyte-like cells (Blasi et al. 2011), and even hepatocyte-like cells 
(Lysy et al. 2007). Human foreskin dermal fibroblasts gave rise to adipocytes, osteocytes and 
chondrocytes (Chen et al. 2007) and fibroblasts isolated from synovial membrane and human 
uterine  tissues  also  could  differentiate  into  adipocytes  and osteocytes  (Jones  et  al.  2007, 
Strakova et al. 2008). It has been discovered that ASCs and fibroblasts employ similar early 
mechanisms of differentiation into adipocytes and osteocytes, but exhibit distinct mechanisms 
of  chondrogenic  differentiation  (Jääger  et  al.  2012).  Contrary  results  have  also  been 
published, showing that human foreskin-derived dermal fibroblasts (Wagner et al. 2005) and 
dermal fibroblasts do not have differentiation potential (Brendel et al. 2005, Jones et al. 2007, 
Cappellesso-Fleury et  al.  2010).  However, it  has  been lately supposed that  such reported 
evidence  indicates  that  fibroblast  preparations  contain  a  heterogeneous  cell  population, 
including MSCs with various levels of differentiation potential and fibroblasts with no ability 
to convert into other cell types (Alt et al. 2011).
The  observation  that  MSC  populations  display  immunosuppressive  effect  on 
lymphocyte proliferation has been studied extensively (Bartholomew et al. 2002, Di Nicola et 
al. 2002, Le Blanc et al. 2003). This ability was attributed exclusively to MSCs, but it has 
been reported that fibroblasts could also inhibit the proliferation of lymphocytes (Haniffa et 
al. 2007,  Jones et al. 2007, Cappellesso-Fleury et al.  2010). They act  in a dose-dependent 
manner via soluble factors after initial cell contact has been made (Jones et al. 2007).
The above-mentioned similarities  make it  particularly  complex to  distinguish MSCs 
from  fibroblasts  in  the  same  culture  and  to  apply  appropriate  techniques  for  successful 
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elimination of fibroblasts (Blasi et al. 2011). The colony-forming capacity has been observed 
both in MSCs and dermal fibroblasts,  but human embryonic lung fibroblasts  do not form 
colonies (Alt et al. 2011). Recently CD106, CD146 and integrin alpha 11 were claimed as 
markers distinguishing BM MSCs from fibroblasts (Halfon et al. 2011). Different expression 
levels of CD10 and CD26 (Cappellesso-Fleury et al. 2010) could help discriminate between 
BM MSCs and fibroblasts. It  may also be possible to evaluate their  angiogenic and anti-
inflammatory  potential,  since  ASCs  seems  to  be  significantly  more  angiogenic  and  anti-
inflammatory than dermal fibroblasts (Blasi et al. 2011).
These differences, although modest, show that MSCs and fibroblasts are not the same. It 
is  still  not  absolutely clear, whether  fibroblasts  are  more mature than MSCs (Blasi  et  al.  
2011), but they are both part of a complex family of stromal cells with specialized niche 
functions  (Haniffa  et  al.  2009).  Some  evidence  indicates  that  MSCs  are  different  from 
fibroblasts and more similar to pericytes (Blasi et al. 2011), as both MSCs and pericytes, but 
not fibroblasts,  show high expression of CD146, while  a fibroblast  marker  FSP-1 is  only 
poorly expressed in MSCs and pericytes (Covas et al. 2008).
Pericytes are extensively branched cells of mesodermal origin that are located in the 
wall of non-muscular microvessels, capillaries, and postcapillary venules (Díaz-Flores et al. 
1991) where they closely encircle endothelial cells that form the microvasculature (Crisan et 
al. 2008). Recently great popularity has been gained by a hypothesis that MSCs are situated 
throughout the body as pericytes and that the perivascular zone comprises the in vivo niche of 
MSCs (Crisan et al. 2008, da Silva Meirelles et al. 2008). This theory is supported by the fact 
that blood vessels are the only shared anatomical structure in the majority of solid tissues 
from  which  MSCs  have  been  isolated  (Lv  et  al.  2014).  Pericytes  share  morphological 
appearance  with  MSCs (Crisan  et  al.  2008,  Covas  et  al.  2008).  Their  immunophenotype 
profile is similar to MSCs since they are positive for the CD73, CD90, CD29, CD13, CD44, 
CD49e, CD54, STRO-1, CD146, CD166, HLA class I markers and negative for CD34, CD14, 
CD45, CD31, CD33, glycophorin A, cadherin 5, KDR, HLA class II markers (Covas et al. 
2008).  Furthermore,  pericytes  are  able  to  differentiate  into  adipocytes,  osteocytes, 
chondrocytes (Covas et al. 2008, Crisan et al. 2008), and myocytes (Crisan et al. 2008).
The  perivascular  origin  of  MSCs  is  further  supported  by  an  observation  that 
perivascular cells natively, before culture, express surface antigens CD44, CD73, CD90, and 
CD105 that  are  used  as  markers  for  MSCs (Crisan  et  al.  2008).  If  MSCs would  be  the 
pericytes in vivo, they could be easily released from their niche and secrete immunoregulatory 
and bioactive factors upon tissue damage, effectively contributing to a physiological turnover 
throughout a body (Lv et  al.  2014). More and more researchers tend to think that not all 
pericytes are MSCs, but all MSCs are pericytes, although some exceptions may exist (Caplan 
2008).
However, this “perivascular niche” theory can not explain the fact that MSCs could be 
also found in avascular tissues, such as articular cartilage and  nucleus pulposus (Lv et al. 
2014). It is possible that pericytes are not the only cell lineage in our body that acts as a 
source of MSCs (Crisan et al. 2008, Feng et al. 2011). Evidence suggests that a contribution 
of  pericyte-derived  and  non-pericyte-derived  MSCs  to  cell  differentiation  in  every  tissue 
depends on the amount of blood vessels in that tissue and the kinetics of growth and repair 
(Feng et al. 2011).
1.6. Markers of pluripotency
1.6.1. OCT4 
The human OCT4 gene (official symbol POU5F1, also known as OCT3, OCT4, OTF3, 
OTF4) is located on chromosome 6p21.31 (Krishnan et al. 1995). It is a transcription factor 
known to be crucial to the establishment of pluripotency (Nichols et al. 1998). The human 
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OCT4 is  expressed  in  totipotent  and  pluripotent  stem cells  starting  from the  unfertilized 
oocytes to the blastocyst (Wang X. et al. 2009). It is also highly expressed in human ESCs 
(Cauffman et al. 2006), embryonic germ cells (Goto et al. 1999), as well as in embryonic 
carcinoma cells  (Jones  et  al.  2004).  Its  expression  in  stem cells  is  downregulated  during 
differentiation (Hay et al. 2004). 
The  alternative  splicing  of  OCT4 gene  results  in  three  transcripts  termed  OCT4A, 
OCT4B (Takeda et al.  1992), and  OCT4B1 (Atlasi et al.  2008) (Figure 1.6.1.1.). All three 
transcript variants differ in their 5' termini, but are identical in 3' termini.  OCT4A contains 
exons 1, 2b, 2d, 3, and 4, among which exon 1 is the unique part that distinguishes it from 
other two transcripts.  OCT4B transcript is very similar to  OCT4A,  but it lacks the exon 1 
which is replaced by exon 2a. OCT4B1 transcript is highly identical to OCT4B, but it contains 
an additional exon 2c (Wang, Dai 2010).
Figure  1.6.1.1. Figure and caption from Wang and Dai 2010: “The schematic structure of 
human OCT4 gene. OCT4 gene can generate three transcripts and four protein isoforms. The 
different regions of  OCT4 isoforms are indicated by different coloured boxes. The identical 
regions of  OCT4 isoforms are indicated by white boxes. CTD - C-transactivation domain; 
NTD - N-transactivation domain; POU – a DNA binding domain.”
The  OCT4A transcript  (NCBI reference sequence  NM_002701.5)  produces a protein 
composed of 360 aa (Figure 1.6.1.2.) (Wang, Dai 2010). The OCT4A is a transcription factor 
belonging  to  POU family  proteins  that  regulate  the  transcription  of  genes  containing  the 
conserved octamer motif (ATTTGCAT) in their promoter or enhancer regions. They bind to 
the octamer motif with their POU domain (Cauffman et al. 2006). The POU domain is build 
of  two  subdomains:  a  75  aa  amino-terminal  POU  specific  (POUS)  region  and  a  60  aa 
carboxyl-terminal homeodomain (POUH), which are connected by a variable linker of 15 to 56 
aa (Pan et al. 2002). The POU domain is flanked by N-transactivation domain (133 aa) and C-
transactivation domain (71 aa) (Wang, Dai 2010). The N-transactivation domain regulates a 
binding of OCT4A to target promoters and it distinguishes OCT4A from other OCT4 protein 
isoforms  (Jez  et  al.  2014).  The  C-transactivation  domain  is  subject  to  cell-type-specific 
regulation mediated by the POU domain (Brehm et al. 1997). The OCT4A protein localizes in 
the nucleus of ESCs, compacted embryo, and blastocyst (Cauffman et al. 2006). It is believed 
that only this isoform of OCT4 proteins contributes to maintenance of pluripotency and self-
renewal (Cauffman et al. 2006, Lee et al. 2006).
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Figure  1.6.1.2. Figure and caption from Wang and Dai 2010: “(A) Schematic structure of 
OCT4  transcript  isoforms.  The  translation  start  and  stop  sites  and  the  putative  internal 
ribosome entry site element on mRNA are indicated. (B) Schematic structure of OCT4 protein 
isoforms  with  their  respective  domains.  CTD  -  C-transactivation  domain;  NTD  -  N-
transactivation domain; IRES - internal ribosome entry site;  POUS -  POU-specific region; 
POUH - POU homeodomain; NLS – nuclear localization signal; aa – amino acids.”
The OCT4B transcript (NCBI reference sequence NM_203289.5) encodes three protein 
isoforms termed OCT4B-265 (commonly referred to as simply OCT4B), OCT4B-190, and 
OCT4B-164 (Figure 1.6.1.2.)  (Wang X. et  al.  2009). The N-transactivation domain of the 
OCT4B-265 protein is 40 aa long and differs it from OCT4A isoform (Wang, Dai 2010). The 
rest 225 aa, comprising the POU domain and the C-transactivation domain, are identical in 
both OCT4B and OCT4A (Takeda et al. 1992). The OCT4B is mainly found in a cytoplasm of 
all  cells  throughout human preimplantation development from the four-cell  stage onwards 
(Cauffman et al. 2006). Although the putative nuclear localization signal, identified in murine 
Oct4 as “RKRKR” (Pan et al. 2004), is present in all protein isoforms of OCT4 (Wang, Dai 
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2010), the cytoplasmic localization of OCT4B implies other biological function than that of 
OCT4A  (Cauffman  et  al.  2006).  It  has  been  shown  that  OCT4B  is  upregulated  under 
genotoxic  stress  in  human  ESCs  and  embryonic  carcinoma  (EC)  cell  lines  and  its 
overexpression can promote cell apoptosis in genotoxic stress response (Gao et al. 2012). The 
OCT4B-190 and OCT4B-164 proteins are diffusely localized both in cytoplasm and nucleus. 
The OCT4B-190 is upregulated under heat shock and oxidative stress in human ESC and 
tumor  cell  lines,  and overexpression of  OCT4B-190 increases  the  resistance  to  apoptosis 
induced by heat shock (Wang X. et al. 2009). The functional role of the OCT4B-164 protein 
has not yet been discovered (Gao et al. 2012).
The OCT4B1 (GenBank accession number EU518650.1) mRNA  has retained the intron 
2 as an additional exon 2c, which contains an in-frame stop codon TGA (Figure 1.6.1.2.) 
(Atlasi et al. 2008). Therefore, it can not encode the full length protein isoforms of OCT4B-
265 and OCT4B-190 and it  is still  not clear whether  OCT4B1 can generate the truncated 
proteins  of  those  two isoforms.  Until  now the  protein  product  of  OCT4B1 has  not  been 
identified (Wang, Dai 2010). An OCT4B1 construct has been created and expressed in human 
bladder cancer cell and unrestricted somatic stem cell lines with a help of lentiviral vectors. 
The results  have shown that  truncated  OCT4B1 protein  is  produced and it  localizes  in  a 
cytoplasm.  The  level  of  the  transcript  and  protein  rises  under  heat-stress  stimulation, 
suggesting its potential role in mediating stress response (Yazd et al. 2011). It has been shown 
that OCT4B1 could be spliced into OCT4B and encode its all three protein isoforms (Gao et 
al. 2010). The  OCT4B1 mRNA is highly expressed in human ESCs and EC cells and, like 
OCT4A, is downregulated upon differentiation (Atlasi et al. 2008). It could potentially serve 
as a marker of stemness (Papamichos et al. 2009). The expression of OCT4B1 has been also 
reported  in  gastric  cancer, where it  could contribute to  tumorigenesis  process  as  an anti-
apoptotic factor (Asadi et al. 2011).
In the last decade numerous studies have detected OCT4 in adult stem cells (Tai et al.  
2005,  Izadpanah  et  al.  2006,  Greco  et  al.  2007,  Kucia  et  al.  2007,  Roche  et  al.  2007, 
Trivanović et al. 2015), and this has led to speculations that somatic stem cells may possess 
greater  similarities  to  ESCs in terms of  regulatory networks  and potency than  previously 
thought (Greco et al. 2007). The expression of OCT4 has been shown even in the human 
peripheral blood mononuclear cells that are terminally differentiated cells (Zangrossi et al. 
2007).  However,  this  observation  was  soon  revisited  by  underlining  that  discrimination 
between OCT4A and OCT4B isoforms was not considered, and the authors have detected 
OCT4B which is not a marker of pluripotency (Kotoula et al. 2008). Designing the primers 
for RT-PCR or using antibodies within the region that is identical in both OCT4A and OCT4B 
isoforms have proved to be a  banana skin for  most  of  the studies  that  have  claimed the 
expression of pluripotency marker OCT4 in adult stem cells (Liedtke et al. 2008). The reliable 
expression of OCT4A isoform in MSCs and somatic tumor cell lines has not been detected 
using  specific  primer  pairs  and  antibodies  for  OCT4A.  A positive  signal  has  been  only 
detected when primers for all three isoforms of OCT4 have been used, providing an evidence 
for the expression of OCT4B or OCT4B1 in these cells  (Mueller et  al.  2009).  Additional 
scientific research using murine cells has shown that OCT4 is not essential for maintaining 
potency  and self-renewal  in  the  adult  mammalian  stem cells  (Lengner  et  al.  2007).  It  is 
thought that albeit pluripotency markers can be observed at a basal level in adult stem cells, 
they may not have the same biological functions as in ESCs (Lengner et al. 2008).
Another  possible  pitfall  that  may  be  a  cause  of  misinterpretation  of  the  OCT4A 
expression in somatic stem cells  is  the existence of  OCT4 pseudogenes.  The detection of 
OCT4B and OCT4B1 isoforms at mRNA level is relatively easy, as no pseudogenes for these 
isoforms have been currently identified in the human genome (Wang, Dai 2010). But there are 
6 known pseudogenes of  OCT4  (Pain et  al.  2005),  among which  OCT4P1,  OCT4P3,  and 
OCT4P4 share a high sequence homology, including the unique N-terminal coding sequence, 
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to OCT4A (Jez et al. 2014). Additionally there are at least 11 OCT4 transcripts and OCT4-like 
sequences originating from chromosome 6 (Liedtke et al. 2007). 
The OCT4P1 was initially regarded as processed pseudogene with a complete ORF that 
can, theoretically, encode a protein that would be 1 aa shorter and have 14 mismatches when 
compared to OCT4A. It has been shown that the putative OCT4P1 protein, likewise OCT4A, 
localizes in a nucleus and even functions as a weak transcriptional activator (Panagopoulos et 
al. 2008). Since it may be a protein coding gene, it has been designated  POU5F1B (NCBI 
reference sequence NM_001159542.1). BM MSCs and umbilical vein-derived stromal cells 
have  been  shown to  express  POU5F1B,  OCT4P3,  OCT4P4,  and  extremely  low level  of 
OCT4A, but neither of corresponding proteins have been detected (Kaltz et al. 2008). The 
expression of the same pseudogenes has been confirmed in different somatic cells, somatic 
tumor cell lines, and adult stem cells (Jez et al. 2014). It is known that in the human ESCs the  
OCT4A  expression  is  downregulated  during  a  differentiation  (Hay  et  al.  2004),  but, 
interestingly, the expression of above-mentioned OCT4 pseudogenes is increased in a parallel 
(Jez  et  al.  2014).  It  has  been shown that  haematopoietic  stem cells  derived from human 
umbilical cord blood express OCT4P3, OCT4P4, and OCT4P5 (Redshaw, Strain 2010).  The 
OCT4P3 and  OCT4P4 have  been  observed  in  freshly  isolated  urothelium and  urothelial 
carcinoma cell lines (Wezel et al. 2013), but POU5F1B and OCT4P5 are transcribed in cancer 
cell  lines  and cancer  tissues  (Suo et  al.  2005).  A high  level  of  POU5F1B expression  is 
associated with aggressive phenotype and poor prognosis in gastric cancer patients (Hayashi 
et al. 2015).
To detect OCT4A alone, using RT-PCR method, the primers must lie in the 5' region of 
the  OCT4A sequence, since the exon 1 is not found in other splice variants and it contains 
three unique polymorphisms (positions 48, 234, and 353, starting at the transcriptional start 
codon  ATG),  that  can  help  in  discriminating  between  parental  OCT4A and  pseudogenes 
(Liedtke et al. 2008). Human somatic stem cells, somatic tumor cells, and some adult cells 
may express OCT4A at a basal level, compared with pluripotent cells. However, the OCT4A 
protein  has  not  been undoubtedly detected  in  non-pluripotent  cells,  and it  is  still  unclear 
whether  the  basal  level  expression  of  OCT4A in  non-pluripotent  cells  has  a  biological 
function (Wang, Dai 2010).
1.6.2. NANOG
The human NANOG gene (NCBI reference sequence  NM_024865.3) consists of 8265 
base  pairs  and  is  located  on  the  short  arm  of  chromosome  12  (12p13.31) (Schorle, 
Nettersheim 2012). It was named after the mythological Celtic land of the ever young – Tir 
nan Og (Chambers et al. 2003, Mitsui et al. 2003). There are four transcript variants that are 
encoded by NANOG gene. The mRNA variants NANOG-001 and NANOG-002 are translated 
into  proteins  with  a  length  of  305  amino  acids  (aa)  and  289  aa,  respectively.  A variant 
NANOG-003 is  known  to  undergo  a  nonsense-mediated  decay,  but  a  NANOG-004 is 
putatively protein coding and its translation would result in a protein of 186 aa. The variant 
NANOG-001 is commonly analysed and referred to as NANOG (Schorle, Nettersheim 2012). 
NANOG protein is a homeodomain (DNA-binding domain) containing transcription factor 
(Ambady et al. 2010) that plays an essential role in defining identity of ESCs and their self-
renewal (Chambers et al. 2003, Mitsui et al. 2003). An equilibrium between monomeric and 
active dimeric forms of NANOG in murine ESCs helps to maintain their self-renewal (Mullin 
et al. 2008), and research suggests that homodimerization through the tryptophan rich region 
will be also required for human NANOG function (Chang et al. 2009). NANOG is expressed 
in  pluripotent  stem cells,  such as  ESCs and embryonic  germ cells,  and its  expression  is  
downregulated during cell differentiation (Chambers et al. 2003). Its presence is also observed 
in tumor cell lines, teratocarcinoma cell lines (Zhang et al. 2006), and somatic tumors such as 
24
breast (Ezeh et  al.  2005),  prostate (Gu et al.  2007), cervical (Ye et  al.  2008), and gastric 
cancer (Zhang et al. 2010). 
The detection of NANOG gene in every human sample must be carefully verified since 
there  are  11  pseudogenes  known  for  NANOG in  the  complete  human  genome.  NANOG 
pseudogene 1 (NANOGP1) is a duplication pseudogene since it contains regions homologous 
to the introns and exons of  NANOG  parent gene.  NANOGP2 to  NANOGP10 are processed 
pseudogenes as they lack introns and eight of them have in-frame stop codons, deletions, or 
frameshifts  producing  stop  codons  (Figure  1.6.2.1.). NANOGP11 is  found  on  a  different 
chromosome and does not include sequence derived from the  NANOG open reading frame 
(ORF) (Booth, Holland 2004). Among the pseudogenes, NANOGP1, P2, P4, P7, P8, P9 and
Figure 1.6.2.1. Figure and caption from Booth and Holland 2004: “(A) Human NANOG gene 
structure. The four exons (labelled 1–4) are represented by horizontal bars; the 5' and 3' UTRs 
are white and the protein coding region is black with the homeobox coloured blue. The three 
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introns are represented by pink lines. The length in nucleotides is written underneath each of 
the exons and introns. The start (ATG) and stop (TGA) codons are labelled and represented by 
a green and a red vertical line, respectively. (B) Nine processed pseudogenes compared to 
human NANOG protein. NANOGP11 is not shown, as it does not include sequence derived 
from  the  NANOG  open  reading  frame.  The  NANOG  protein  is  represented  by  a  black 
horizontal bar with the homeodomain coloured blue. The start codon is represented by a green 
vertical line and the stop codon by a red vertical line. Intron positions are shown by pink 
triangles. For each pseudogene the black horizontal bar represents sequence similarity to the 
NANOG open reading frame, which can move between pseudogene reading frames (rf1, rf2, 
rf3) as a result of insertions and deletions. Insertions are represented by turquoise vertical 
lines and deletions by the absence of sequence similarity to NANOG. Below each insertion is 
a plus sign and below each deletion is a minus sign, followed by the number of nucleotide 
bases inserted/deleted at that point. Substitution mutations are not shown, except where these 
introduce stop codons into the reading frame homologous to  NANOG. Red vertical  lines 
indicate stop codons. These are shown when they occur in the reading frame homologous to 
NANOG or when they are the first stop codon encountered in rf1. In three of the pseudogenes 
(NANOGP2, P6, P9) insertions or deletions have caused reading-frame shifts before a stop 
codon was encountered in rf1. In these cases, the grey dashed lines indicate continuation of 
rf1 until the first stop codon is encountered.”
P10 show more than 90% homology, and  NANOGP5 exhibits about 85% homology to the 
parent gene in their ORFs (Ambady et al. 2010). Most NANOG pseudogenes do not have the 
potential  to  produce  functional  proteins  due  to  a  critical  mutations,  but  NANOGP7 and 
NANOGP8 are exceptions, since they do not contain insertions or deletions in the region that 
is homologous to the NANOG ORF. NANOGP7 possesses an in-frame stop codon close to the 
start of the ORF, but NANOGP8 has a complete ORF, extremely similar to original NANOG 
(Booth, Holland 2004).
NANOGP8 (NCBI reference sequence  NC_000015.10) shows 99,5% homology to the 
original NANOG ORF (Ambady et al. 2010), but the exact amount of distinctive nucleotides 
between those two is ambiguous. Some comparison has shown differences at 5 positions in 
their ORF (Ambady et al. 2010), while most studies report 6 different nucleotides between 
NANOG and  NANOGP8 (Booth,  Holland  2004,  Zhang  et  al.  2006,  Jeter  et  al.  2009). 
However, not all 6 identified nucleotide changes are identical to every study. Our sequence 
alignment of both ORFs shows 5 unique nucleotides distinguishing NANOG from NANOGP8 
(at the positions 47, 144, 246, 531, 759) (Appendix 4). These results indicate that there are 
modern  polymorphisms  within  NANOG and  NANOGP8 that  exist  in  actual  reference 
sequences,  thus  leading  to  possible  misidentification  of  RT-PCR products  of  NANOG or 
NANOGP8 (Fairbanks et al. 2012). Naturally occurring variation in the NANOG sequence at 
the  position  246  (relative  to  the  ATG  start  codon),  resulting  in  lysine  substitution  with 
asparagine,  has  been  reported  previously  (Booth,  Holland  2004).  Further  comparison  of 
current and previous reference sequences has shown a high degree of modern polymorphisms 
within NANOG itself - 16 substituted and 27 deleted nucleotides within the 2115 nucleotides 
of the mRNA, six of which are in the ORF. It turns out that all but two (144 G > A, 759 G > 
C) variants between NANOG and NANOGP8 ORFs detected in previous studies are modern 
polymorphisms. Only one of the fixed variants (759 G > C) between those two results in an aa 
change, thus making proteins encoded by NANOG and NANOGP8 differ by only one fixed aa 
substitution (Fairbanks et  al.  2012). Table 1.6.2.1. and Appendix 4 summarize all  variants 
found  between  NANOG and  NANOGP8 ORFs,  identifying  fixed  variants  and  modern 
polymorphisms in both of them. 
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Table  1.6.2.1. Table  and caption  partially  from Fairbanks  et  al.  2012:  “Variants  between 
NANOG and  NANOGP8 ORF sequences  detected  by  comparison  of  current  primary  and 
alternate  reference  assemblies  and  sequences  obtained experimentally  by  Fairbanks  et  al. 
2012. Polymorphic variants are indicated with a slash, separating the ancestral and derived 
variants,  with  the  ancestral  variant  indicated  first.  All  variants  are  polymorphic  in  either 
NANOG or NANOGP8 except for two, indicated in red. Polymorphic variants not present in 
the  comparison  of  primary  and  alternate  reference  assemblies  of  NANOGP8 or  in  other 
studies, but observed in at least two individuals by Fairbanks et al. 2012 are indicated in blue. 
a - nucleotides in the reading frame are numbered relative to the first nucleotide in the ATG 
initiation codon; the symbol “=” denotes that a nucleotide substitution has no effect on the 
protein.”
Variant in coding 
DNAa Variant in protein
a NANOG NANOGP8
47 C > A Ala16Glu C C/A
126 T > C = T T/C
144 G > A = G A
165 T > C = T/C T
190 G > T Asp64Tyr G G/T
246 T > G Asn82Lys T/G T
276 G > A = G/A G
363 C > T = C/T C
531 C > T = C/T C
552 A > T = A A/T
629 C > T Thr210Ile C C/T
754 A > C Met252Leu A A/C
759 G > C Gln253His G C
798 C > T = C/T C
NANOGP8 is  transcriptionally  active as a retrogene in several cancer  cell  lines and 
different  types of cancer cells  (Zhang et  al.  2006, Jeter at  al.  2009, Ambady et  al.  2010, 
Ibrahim et al. 2012). Although  NANOG gene and  NANOGP8 are both expressed in cancer 
cells,  it  seems that cancer cells  mostly express  NANOGP8 and it  promotes tumorigenesis 
more  readily  than  NANOG  (Fairbanks  et  al.  2012).  Moreover,  downregulation  of 
NANOG/NANOGP8 mRNA in cancer cells inhibits tumor development and clonal expansion 
of prostate, breast, and colon cancer cells, suggesting that its suppression may potentially be 
developed as a treatment for cancer (Jeter et al. 2009).  NANOGP8 expression has also been 
detected alongside with NANOG in human adult fibroblasts, umbilical vein endothelial cells, 
and total heart tissue, but smooth muscle cells express exclusively NANOGP8 (Ambady et al. 
2010). Research shows that recombinant NANOGP8 protein, like NANOG, localizes in a cell 
nucleus and promote an entry of cells into S-phase (Zhang et al. 2006). Further studies have 
verified this by showing that NANOGP8 is translated into protein that exhibits predominantly 
nuclear  localization  and  may  play  a  functional  role  in  the  certain  cell  types.  These 
observations suggest that low levels of expression of NANOG alongside with NANOGP8 may 
be necessary for normal cell function even in differentiated cells (Ambady et al. 2010). 
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1.6.3. SOX2
The human SOX2 gene (NCBI reference sequence NM_003106.3) is an intronless gene 
located on chromosome 3q26.3-q27. It belongs to the SOX family of transcription factors that 
has an important role in developmental and stem cell biology (Weina, Utikal 2014). These 
transcription  factors  contain  a  high-mobility  group  (HGM)  box  (Thiel  2013)  that  was 
originally identified in the sex-determining region on the chromosome Y and was termed SRY 
(Sinclair et al. 1990). The HMG domain allows precise DNA recognition and binding. The 
proteins that contain this domain with amino acid similarity of 50% or higher to the HMG 
domain  of  SRY are  termed SOX (SRY-related  HMG box) proteins  (Sarkar, Hochedlinger 
2013). These SOX proteins bind consensus sequence (A/T)ACAA(T/A) and interact with the 
minor DNA groove forcing the DNA helix apart in order to bend the target DNA up to 90 
degrees.  Additionally, the HMG box contains nuclear localization signals and calmodulin-
binding site (Sekido, Lovell-Badge 2009).  There are 20 different  SOX genes expressed in 
mice and humans (Schepers et al. 2002). Based on the primary structure of their HMG box 
(the HMG domain sequence identity  must be at  least  80%), they are divided into groups 
termed A to H.  SOX2 belongs to the SOXB1 subgroup that also includes  SOX1 and  SOX3 
(Sarkar, Hochedlinger 2013). The  SOX2 transcript encodes a 317 aa long protein which is 
composed  of  three  domains:  N-terminal,  HMG,  and  C-terminal  transactivation  domain 
(Figure 1.6.3.1.) (Weina, Utikal 2014).
Figure 1.6.3.1. Figure and caption from Wiena and Utikal 2014: “SOX2 homology, structure, 
and protein function. (A) SOXB1 subgroup containing SOX1, SOX2, and SOX3 proteins that 
share large homology and contain three major domains: N-terminal, HMG, and C-terminal 
domain. (B) The HMG domain of SOX2 remains fairly conserved between Homo sapiens, 
Mus musculus and Danio rerio (Swiss-Prot: P48431, P48432, Q6P0E1). The HMG domain 
also serves as potential binding sites for protein partners. Moreover, nuclear import signals 
28
(NIS) and nuclear export signals (NES) bind to the HMG domain regulating SOX2 itself. The 
transactivation domain functions as the region responsible for promoter binding, which in turn 
leads to activation or repression of target genes.”
Developmental  studies  in  mouse  embryo  have  shown  that  murine  Sox2  protein  is 
initially present in ICM, epiblast, and germ cells, similarly to Oct4. However, unlike Oct4, 
Sox2 is also expressed in extra-embryonic ectoderm. Sox2 is essential for maintaining the 
cells of epiblast in an undifferentiated state, as in its absence they become trophectoderm or 
extra-embryonic endoderm. The lack of Sox2 results in early embryonic lethality (Avilion et 
al.  2003)  because  its  signalling  is  critical  for  the  formation  of  different  endodermal  and 
ectodermal  tissues  during  fetal  development,  including  nervous  system,  lens  epithelium, 
anterior foregut endoderm and its derivatives, as well as sensory cells of a taste bud, inner ear, 
and retina (Arnold et al. 2011).  Later in development, Sox2 is involved in specification and 
maintenance of neural  stem cells  during neurogenesis (Bylund et  al.  2003, Graham et  al. 
2003),  therefore  it  is  a  known  marker  for  neural  development,  as  it  is  expressed  in 
undifferentiated precursor cells (Thiel 2013). It has been shown that Sox2 is involved in a 
branching of a bronchial tree and is necessary for differentiation of the epithelium of airways 
(Gontan et al. 2008). A forced expression of Sox2, or its paralogues Sox1 and Sox3, maintains 
neural  progenitor  cells  in  an  undifferentiated  state  and  prevents  neuronal  differentiation 
(Bylund et al. 2003).
Sox2 is also found in embryonic and adult neural stem cells (Thiel 2013). The silencing 
of this gene in ESCs by RNA interference leads to differentiation of these cells, indicating its 
critical role in the maintenance of ESC pluripotent state (Chew et al.  2005). Furthermore, 
Sox2 expression has also been detected in adult mammalian tissues, such as progenitors of 
brain  and  retina,  trachea,  tongue  epithelium,  dermal  papilla  of  the  hair  follicle,  putative 
progenitors of pituitary gland, testis, forestomach, glandular stomach, anus, cervix, lens, as 
well as glands associated with oral cavity, trachea, and cervix where it marks unipotent and 
multipotent stem cells (Arnold et al. 2011).
Aside from its crucial role in development and stem cell maintenance, SOX2 has been 
closely associated with cancer as well. It has been discovered that SOX2 is involved in many 
cancer-associated  processes,  such  as  cell  proliferation  (breast,  prostate,  pancreatic,  and 
cervical  cancers),  evading  apoptotic  signals  (prostate,  gastric,  and  non-small  cell  lung 
cancers), and promoting invasion, migration, and metastasis (melanoma, glioma, colorectal, 
gastric, ovarian cancers, and hepatocellular carcinoma) (Weina, Utikal 2014). High expression 
of SOX2, as well as OCT4, proteins has been significantly associated with poorer clinical 
survival of esophageal squamous cancer patients (Wang Q. et al. 2009). SOX2 has also been 
proposed as  a  marker  for  pancreatic  cancer  stem cells  which,  based  on cancer  stem cell 
hypothesis,  are  the  main  cause  of  cancer  progression,  drug  resistance,  and  recurrence 
(Herreros-Villanueva et al. 2013).
1.6.4. Interactions of OCT4, NANOG, and SOX2
Cellular pluripotency is defined as the ability of a cell to differentiate into every type of 
cell of ectodermal, mesodermal or endodermal origin. During mammalian development only 
specific group of cells in the early stage embryos is transiently endowed with pluripotency. 
ESCs are directly obtained from such pluripotent cell populations and can maintain this ability 
under special culture conditions in vitro (Niwa 2001). In the field of ESC research it is well-
established practice to characterize these cells by the expression of particular pluripotency 
markers, that signify their ability to self renew and differentiate into each cell type within the 
organism, except extraembryonic tissues.  OCT4, NANOG, and SOX2 are regarded as the 
central transcriptional regulators maintaining the pluripotency of ESCs (Boyer et al. 2005). 
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The interactions of these key pluripotency factors control a whole set of target genes, as well 
as  each  other,  to  sustain  the  properties  of  ESCs  (Pan,  Thomson  2007).  It  has  been 
demonstrated that OCT4, NANOG, and SOX2 co-occupy the promoters of at least 353 target 
genes in human ESCs. Together they activate genes encoding components of key signalling 
pathways and repress the expression of genes that are essential to developmental processes, 
thus maintaining pluripotent state of ESCs (Boyer et al. 2005).
The exact molecular mechanisms that govern activity of OCT4, NANOG, and SOX2 
are complex and not  yet  completely characterized (Lakatos et  al.  2014).  It  is  known that 
NANOG knock-down leads to differentiation of ESCs into the lineages of extraembryonic 
endoderm  and  trophectoderm  (Hyslop  et  al.  2005),  and  removal  of  OCT4  also  leads  to 
differentiation into trophectoderm (Niwa et al. 2000). However, overexpression of NANOG 
enables a propagation of human ESCs without feeder cells or conditioned media and leads to 
the  expression  of  markers  specific  to  a  primitive  ectoderm  (Darr  et  al.  2006),  while 
upregulation of OCT4 induces commitment to primitive endoderm and mesoderm lineages 
(Niwa et al. 2000). The results from mouse ESCs indicate, that the primary function of OCT4 
is to prevent differentiation of ESCs into trophectoderm, but NANOG inhibits differentiation 
into extraembryonic endoderm and actively maintains pluripotency (Mitsui et al. 2003).
Scientific observations suggest that OCT4 is different from many known transcription 
regulators, that seem to function in a binary on-off manner, because it controls the pluripotent 
state of the stem cells in a quantitative fashion (Pan et al. 2002). Only a specific level of  
OCT4 can maintain a stem cell renewal. 50% above or below the normal expression level in  
pluripotent  stem  cells  trigger  differentiation  into  endoderm/mesoderm  or  trophectoderm, 
respectively  (Niwa  et  al.  2000).  Similarly,  SOX2  levels  must  also  be  maintained  within 
narrow  limits  since  increase  in  SOX2  protein  reduces  self-renewal  and  promotes 
differentiation of ESCs (Kopp et al. 2008). The expression pattern of NANOG is also unusual. 
Despite  its  crucial  role  in  maintaining  pluripotency,  the  expression  of  NANOG  is 
heterogeneous in a population of ESCs. These cells can express different levels of NANOG 
and  thus  exhibit  variable  resistance  to  differentiation  (Chambers  et  al.  2007).  This 
heterogeneity is dynamically controlled, with individual cells exhibiting transient changes in 
expression levels (Lakatos et al. 2014). Furthermore, the expression of NANOG is mosaic in 
the inner cell mass of a blastocyst as well (Chazaud et al. 20006). The NANOG-positive cells 
give rise to epiblast, from which all three germ layers emerge, but NANOG-negative cells 
form the primitive endoderm, which contributes to extraembryonic tissues (Navarro et  al. 
2012).
To sustain pluripotency in ESCs, the target genes are regulated both by NANOG and 
OCT4 individually, and by NANOG and the combination of OCT4/SOX2, since OCT4 can 
heterodimerize with SOX2 in order to affect the expression of genes (Boyer et al.  2005). 
During  the  last  decade  several  models  have  been  suggested,  describing  the  interactions 
between the key transcription factors OCT4, SOX2, and NANOG (Figure 1.6.4.1.). 
The transcriptional network consisting of OCT4, SOX2, and NANOG behaves like a 
bistable switch resulting from several positive feedback loops. OCT4 and SOX2 regulate each 
other  through  the  formation  of  a  heterodimer.  The  OCT4/SOX2  heterodimer  regulates 
NANOG, which feeds back to OCT4 and SOX2 (Figure 1.6.4.1.A). Through these feedback 
loops the expression of all three transcription factors can be collectively triggered or blocked 
by the input environmental signals. The switch stabilizes the expression of these three key 
genes and, by regulating their  downstream target genes,  leads to a binary decision: when 
OCT4, SOX2, and NANOG are expressed and the switch is ON, the self-renewal genes are 
ON and the genes involved in a differentiation process are OFF. When the switch is OFF,  the 
opposite takes place,  leading to the loss of pluripotency and initiation of a differentiation 
(Chickarmane et al. 2006).
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Figure 1.6.4.1. Figure and caption from Lakatos et al. 2014: “Suggested interactions of the 
OCT4-SOX2-NANOG core module of transcriptional embryonic stem cell  regulation.  (A) 
The symmetrical model considered by Chickarmane et al. 2006. (B) The model suggested by 
Pan,  Thomson  2007,  that  includes  negative  feedback  through  OCT4.  (C)  The  NANOG 
autoinhibitory  circuit  suggested  by  Navarro  et  al.  2012.  Black  arrows  represent  complex 
formation, green – transcriptional activation, red – repression, and blue – translation.”
 Additional research introduced a negative feedback loop formed by NANOG, OCT4, 
and  another  pluripotency  factor  FOXD3 (Pan  et  al.  2006).  It  was  suggested,  that  OCT4 
activates NANOG promoter, when expressed below normal level, but represses it, when its 
expression is above normal level in ESCs. When the expression of OCT4 rises above normal 
level, it represses its own promoter as well, thus keeping its expression level at a steady state 
(Figure 1.6.4.1.B). This negative feedback regulation loop is thought to explain the previous 
observations by Niwa et al.  2000, describing the dose dependencies of OCT4 in order to 
regulate the pluripotency of stem cells (Pan et al. 2006, Pan, Thomson 2007).
Previously it was widely accepted, that all three key pluripotency factors autoactivate 
themselves  (Jaenisch,  Young  2008),  but  later  studies  showed,  that  NANOG  activity  is 
autorepressive (Figure 1.6.4.1.C) (Navarro et  al.  2012). Since the known fluctuations in a 
NANOG transcription occur within stem cells that express relatively uniform levels of OCT4 
and SOX2 (Chambers et al.  2007), the discovered autorepression most likely takes part in 
controlling  the  dynamic  transitions  between  NANOG transcription  states.  Furthermore,  it 
turned out, that NANOG does not activate the expression of both OCT4 and SOX2 (Navarro 
et al. 2012).
The latest modelling approach showed that the model, suggested by Chickarmane et al. 
2006, can not explain oscillations in NANOG expression. The direct OCT4 negative feedback 
on NANOG expression, proposed by Pan et al. 2006, is also unlikely to play an important 
role, since the feedback mechanism, that does not require changes in OCT4, is in accordance 
with its stable expression level (Chambers et al. 2007) and the observation, that changes in 
OCT4 expression levels trigger differentiation (Niwa et al. 2000). It is likely, that fluctuations 
in NANOG expression reflect individual cell-specific changes in parameters of an autocrine 
feedback loop, instead of changes in core regulatory cluster of OCT4-SOX2-NANOG itself. 
These external changes could result from modifications in ligand capture efficiency, receptor 
numbers,  or  the  presence  of  crosstalks  within  MAPK  signal  pathway.  Furthermore,  the 
authors suggested, that NANOG fluctuations represent distinct sub-states within the ON state 
of the core NANOG switch, not transition states between the ON and OFF states, as proposed 
previously (Lakatos et al. 2014).
1.7. Stem cells for a treatment of type 1 diabetes
Diabetes  mellitus  or simply diabetes  is  called the epidemic of the 21st  century and 
according to the International Diabetes Federation 387 million people had diabetes in 2014, 
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but there will be 592 million by 2035. Although type 2 diabetes (T2D) accounts for 85%-95% 
of  all  diabetes  cases,  the  incidence  of  type  1  diabetes  (T1D)  is  also  increasing  by 
approximately 3% each year. It  is estimated that approximately 79 000 children under 15 
years develop T1D each year. Worldwide there are approximately 497 000 children with T1D 
and 26% of them live in Europe (idf.org). There were 84 683 registered patients with diabetes 
in Latvia in 2014. Of these 4188 were T1D patients (spkc.gov.lv).
Diabetes is a group of complex metabolic diseases characterized by high blood sugar, 
i.e., hyperglycemia, resulting from insufficient amount of insulin, insulin resistance, or both. 
There are two main categories of diabetes: T1D and T2D. Additionally, gestational diabetes 
mellitus and other specific types of diabetes are also distinguished (Anonymous 2010). T2D 
(non-insulin-dependent diabetes) is characterized by a decline in pancreatic β cell function in 
combination with insulin resistance, or the inability to effectively use insulin in peripheral 
tissues.  People with T2D must  control their  hyperglycemia by the means of healthy diet, 
increased  exercise,  blood glucose-lowering  drugs,  or  daily  insulin  injections  (Goldthwaite 
2010). This type of diabetes usually occurs in adults and almost half of them is between 40 
and 59 years old. More than 80% of T2D patients in this age group live in low- and middle-
income countries. Lately, increasing number of children and adolescents are also diagnosed 
with T2D (idf.org).
T1D (insulin-dependent diabetes) results from autoimmune destruction of the pancreatic 
β cells leading to a lack of insulin secretion (Anonymous 2010). Therefore, people with T1D 
require daily insulin administration to survive (Goldthwaite 2010). Since this form of diabetes 
is  usually  diagnosed  in  children  and  young  adults,  although  it  can  develop  at  any  age 
(Anonymous 2010), the impact on a future quality of their life is more critical than of those 
with T2D. Even though insulin injections partly compensate the function of β cells, they are 
not  able  to  regulate  blood  sugar  as  precisely  as  the  endogenous  insulin.  This  inaccurate 
control  of  blood  glucose  homoeostasis  in  a  long  run  results  into  such  complications  as 
diabetic retinopathy, nephropathy, neuropathy, foot ulcers, and cardiovascular diseases (Zhong 
et al. 2012). The cause of T1D is still not fully understood, but it is thought to develop from 
interactions between genetic and environmental factors. For example, individuals with HLA 
DR3-DQ2/DR4-DQ8 genotype have approximately 20 times higher risk to develop T1D than 
general population. There are other HLA class II genotypes that bear moderately increased 
risk for T1D, but protective genotypes also exist (Nokoff et al. 2012). Non-HLA associated 
risk  loci  for  T1D  include  the  genes  for  INS,  PTPN22,  IL2RA,  SH2B3  which  influence 
immunity, ERBB3 which is involved in insulin production and metabolism, and many others 
(Concannon et al. 2009). Still unknown environmental factors are also thought to influence 
development of T1D since rising incidence, outbreaks, and a seasonal pattern could not be 
explained by genetics alone (Nokoff et al. 2012). An increasing environmental pressure has 
caused substantial changes in the distribution of T1D associated HLA genotypes, and this has 
resulted  in  a  higher  disease  progression  rate  among  individuals  with  protective  HLA 
genotypes (Hermann et al. 2003). One of the most studied environmental factor in relation to 
T1D is enterovirus infection, and a recent meta-analysis has shown a significant association 
between those two (Yeung et al. 2011). 
 One of the main strategies for T1D treatment is pancreatic islet transplantation from 
two or more donors. Unfortunately, the lack of appropriate donors, damages of transplantable 
tissue, and use of immunosuppressive drugs limit the use of this method. Additionally, the 
function of pancreatic islets decreases relatively quickly after transplantation (Goldthwaite 
2010).  It  has  been  shown  that  only  10%  of  islet  transplant  recipients  maintain  insulin 
independence five years after  transplantation (Ryan et al.  2005). The use of SCs for T1D 
treatment is being explored as an alternative solution, as they could be injected into a patient, 
where they would migrate to the damaged pancreas and differentiate, replenishing β cells, or 
they  could  be  employed  in  vitro,  differentiating  them into  insulin-producing  β cells  and 
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afterwards introducing back into the patient (Goldthwaite 2010). However, the restoration of 
glucose-responsive and insulin-producing β cells is only one of two challenges that must be 
overcome to  successfully  cure  T1D.  The  second  obstacle  manifests  as  a  need  to  protect 
implanted  β cells from repeated autoimmune destruction that caused the disease in the first 
place (Chhabra, Brayman 2013). This can be achieved by different immunosuppressive drugs, 
that  is  a  common  practice  for  most  tissue  transplants,  or  by  alternative  methods.  These 
methods  include  the  use  of  specific  antibodies,  fusion  proteins,  or  oligonucleotides  to 
eliminate the majority of the autoreactive cells, transplanting BM from a diabetes-resistant 
donor  (Goldthwaite  2010),  or  exploiting  immunoisolation.  Using  the  immunoisolation 
technique, cells are enclosed in a semipermeable barrier device that allows the exchange of 
oxygen,  nutrients,  and  insulin,  but  protects  these  cells  from  the  immune  system.  Such 
materials  as  alginate,  agarose,  polyethylene  glycol,  chitosan,  silica,  and others  have  been 
tested  to  encapsulate  pancreatic  islets  (O'Sullivan  et  al.  2011).  Currently  there  are  two 
companies: ViaCyte and BetaLogics that use encapsulation devices to shield cell transplants 
(Venkat et al. 2014). ViaCyte has developed a therapy called VC-01 which is made up of 
encapsulated  pancreatic  progenitor  cells  that  have  been  differentiated  from  ESCs.  These 
precursor cells are expected to differentiate into mature pancreatic cells, once implanted in the 
body. This product is currently being tested in Phase I/II human clinical trials (viacyte.com). 
In contrast, BetaLogics uses mature  β-like cells, also differentiated from ESCs, that secrete 
insulin  upon glucose stimulation.  Animal  studies have shown that  these cells  can reverse 
diabetes  in  approximately  six  weeks  while  progenitor  cells  used  by ViaCyte  could  reach 
similar response after three to four month, as they need time to become mature and functional 
β cells. Despite the extra time needed for progenitor cells to fully differentiate, these cells can 
better survive hypoxic conditions after transplantation, they can give rise to other cell types of 
pancreatic islets, and their manufacturing is less costly (Venkat et al. 2014).
So far most of the research in this field has been carried out using ESCs due to their 
higher differentiation potential.  The first proof of concept that ESCs can differentiate into 
insulin-producing  cells  was  published  fifteen  years  ago  (Soria  et  al.  2000),  and the  first 
directed differentiation protocol, utilising five subsequent stages to obtain islet-like clusters 
composed of the cells positive for insulin, glucagon, and somatostatin, followed soon after 
(Lumelsky 2001). This protocol gained high popularity, but later it was discovered that the 
cells differentiated according to Lumelsky protocol was subjected to apoptosis or necrosis and 
the observed insulin release was most  likely due  to  the  uptake of  significant  amounts  of 
insulin that was present in the differentiation medium rather than de novo synthesis (Hansson 
et al. 2004). Meanwhile, stepwise protocols that mimicked in vivo development of pancreas 
were starting to emerge. One of the most influential differentiation protocols simulating in  
vivo pancreatic organogenesis guided ESCs through stages of definitive endoderm, gut tube 
endoderm,  and  pancreatic  endoderm  leading  to  endocrine  precursor  cells  that  expressed 
endocrine hormones. Although obtained results suggested that generated cells may be more 
similar to immature fetal β cells than to adult β cells because of a very low insulin secretion in 
response to glucose stimulation and a coexpression of insulin and glucagon or insulin and 
somatostatin  (D'Amour  et  al.  2006),  this  research  set  a  course for  future  advancement  in 
creation of insulin-producing cells. The protocol was later optimised (Kroon et al. 2008) by 
the same research group from ViaCyte company (at that time known as Novocell) and is now 
used  as  a  base  for  their  proposed  VC-01  therapy  to  treat  diabetes  in  the  nearest  future 
(viacyte.com). Different variations of this protocol and similar approaches have been reported 
with variable  degrees of success (Jiang et  al.  2007, Chen et  al.  2009, Zhang et  al.  2009, 
Kunisada et al. 2012). The main problems in the differentiation process are generation of cells 
with immature or abnormal phenotypes, production of various cell types from different germ 
layers and not pure monolineage culture, tumorigenic properties of undifferentiated ESCs and 
iPSCs (Cheng X. et al. 2012), and a low yield of insulin-positive cells (Hosoya 2012). As of 
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recently, the percentage of insulin-positive cells differentiated from ESCs or iPSCs were from 
0,8% (Chen et al. 2009) to roughly 8% (D'Amour et al. 2006, Jiang et al. 2007, Kunisada et 
al. 2012), with the highest reported percentage being approximately 25% (Zhang et al. 2009). 
However, last year researchers from BetaLogics and their collaborators developed a protocol 
which can generate insulin-producing cells, similar to mature  β  cells, from ESCs with 50% 
efficiency that exhibit glucose-responsive insulin secretion and rapidly reverse diabetes after 
transplantation in mice (Rezania et al.  2014). Together with a report showing very similar 
results and offering differentiation protocol to generate large quantities of glucose-responsive 
β  cells (Pagliuca et al. 2014) a treatment for diabetes has been definitely brought one step 
closer.
Despite attractiveness of the pluripotent SCs for such applications, ethical issues, the 
risk of teratoma development, and a need to find an appropriate donor limit their therapeutic 
use (Goldthwaite 2010). Therefore, adult SCs have been explored as a possible alternative. 
Experimental data show that SCs isolated from human UC blood (Sun B. et al. 2007, Hu et al. 
2010), placenta (Chang et al. 2007), BM (Sun Y. et al. 2007, Tang et al. 2012), and adipose 
tissue (Timper et al. 2006, Lee et al. 2008, Okura et al. 2009, Chandra et al. 2011, Kang et al. 
2011,  Buang  et  al.  2012)  are  also  able  to  differentiate  into  insulin-producing  cells. 
Differentiation protocols used for somatic SCs usually include multiple stages, similarly to 
protocols employed for ESCs, and part of the extrinsic factors added to induction media is 
identical in both cases. Reported differentiation protocols for adult SCs last for few weeks on 
average, but there are protocols that require two to four months to obtain insulin-producing 
cells  (Tang et  al.  2012).  On contrary, other  researchers  claim to  differentiate  MSCs into 
insulin-positive cells within 34 hours (Chen et al. 2004) or 3 days (Timper et al. 2006) only. 
However, these results are highly questionable, and an attempt to reproduce them has failed 
(Oishi  et  al.  2009).  Since  protocols  for  pluripotent  SCs  take  approximately  20  days  to 
complete and in the human fetal pancreas insulin-producing cells could be first detected only 
at around eight weeks of development (Naujok et al. 2011), it is very unlikely that an actual  
transdifferentiation of MSCs into insulin-producing cells could be achieved in such a short 
time span. Although several studies have demonstrated promising results (Chang et al. 2007, 
Sun Y. et al. 2007, Okura et al. 2009, Chandra et al. 2011), the problems, similar to those 
when using pluripotent SCs, must yet be overcome. The lack of an efficient standard method 
for functional insulin-producing cell generation, inability to consistently produce clinically 
significant  amounts  of  insulin,  and  differentiation  on  a  large  scale  will  require  further 
scientific efforts before adult SCs can be used for the treatment of diabetes (Wong 2011).
1.8. Differentiation of stem cells into insulin-producing cells
To successfully differentiate SCs into insulin-producing cells  in vitro,  it  is crucial to 
understand the mechanisms that govern development of pancreas in vivo. The greatest part of 
our  knowledge  about  pancreatic  development  comes  from embryological  studies  of  such 
model  organisms  as  mouse,  chicken,  zebrafish  (Danio  rerio),  or  frog  (Xenopus  laevis). 
Although these vertebrates seem very distinctive,   a development  of pancreas is  a highly 
conserved process, giving researchers the possibility to draw parallels with humans (Van Hoof 
et al. 2009).
According to the current scientific knowledge, pancreas emerges from the endoderm - 
the inner germ layer of an embryo. During the gastrulation endoderm precursors ingress in the 
anterior primitive streak forming a definitive endoderm (DE) (Grapin-Botton 2008) (Figure 
1.8.1.).  The  DE  initially  consists  of  a  flat  sheet  of  cells  with  anterior-posterior  pattern 
information. Afterwards, from this flat sheet a primitive gut tube with specified domains for 
various endoderm organ primordia is formed. Pancreas develops from the posterior foregut, 
emerging as buds from the dorsal and ventral sides of the gut tube. At this point the formation
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Figure 1.8.1. Figure and caption from Naujok et al. 2011: “Simplified schematic presentation 
of the pancreas development in mice. The inner cell mass (blue) of the blastocyst gives rise to 
the three germ layers in the process of gastrulation. The definitive endoderm is then formed 
by  the  recruitment  of  epiblast  cells  through  the  primitive  streak  via  a  mesendodermal 
progenitor with the latter cells of the foregut (blue), midgut (purple), and hindgut (yellow). 
Morphogenesis of the primitive gut is a result of an invagination movement by which the 
layered definitive endoderm becomes a tube structure. The pancreas formation begins with the 
independent budding of the dorsal and ventral buds at the posterior region of the foregut. 
These two buds grow into the surrounding mesenchyme, branch in a tree-like structure and 
eventually fuse after rotation of the gut to form the definitive pancreatic endoderm. This pre-
differentiated epithelium grows in size with distinct endocrine and exocrine differentiation. 
The endocrine cells are organized in islets which are embedded in exocrine tissue and are 
composed of four major hormone-secreting cells types. Insulin is secreted by β cells (blue), 
glucagon by α cells (yellow), somatostatin by Δ cells (green), and pancreatic polypeptide by 
PP cells  (purple).  The  timeline  plots  these  key  events  for  mouse.  For  comparison  only, 
comparable stages of human β cell development have been mapped on the timeline. Several 
markers characteristic of each developmental step are listed. DE - definitive endoderm; GLC - 
glucagon; ICM - inner cell mass; PP - pancreatic polypeptide; SST – somatostatin.”
of pancreas depends on retinoid signalling and on inhibition of hedgehog signalling (D'Amour 
et al. 2006). The developing pancreas consists of Pdx1 positive progenitors that will give rise 
to the islets, exocrine cells, and ductal cells (Gu et al. 2002). After the initial pancreatic bud 
formation, further morphogenesis, involving growth, branching, and differentiation, includes 
interactions between pancreatic epithelium and adjacent mesenchyme signals, e.g., fibroblast 
growth factor 10 (FGF10) (Bhushan et al. 2001). The specification of endocrine cells occurs 
in the next stage of pancreas development. Only Ngn3 positive pancreatic cells will give rise 
to all four types of endocrine islet cells (Gu et al. 2002), but the expression of Ngn3 gene is 
permitted through the absence of Notch signalling (Wilson et al. 2003). The Ngn3 initiates the 
expression of such transcription factor genes as  Nkx2-2,  Neurod1,  Nkx6-1,  Pax4,  Pax6, and 
Isl1 that control endocrine cell differentiation. During this period the developing endocrine 
cells migrate from the branched epithelium into surrounding mesenchyme in order to form the 
islets of Langerhans. When hormone-expressing pancreatic cells have formed, they mature 
further to reach a fully functional state. For  β  cells it means that they acquire the ability to 
35
release insulin in response to elevated glucose level (D'Amour et al. 2006). An example of the 
main intermediates in pancreatic endoderm differentiation in vitro using ESCs is depicted in 
Figure 1.8.2. 
Figure  1.8.2. Schematic  representation  of  the  main  intermediate  states  for  in  vitro 
differentiation  of  embryonic  stem cells  into  hormone-expressing  endocrine  cells  and  key 
marker expression of each intermediate cell  population.  ES – embryonic stem cell; ME – 
mesendoderm; DE - definitive endoderm; PG - primitive gut tube; PF -  posterior  foregut 
endoderm;  PE -  pancreatic  endoderm and endocrine  precursor;  EN -  hormone-expressing 
endocrine cell. Figure from D'Amour et al. 2006.
For  the  SC differentiation  into  insulin-producing cells  most  of  the  protocols  utilize 
addition and withdrawal of various extrinsic factors in a stepwise manner. Below are given the 
most common factors used in the induction protocols, as well as those factors or conditions 
which have shown significant impact on the course of SC differentiation into pancreatic β 
cells.
Activin A. The first step to successfully differentiate SCs into pancreatic endocrine cells 
is  to induce DE differentiation.  It  is  known that both Wnt/β-catenin and TGFβ signalling 
pathways are implicated in the formation of DE (Zorn et al. 1999). A member of the TGFβ 
superfamily, namely Nodal, is essential for endoderm specification in mice, and higher levels 
of Nodal signalling are required to form endoderm than mesoderm (Stainier 2002). Since a 
source of highly active Nodal protein is not readily available, it  is possible to use activin 
instead. It is another TGFβ family member that binds practically the same receptors as Nodal 
and triggers similar signalling cascades. It has been demonstrated that high concentrations of 
activin A under an absence or low concentrations of serum facilitates the differentiation of 
human ESCs into definitive endoderm (D'Amour et al. 2005). If lower doses of activin A are 
used,  differentiation  into  endocrine  cells  is  considerably  reduced  (D'Amour  et  al.  2006). 
Additionally, suppression of phosphatidylinositol 3-kinase (PI3K) signalling and reduction of 
insulin/insulin-like growth factor  signalling  promotes  the efficiency of  DE differentiation. 
LY294002 has been often used as a potent inhibitor of PI3K signalling (McLean et al. 2007). 
For the last decade activin A has been included in most of the induction protocols, both for 
ESC and adult  SC differentiation into  DE,  and the  biggest  part  of  studies  claim positive 
results. However, others have found that stimulation of Nodal signalling with activin A is not 
sufficient to induce differentiation of DE from UC blood SCs (Filby et al. 2011).
CHIR99021. Since Wnt/β-catenin signalling is involved in the formation of DE (Zorn 
et al. 1999), fraction of induction protocols uses extrinsic factors to activate this pathway at 
the beginning of differentiation. The most commonly used is Wnt3a protein (D'Amour et al. 
2006, Kroon et al.  2008, Chen et al.  2009). Its combination with activin A is expected to 
mimic coordinated expression of Wnt/β-catenin and Nodal signalling respectively, as it would 
be during the primitive streak formation (Hosoya 2012). Some of the effects of Wnt/β-catenin 
signalling can be reached by inhibition of glycogen synthase kinase 3 β (GSK3β) activity. 
CHIR99021 is a GSK3β and GSK3α-specific inhibitor, and it can be used instead of Wnt3a. It 
has been demonstrated that a combination of activin A and CHIR99021 induces DE more 
effectively than activin A and Wnt3. Moreover, the stability and cost of CHIR99021 makes it 
more attractive candidate for induction media than Wnt3a (Kunisada et al. 2012).
Sodium  butyrate.  Histone  deacetylase  inhibitors  modulate  gene  expression  by 
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increasing  histone  acetylation,  thus  regulating  chromatin  structure  and  activating  gene 
transcription by rendering the target DNA more accessible to transcription factors (Li et al. 
2008). Sodium butyrate is a known histone deacetylase inhibitor (Candido et al. 1978) that 
can  inhibit  proliferation,  induce  differentiation,  and induce  or  repress  gene  expression  in 
mammalian  cell  cultures  (Davie  2003).  It  has  been  shown that  sodium butyrate  alone  is 
mostly ineffective in inducing endoderm differentiation of ESCs, but its combination with 
activin A generates higher levels of  SOX17,  FOXA2,  HNF4A,  and  PDX1 gene expression 
(Jiang et al. 2007).
FGF10.  Since one of the pathways involved in pancreatic development is fibroblast 
growth factor and their receptor signalling, such factors as basic FGF, FGF7, and FGF10 are 
frequently  used  in  differentiation  protocols  (Hosoya  2012).  FGF10  is  a  key  signalling 
molecule  engaged in  the  mesenchymal-epithelial  interactions  that  are  essential  during the 
early stages of pancreatic development. Its main role is to regulate the proliferation of PDX1-
positive progenitor cells and, therefore, the size of developing pancreas (Bhushan et al. 2001). 
Since persistent expression of FGF10 during embryogenesis activates Notch signalling, which 
inhibits the endocrine cell differentiation by blocking the expression of NGN3 gene, it must be 
used only in the initial steps of differentiation (Hart et al. 2003).
Retinoic acid.  It  has been demonstrated that retinoic acid signalling is essential  for 
specifying  pancreas  during  development,  and  its  role  is  conserved  among  vertebrates 
(Stafford  et  al.  2004).  Retinoic  acid  stimulates  the  generation  of  Pdx1-positive  cells  that 
coexpress a transcription factor Ptf1a, an indicator of pancreatic commitment (Micallef et al. 
2005). When used in combination with activin A during the initial steps of ESC differentiation 
protocol, induced cells express high levels of such pancreatic progenitor markers as  Pdx1, 
Hnf3B, and Hnf4A. The obtained results suggest that retinoic acid facilitates the formation of 
pancreatic precursor cells and is critical for pancreatic β cell development and maturation (Shi 
et al. 2005). If retinoic acid is not added to the induction medium, noticeable levels of NGN3, 
INS, or  GCG expression are not detected at later stages of differentiation, in spite of  PDX1 
expression (D'Amour et al. 2006).
Nicotinamide.  Already more than two decades ago nicotinamide has been shown to 
induce  differentiation  and  maturation  of  human  fetal  pancreatic  islet  cells  in  culture 
(Otonkoski  et  al.  1993).  More  recently,  many  studies  use  it  in  the  final  stages  of  their 
differentiation protocols, as addition of nicotinamide results in sustained expression of PDX1 
gene, induction of  β cell differentiation (Cho et al.  2008), increase of the insulin content 
(Vaca et al. 2003), and improvement of the yield of pancreatic endocrine cells (Jiang et al. 
2007,  Kunisada  et  al.  2012).  Furthermore,  nicotinamide  is  reported  to  protect  cells  from 
diminished sensitivity caused by prolonged exposure to high amounts of glucose present in 
differentiation medium, and it can be used to preserve viability and function of differentiated 
endocrine cells (Neshati et al. 2010).
Exendin-4. A hormone glucagon-like peptide-1 (GLP-1) is produced in the intestinal 
epithelial endocrine L-cells, and its main role is to stimulate insulin secretion and to inhibit 
glucagon  secretion  (Holst  2007).  When  GLP-1  is  added  to  the  endoderm  precursor 
differentiation medium, the level of  PDX1 and  INS transcription, as well as the amount of 
insulin-producing cells is slightly elevated. However, when sodium butyrate is used in early 
stages  of  differentiation followed by addition of  GLP-1 in  later  stages,  the expression of 
PDX1 and  later  NGN3 is  significantly  increased.  This  combination  results  in  insulin-
producing cell  increase from 8% to 45% (Li et  al.  2008).  Since natural GLP-1 is rapidly 
degraded, it is possible to replace it by its long-acting analogue exendin-4 (Xu et al. 1999). 
Exendin-4 has been isolated from the venom of the lizard Heloderma suspectum (Eng et al. 
1992),  and it  shares  53% sequence  homology with  GLP-1 and acts  as  a  GLP-1 receptor 
agonist (Göke et al. 1993). It has been shown that exendin-4 stimulates differentiation of β 
cells from ductal progenitor cells and proliferation of β cells when given to rats (Xu et al. 
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1999). High amount of the protein increases the differentiation efficiency of mouse ESCs into 
β-like cells, their insulin synthesis and release (Li et al. 2010).
DAPT.  To allow the expression of  NGN3 gene that is  recognized as a  regulator of 
pancreatic endocrine cell formation, the Notch signalling pathway must be blocked at later 
stages of differentiation. DAPT (N-[N-(3,5-difluorophenacetyl)-1-alanyl]-S-phenylglycine t-
butyl  ester)  is  a  γ-secretase  inhibitor  that  arrests  Notch  signalling  and  is  often  used  in 
pancreatic induction protocols (Champeris Tsaniras, Jones 2010). However, other evidence 
suggests  that  the  use  of  DAPT has  only  a  slight  positive  effect  on  promoting  endocrine 
differentiation (D'Amour et al. 2006).
Glucose. Fraction of induction protocols changes the glucose concentration at various 
stages of differentiation. Since it has been demonstrated that low concentrations of glucose (5 
mM) increase  insulin  content  in  islet-like  clusters,  but  higher  concentrations  (20-30 mM) 
increase replication of β cells in vivo and in vitro (Bonner-Weir et al. 1989 after Wong 2011), 
it is well founded to vary the glucose concentration to facilitate β cell replication and enhance 
insulin  content  and  its  secretion  (Wong  2011).  There  are  protocols  that  employ  high 
concentrations of glucose at the beginning of differentiation and switch to low concentrations 
at later stages (Segev et al. 2004, Kang et al. 2011, Tang et al. 2012). Reduction of glucose 
concentration at the end of induction also helps to restore the sensitivity of cells to a glucose 
challenge, often performed after the differentiation has been completed (Tang et al. 2012). 
However, others use high concentrations of glucose throughout the differentiation (Sun Y. et 
al. 2007, Neshati et al. 2010). Evidence suggests that murine BM MSCs cultured under high-
glucose for 2-4 months differentiate towards pancreatic endocrine cells (Tang et al. 2004). But 
exposure of mice to elevated blood glucose levels for only 3 days activates transcription of 
Insulin gene and produces proinsulin-positive cells in liver, adipose tissue, spleen, BM, and 
thymus suggesting that high levels of glucose could facilitate generation of insulin-producing 
cells from non-β cells (Kojima et al. 2004).
Oxygen. Low levels of oxygen (3% - 5%) have been shown to facilitate proliferation of 
SCs and maintain their undifferentiated state, while normoxic conditions (21% oxygen) tend 
to induce SC differentiation (Ezashi et al. 2005, D'Ippolito et al. 2006, Berniakovich, Giorgio 
2013). The pancreatic islets are known for their high oxygen requirements, since they make 
up only 1% - 2% of the total number of cells of the pancreas, but use 25% of the pancreatic 
oxygen supply (Fraker et al. 2007). Additional research has demonstrated that high levels of 
oxygen (35% - 80%) stimulate differentiation of endocrine cells in murine pancreatic buds 
(Fraker  et  al.  2007,  Heinis  et  al.  2010),  as  well  as  from mouse ESCs and human iPSCs 
(Hakim et al.  2014).  This is  achieved through suppression of hypoxia-inducible factor 1α 
(HIF-1α) activity. In normoxic conditions  HIF-1α protein is rapidly degraded, but hypoxic 
conditions stabilize  HIF-1α inducing its accumulation and, therefore, interaction with target 
genes  (Berra  et  al.  2006).  HIF-1α  interacts  with  the  intracellular  domain  of  Notch,  thus 
activating its signalling cascade (Gustafsson et al.  2005). On contrary, higher oxygenation 
would  destabilize  HIF-1α,  thus  inhibiting  Notch  signalling  and,  therefore,  promoting 
endocrine  differentiation.  Furthermore,  degradation  of  HIF-1α  up-regulates  Wnt/β-catenin 
signalling  pathway  that  is  critical  for  DE differentiation. Since  HIF-1α is  also  known to 
interact with histone deacetylases leading to transcriptional repression, high levels of oxygen 
could  act  similarly  to  histone  deacetylase  inhibitors  by  eliminating  HIF-1α  (Fraker  et  al. 
2009).
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2. Materials and methods
2.1. Source of biological samples
The  Latvian  Central  Medical  Ethics  Committee  has  approved  the  current  research 
involving  human  participants  (permit  No.12).  The  human  adipose  tissue  and  blood  were 
collected after written consent was obtained from the donors. Human abdominal subcutaneous 
adipose tissue and blood were derived during planned operations. Blood and tissue samples 
were processed in collaboration with “Cilmes Šūnu Tehnoloģijas” Ltd. within 3-5 hours after 
collection. 
Most of the results described in this work have been obtained from an adipose-derived 
stem cell culture originating from one donor (donor No.4) and have been supplemented with 
the experimental data from four other donors (for more information, see Table 2.1.1.).
Table 2.1.1. Information about human donors used in the current study.
Donor code 
number
Type of adipose tissue 
collected Age Gender State of health
No.3 abdominal subcutaneous 63 male healthy
No.4 abdominal subcutaneous 40 male healthy
No.5 abdominal subcutaneous 47 male healthy
No.8 abdominal subcutaneous 30 female Type 1 diabetes
No.9 abdominal subcutaneous 28 male healthy
2.2. Preparation of autologous serum
Collected blood was allowed to clot for 1 hour at room temperature. The serum was 
collected, centrifuged at 2000 rpm for 30 min, filtered through 0,2 μm mesh, aliquoted, and 
stored at -200C.
2.3. Isolation and expansion of ASCs
2-5 ml of adipose tissue were scissored and treated with 0,3% pronase (EMD Millipore, 
USA) for 1 h at RT with gentle rotation followed by centrifugation for 7 min at 1000 rpm. The 
pellet  was  suspended,  filtered  through  40  μm  mesh  and  centrifuged  again  for  5  min. 
Erythrocytes were lysed for 3 min at +370C using erythrocyte lysis buffer Hybri-Max (Sigma-
Aldrich,  Germany).  Obtained  cell  pellet  was  suspended  in  a  fresh  cell  culture medium 
(DMEM/F-12 (Life Technologies, UK) containing 10% autologous serum, 2 mM L-glutamine 
(Life Technologies, UK), 20 ng/ml basic fibroblast growth factor (BD, USA), 100 U/ml : 100 
μg/ml penicillin - streptomycin (Life Technologies, UK)) and seeded onto a 75 cm2 tissue 
culture flask (regarded as passage 0 (P0)). Cells were cultured at +370C, 5% CO2. 
Non adherent cells were removed on the next day by extensive washing with phosphate-
buffered saline (PBS) (Life Technologies, UK). The remaining cells were cultivated in the 
medium supplemented with 10% AS for first 10 days and 5% AS afterwards. The cell culture 
medium was changed every third day. When the cells reached 80-90% confluence they were 
reseeded for the propagation purposes. 
The methods of subsequent passaging and freezing of ASCs were done as follows. After 
the  second  passage,  cells  were  frozen  in  DMEM/F12  supplemented  with  10%  dimethyl 
sulfoxide  (Sigma-Aldrich,  Germany)  and 20% AS  and  stored  in  a  liquid  nitrogen. After 
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thawing ASCs were cultivated as previously through P3 to P8, freezing a fraction of cells 
before the each subsequent passage. After more than 4 years ASCs from passages 2 to 8 were 
thawed and used for the characterization. 
2.4. Karyotyping
Karyotyping of ASCs (donor No.4) was performed at passage 3. The cells were treated 
with  10  μg/ml  KaryoMAX Colcemid  (Life  Technologies,  UK)  for  30  min  at  +370C and 
detached using 0,25% trypsin/versen (Life Technologies, UK) solution for 5 min at +370C. To 
inactivate the trypsin AmnioMAX II Complete Medium (Life Technologies, UK) was added 
and the cell  suspension was centrifuged for 5 min at 1000 rpm. Resulting cell  pellet  was 
exposed to pre-warmed 1% sodium citrate solution for 45 min at +370C. After centrifugation 
for 5 min at 1000 rpm the cells were fixed three times in cold methanol/acetic acid (3:1) for 
20 min at -200C followed by repeated centrifugation as detailed above. 3 - 4 droplets of cell 
suspension in fixative was transferred to wet microscope slides, air-dried and heated for 1 h at 
+900C. Chromosomes were visualized by the standard GTG-banding technique using 0,005% 
trypsin/phosphate buffer (pH 6,8) solution for 1 min and 3% Giemsa stain for 5 min.  This 
analysis was performed in the E. Gulbja laboratory (Latvia) by I.Grīviņa.
2.5. Immunocytochemistry
The immunocytochemistry method for the detection of cell surface markers was done as 
follows. After P3 ASCs were plated onto 8 well plastic chamber slides. After 48 h the cells 
were washed with PBS (+370C) and blocked in a 6% BSA (Sigma-Aldrich, Germany)/PBS 
solution for 1 h at RT. Primary antibodies (mouse monoclonal anti-CD34 (Abcam, UK), anti-
CD45 (EMD Millipore,  USA), anti-CD73 (Invitrogen, USA), anti-CD90 (EMD Millipore, 
USA) and anti-CD105 (EMD Millipore, USA)) were diluted  in a 1% BSA/PBS (1:100) and 
incubated for 1,5 h at RT. After washing with 1% BSA/PBS, secondary antibodies (goat anti-
mouse IgG (Fab specific; FITC) (Sigma-Aldrich, Germany) and anti-mouse IgM (Alexa Fluor 
488) (Life Technologies, UK)) diluted in a 1% BSA/PBS (1:200) were applied in dark for 1 h 
at RT. The cells were washed with PBS and incubated with wheat germ agglutinin (Alexa 
Fluor®633 conjugated) (Life Technologies, UK) (10 μg/ml) for 10 min at RT. After repeated 
washing the cells were fixed with 3,7% formaldehyde (Sigma-Aldrich, Germany) for 20 min 
at +370C. Cell nuclei were counterstained with DAPI (4 μg/ml) (Sigma-Aldrich, Germany) for 
7 min. The samples were mounted in ProLong Antifade reagent (Life Technologies, UK) and 
kept in dark for 12 h at +40C. Fluorescence microscope DM 6000B (Leica, Germany) and 
laser scanning confocal system TCS SP2 SE (Leica, Germany) were used for the  analysis of 
obtained samples. 
To identify the expression of intracellular pluripotency markers the ASCs from P4 were 
grown onto 13 mm uncoated glass coverslips. When adherent ASC bodies started to form, the 
immunocytochemistry was performed as  follows:  the coverslips  were gently washed with 
prewarmed PBS, fixed in cold methanol (Sigma-Aldrich, Germany) for 10 min at -200C and 
10 times dipped in ice cold acetone. After extensive washing with 1x Tris-buffered saline 
(TBS), cells were blocked in 1% BSA/TBS solution for 15 min at room temperature. Primary 
antibodies (mouse monoclonal anti-NANOG (Sigma-Aldrich, Germany) and anti-OCT4A (sc-
5279) (Santa  Cruz  Biotechnology, USA))  were  diluted  in  1% BSA/TBS (1:100 and 1:75 
respectively) and incubated overnight at 40C. In the next day cells were washed with 1x TBS 
and secondary goat anti-mouse Alexa Fluor 488 antibody (Life Technologies, UK), diluted in 
1x  TBS  1:300,  was applied  in  dark  for  40  min  at  room temperature.  The  samples  were 
mounted in ProLong Gold Antifade reagent with DAPI (Life Technologies, UK) and analysed 
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after 12 hours using laser scanning confocal system TCS SP2 SE.
Additionally goat polyclonal anti-OCT4B (sc-8630) (Santa Cruz Biotechnology, USA) 
antibody  (dilution  1:500)  and  rabbit polyclonal  anti-NANOG (Santa  Cruz  Biotechnology, 
USA) antibody (dilution 1:150) with respective secondary rabbit anti-goat IgG Cy3 (Sigma-
Aldrich, Germany) (dilution 1:400) and goat anti-rabbit IgG Cy3 (Sigma-Aldrich, Germany) 
(dilution 1:200) antibodies were used on monolayer ASC culture of the donor No.4.
To  detect  the  intracellular  markers  confirming  the  differentiation  of  ASCs  into  a 
pancreatic  lineage,  the  following immunocytochemistry method was used.  The cells  were 
fixed with 3,7% formaldehyde for 15 min at room temperature (for anti-SOX17, anti-INS, 
anti-GCG, anti-NGN3, anti-C-peptide and anti-SST antibodies) or with cold methanol for 10 
min at -200C (for anti-PDX1 antibody). After double washing with 1x PBS, the cells were 
further incubated in 1x PBS for 15 min at room temperature. Formaldehyde fixed samples 
were  additionally  permeabilized  in  0,25%  Triton-X100  (Sigma-Aldrich,  Germany)/PBS 
solution for 20 min at  room temperature.  For a blocking of all  samples,  a 6% BSA/PBS 
solution was used for 30 min at room temperature. Primary antibodies (rabbit polyclonal anti-
SOX17, anti-PDX1, anti-NGN3 (Santa Cruz Biotechnology, USA), anti-C-peptide, anti-SST 
(Abcam, UK) and mouse monoclonal anti-INS (Santa Cruz Biotechnology, USA), anti-GCG 
(Abcam, UK)) were diluted in 1% BSA/PBS 1:100 and incubated overnight at +40C. In the 
next day cells were  washed three times with 1x PBS and secondary goat anti-rabbit Alexa 
594 or goat anti-mouse IgG (H+L) Alexa 488 antibodies (Life Technologies, UK), diluted in 
1% BSA/PBS 1:200, were applied in dark for 60 min at room temperature. After extensive 
washing,  the  samples  were  mounted  in  ProLong  Gold  Antifade  reagent  with  DAPI  and 
analysed after 24 hours using fluorescence microscope DM 3000 (Leica, Germany).
For  each  immunocytochemical  staining  negative  control  sample  with  secondary 
antibody  only  was  always  performed,  allowing  to  subtract  possible  background  staining 
caused by secondary antibody.
2.6. Multi-colour flow cytometry
Flow cytometry was performed on ASCs of the donor No.4 at P2, P3, P4, P5, and P8. 
After  more than 4 years of cryopreservation,  ASCs of each passage were rapidly thawed, 
resuspended in 2 ml of PBS, centrifuged for 5 min at 600 x g and used for immunostaining. 
Fluorochrome-labeled  anti-human  monoclonal  antibodies  to  HLA-DR-V450, 
CD14/CD19/CD45  cocktail-V500,  CD29-PerCP-Cy5.5,  CD44-APC-H7  (BD,  USA)  and 
CD34-FITC, CD105-PE, CD73-PE-Cy7, CD90-APC (eBioscience, USA) were used for 8-
colour  flow  cytometric  analysis.  Corresponding  isotype  controls  for  gate  setting  were 
included in every experiment.  In addition,  cell  viability in every sample was tested using 
Syto16 fluorescent nucleic acid stain  (Life Technologies, UK)  at FITC channel. Cells were 
stained as recommended by the manufacturers, washed with PBS, and analysed by 3-laser BD 
FACSCanto II flow cytometer (BD, USA) using FACSDiva v6.1.3 software. Obtained results 
were analysed and presented using Infinicyt  v1.5.0 (Cytognos,  Spain)  software.  The flow 
cytometry was performed by S.Ņikuļšins and U.Bērziņš.
2.7. Total RNA extraction
RNA  was  extracted  from  ASCs  using  TRI  Reagent  (Sigma-Aldrich,  Germany) 
according  to  the  manufacturer's  instructions.  Quantity  and  quality  of  the  samples  were 
assessed  by  measuring  the  concentration  of  total  RNA  and  A260/A280  ratio  using 
NanoDrop® ND-1000  spectrophotometer  (Thermo Scientific,  USA)  as  well  as  by  visual 
evaluation in 1% TBE agarose gel.
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2.8. DNase I treatment and cDNA synthesis
1  μg  of  total  RNA of  ASCs  was  treated  with  1  U  RNase-free  DNase  I  (Thermo 
Scientific,  Lithuania)  for  30 min  at  +370C to  remove traces  of  genomic  DNA. After  the 
measurement  of  concentration  of  DNase-treated  sample  with  NanoDrop®  ND-1000 
spectrophotometer,  500 ng of  RNA were  reverse  transcribed  into  cDNA with  oligo(dT)18 
primers using RevertAid first strand cDNA synthesis kit (Thermo Scientific, Lithuania) in a 
total volume of 20 μl according to the manufacturer's instructions. Minus reverse transcriptase 
(RT) sample was also prepared in the same manner by omitting RT from the reaction. 
 To obtain cDNA from human pancreas, commercially available total RNA of normal 
adult pancreas (BioChain, USA) was used according to the above-mentioned method. Except 
in  this  case  DNase  I  treatment  was  not  performed,  since  it  was  already  completed  by 
manufacturer.
Commercially available cDNA of ESCs (from total RNA at 10 ng/μl) from Human ESC 
Germ Layer PCR Kit (EMD Millipore, USA) was exploited as a positive control for detection 
of pluripotency marker genes using RT-PCR.
2.9. Reverse transcription polymerase chain reaction (RT-PCR)
RT-PCR  was  performed  to  detect  expression  of  a  housekeeping  gene  β-Actin and 
pluripotency marker genes OCT4A,  NANOG, and SOX2. Each RT-PCR reaction contained 1 
μl of ASC cDNA template or 2,5 μl of ESC cDNA template to yield equal amount of input  
cDNA, primer pairs (synthesized at Metabion, Germany) at a final concentration of 400 nM 
(for  β-Actin)  or  200  nM (for  OCT4A,  NANOG,  SOX2),  12,5  μl  of  2x  PCR Master  Mix 
containing  Taq DNA polymerase  (Thermo  Scientific,  Lithuania)  and  nuclease-free  water 
(Thermo Scientific, Lithuania) to 25 μl. The primer sequences used in RT-PCR are listed in 
Table 2.9.1.  Reactions  were carried out  in  a  GeneAmp PCR System 9700 thermal  cycler 
(Applied Biosystems, USA) under the following cycling conditions: 40 cycles (30 cycles for 
β-Actin) of 940C for 30 s, 600C - 650C (Table 2.9.1.) for 30 s and 720C for 30 s, with a final 
extension of 720C for 5 min. Minus RT controls as well as non-template control were run each 
time to inspect for possible contamination. PCR products were separated using a 3% TAE 
agarose gel electrophoresis method. 
2.10. Purification and sequencing of RT-PCR products
In order to prepare RT-PCR products for sequencing, 3 μl of each RT-PCR product were 
incubated for 60 min at  +370C with 0,5 μl of Exonuclease I (20 U/μl) (Thermo Scientific, 
Lithuania), 1 μl of Shrimp Alkaline Phosphatase (1 U/μl) (Thermo Scientific, Lithuania ) and 
2,5 μl of DEPC treated water (Thermo Scientific, Lithuania) followed by 15 min heating at 
+850C. 3 ng of the purified product were used for a direct sequencing in a 20 μl final reaction 
volume containing 4 μl of 5x sequencing buffer, 1 μl of ABI PRISM BigDye Terminator v.3.1 
Ready Reaction Mix (Applied Biosystems, USA) and primer at a final concentration of 250 
nM.  The RT-PCR product  identity  was  determined by 3130xl  Genetic  Analyser  (Applied 
Biosystems, USA).
2.11. Quantitative real-time RT-PCR
Real-time RT-PCR was used to detect the expression of surface marker genes and genes 
involved in pancreatic differentiation. It was carried out using MiniOpticon Real-time PCR 
System (Bio-Rad,  USA).  Each reaction  contained 1  μl  of  9-fold diluted  cDNA template,
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                                                                   Table 2.9.1. Primer sequences used in PCR analysis.
Analysis Gene Primer sequence (5' → 3') Annealing temperature (0C) Reference
H
ou
se
ke
ep
in
g 
ge
ne
s
β-Actin
Fw: GAGCTACGAGCTGCCTGAC
60
Rw: GGATGCCACAGGACTCCATG
GUSB
Fw: CTGCATCACCACATGCAGGTG
60
Rw: GAGTTGCTCACAAAGGTCACAGG
YWHAZ
Fw: CTACGACGTCCCTCAAACCTTG
60
Rw: CAGGCTGCCATGTCATCATATCG
Pl
ur
ip
ot
en
cy
 g
en
es
NANOG_1
Fw: CTTCCTCCATGGATCTGCTTATTCA
60
Rw: CAGGTCTTCACCTGTTTGTAGCTGAG
NANOG_2
Fw: GCTTGCCTTGCTTTGAAGCA
60 EMD Millipore kit
Rw: TTCTTGACCGGGACCTTGTC
OCT4A
Fw: GATGGCGTACTGTGGGCCC
65 Liedtke et al. 2007
Rw: TGGGACTCCTCCGGGTTTTG
SOX2
Fw: GTACTGGCGAACCATCTCTGTG
65
Rw: CCAACGGTGTCAACCTGCATG
Su
rf
ac
e 
m
ar
ke
r g
en
es
CD29
Fw: GAGAAGGATGTTGACGACTGTT
60
Rw: CAGTGGGACACTCTGGATTCT
CD44
Fw: CCTCTGCAAGGCTTTCAATA
60
Rw: CTTCTATGAACCCATACCTGC
CD73
Fw: CAGCATTCCTGAAGATCCAAG
60
Rw: GATTGAGAGGAGCCATCCAG
CD90
Fw: GTCCTCTACTTATCCGCCTTC
58
Rw: GACCAGTTTGTCTCTGAGCAC
CD105
Fw: CTCAAGACCAGGAAGTCCATA
60
Rw: GATGAGGAAGGCACCAAAG
G
en
es
 in
vo
lv
ed
 in
 p
an
cr
ea
tic
 d
iff
er
en
tia
tio
n
WNT3
Fw: GCACGACTATCCTGGACCAC
60
Rw: GAGGAAGTCACCGATGGCAC
SOX17
Fw: GCATGACTCCGGTGTGAATCT
60
Rw: CACACGTCAGGATAGTTGCAGT
SOX17_C
Fw: AGGAAATCCTCAGACTCCTGGGTT
60 Chandra et al. 2011
Rw: CCCAAACTGTTCAAGTGGCAGACA
CK19
Fw: ATATGAGGTCATGGCCGAGCAGAA
60 Chandra et al. 2011
Rw: ACTGCAGCTCAATCTCAAGACCCT
FOXA2
Fw: GGGAGCGGTGAAGATGGA
60 D'Amour et al. 2006
Rw: TCATGTTGCTCACGGAGGAGTA
FOXA2
Fw: GCGACCCCAAGACCTACAG
60 Lee et al. 2008
Rw: GGTTCTGCCGGTAGAAGGG
CXCR4
Fw: CACCGCATCTGGAGAACCA
60 D'Amour et al. 2006
Rw: GCCCATTTCCTCGGTGTAGTT
HNF1B
Fw: GGAATGCAACAGGGCAGAATGT
60
Rw: CAAACCAGTTGTAGACACGGAC
HNF1A
Fw: GAGTGCAATAGGGCGGAATG
60
Rw: CAGTTGTAGACACGCACCTC
HNF4A
Fw: CTCGGAGCCACCAAGAGATC
60
Rw: CTCGTCAAGGATGCGTATGGA
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Analysis Gene Primer sequence (5' → 3') Annealing temperature (0C) Reference
G
en
es
 in
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ed
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ea
tic
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iff
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en
tia
tio
n
PDX1
Fw: GATGAAGTCTACCAAAGCTCACGC
60
Rw: GGAACTCCTTCTCCAGCTCTAGC
NKX6-1
Fw: CTGTACCCCTCATCAAGGATC
60
Rw: GTTCGAAAGTCTTCTCCAGGG
PAX6
Fw: GTGAATGGGCGGAGTTATGAT
60
Rw: GAACTGGAACTGACACACCAG
MNX1
Fw: CTCTGGAGCCGCCATTCTG
60
Rw: CAGCAGTTTGAACGCTCGTG
INS
Fw: GGGAGGCAGAGGACCTG
60 Jiang et al. 2007
Rw: CCACAATGCCACGCTTCT
SST
Fw: CAGACTCCGTCAGTTTCTGC
60
Rw: CATCATTCTCCGTCTGGTTGG
PPY
Fw: GGCCTAGGTATGGGAAAAGAC
60
Rw: AGTCGTAGGAGACAGAAGGTG
ISL1
Fw: GTGGGCTGTTCACCAACTGTA
60
Rw: GTGAATCTGATTGCCGCAACC
GCG
Fw: CTTGGTGCAGAAGTACAGAG
60
Rw: CTGCTGTCTTCTGGTAGTGT
PTF1A
Fw: CAGAAGGTCATCATCTGCCATC
60
Rw: AGTCCATGAGAGAGAGTGTCCT
primer  pairs  (synthesized  at  Metabion,  Germany)  as  listed  in  Table  2.9.1.  at a  final 
concentration of 400 nM, 12,5 μl 2x ABsolute Blue QPCR SYBR Green Low ROX Mix 
(Thermo Scientific,  Lithuania)  and nuclease-free  water  to  25  μl.  PCR cycling  conditions 
included a 950C heating step for 15 min to activate DNA polymerase, then 40 cycles of  950C 
for 30 s,  580C - 600C (Table 2.9.1.) for 30 s and 720C for 30 s. A melting curve was generated 
at the end of every run to ensure the amplification of a single product. Minus RT controls as  
well as non-template control were run each time to inspect for possible contamination. For the 
analysis of relative gene expression 2-∆CT method was used.
PCR efficiencies of each primer pair used to detect the expression of surface marker 
genes were obtained from standard curves using 3-fold dilution series of cDNA sample. PCR 
efficiencies of all primer pairs used in the experiment were in a range from 93% to 99%. Each 
reaction was run in triplicate.
For  the  samples  obtained  during  pancreatic  differentiation  of  ASCs  only  initial 
screening  was  performed,  meaning  that  PCR efficiencies  for  each  primer  pair  were  not 
determined and no replicates were run. The differentiation samples were compared to human 
pancreas sample that served as a positive control.
2.12. Detection of alkaline phosphatase activity
Alkaline phosphatase activity was tested in the monolayer ASC culture and ASC bodies 
after the transfer to a new adherent plastic culture flask. The cell samples were fixed in 3,7% 
formaldehyde for 15 min at +40C, washed with distilled water and air-dried. To prepare a 
working solution, a Fast Blue BB salt (Lach-Ner, Czech Republic) was dissolved in a stock 
solution  (58,3  mM  naphthol  AS  phosphate  (Lach-Ner,  Czech  Republic)  dissolved  in  a 
dimethyl  sulfoxide  (final  concentration  0,583  mM),  90  mM  Tris-HCl  (Sigma-Aldrich, 
Germany), pH 9,0-9,2, 5 mM MgCl2 (Merck Millipore, Germany)) to a concentration of 1 
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mg/ml right before use. Addition of levamisole (Serva, Germany) to the working solution at a 
final concentration of 1 mM served as a negative control. After filtration the naphthol AS 
phosphate/Fast Blue BB working solution was added to the cells and incubated in dark for 25 
min at room temperature followed by washing with distilled water.
2.13. In vitro differentiation of ASCs
To induce differentiation of ASCs into adipocytes, osteoblasts and chondroblasts, the 
ASCs were cultured in the appropriate induction medium at +370C, 5% CO2. Non-induced 
cells  were maintained in a control medium.  Medium was changed every third day. Three 
replicates for each differentiation were always tested. 
2.13.1. Adipogenic differentiation
For  adipogenic  differentiation,  ASCs were  cultured  in  DMEM (high  glucose)  (Life 
Technologies,  UK)  supplemented  with  10%  FBS  (Life  Technologies,  UK),  2  mM  L-
glutamine, 10 μg/ml human insulin (Life Technologies, UK), 1 μM dexamethasone (Sigma-
Aldrich,  Germany),  100  μM  indomethacin  (Sigma-Aldrich,  Germany),  0,5  mM  isobutyl-
methylxanthine (Sigma-Aldrich, Germany), and 5 μg/ml gentamicin (Life Technologies, UK). 
DMEM  (high  glucose)  supplemented  with  10%  FBS,  2  mM  L-glutamine,  and  5  μg/ml 
gentamicin  was  used  as  a  control  medium.  Differentiation  was  confirmed  on  day  16. 
Differentiated cells were fixed with 10% formaldehyde for 1 h at RT and washed with 60% 
isopropyl alcohol. After incubation in a 0,21% Oil Red O (Sigma-Aldrich, Germany) solution 
for 10 min at RT, the cells were counterstained with hematoxylin GILL No.3 (Sigma-Aldrich, 
Germany) for 3 min.
2.13.2. Osteogenic differentiation
To promote osteogenic differentiation, ASCs were treated with DMEM (low glucose, 
without L-glutamine and phenol red) (Life Technologies, UK) supplemented with 10% FBS, 2 
mM  L-glutamine,  10  mM  glycerol-2-phosphate  (Sigma-Aldrich,  Germany),  0,1  μM 
dexamethasone, 50 μM L-ascorbic acid (Sigma-Aldrich,  Germany), and  5 μg/ml gentamicin. 
Control medium consisting of DMEM (low glucose), 10% FBS, 2 mM L-glutamine, and 5 
μg/ml gentamicin  was used for  non-induced cells  in  osteogenic,  as  well  as  chondrogenic 
differentiation.  Osteogenesis  was  demonstrated  on  day  28  using  Alizarin  Red  S  (Sigma-
Aldrich, Germany) to detect calcified extracellular matrix. Before staining cells were fixed 
with 3,7% formaldehyde for 1 h at RT followed by staining with 2% Alizarin Red S solution 
(pH 4,1 – 4,3) for 4 min.
2.13.3. Chondrogenic differentiation
For  chondrogenic  differentiation,  10  µl  of  ASCs  suspension  (concentration  8x106 
cells/ml) were allowed to attach to a plastic plate for 30 min at +370C, 5% CO2. Then control 
medium or chondrogenic differentiation medium consisting of DMEM (low glucose, without 
L-glutamine, and phenol red) supplemented with 10% FBS, 2 mM L-glutamine, 1x insulin-
transferrin-selenium-plus (BD, USA), 50 μM L-ascorbic acid, 40 μg/ml L-proline (Sigma-
Aldrich,  Germany),  0,1  μM  dexamethasone,  10  ng/ml  recombinant  human  transforming 
growth factor β3 (Life Technologies, UK), and 5 μg/ml gentamicin was added. After 29 days 
of chondrogenic induction, differentiated cells from P3 were fixed with 3,7% formaldehyde 
for 1 h at RT and then stained with 1% Alcian Blue (pH 2,5) (Sigma-Aldrich, Germany) for 
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30 min. When ASCs from P6 of the donor No.4, as well as ASCs of the donor No.5, were  
differentiated into chondrogenic lineage, the formed cell aggregates were collected, fixed in 
10% formaldehyde overnight, embedded in paraffin, sectioned, and stained with 1% Alcian 
Blue in 0,1 N HCl (pH~1,3) for 30 min followed by washing with 0,1 N HCl.
2.13.4. Differentiation into insulin-producing cells
For the  in  vitro differentiation of ASCs into insulin-producing cells  the following 5 
protocols were used (for the overview, see Table 2.13.4.1.):
2.13.4.1. Protocol 1
The ASCs from the donor No.4 after P4 were seeded at a density of 3,125x104 cells per 
cm2 and allowed to adhere for 24 h at +370C, 5% CO2 in the cell culture medium containing 
5% AS. On a next day the cells were washed with PBS to remove traces of serum and the first 
stage differentiation medium (DMEM/F12 containing 4 nM Activin A (Life Technologies, 
UK), 0,5 mM 2-mercaptoethanol (Life Technologies, UK), 1 mM sodium butyrate (Sigma-
Aldrich, Germany), 2 mM L-glutamine, 100 U/ml : 100 μg/ml penicillin - streptomycin) and 
the first stage control medium (DMEM/F12 containing 2 mM L-glutamine, 100 U/ml : 100 
μg/ml penicillin - streptomycin) were applied. After 3 days the second stage differentiation 
medium (DMEM/F12 containing 50 ng/ml recombinant human FGF10 (R&D Systems, UK), 
1x B-27 supplement (Life Technologies, UK), 2 μM retinoic acid (Alfa Aesar, UK), 2 mM L-
glutamine,  100 U/ml :  100 μg/ml  penicillin  -  streptomycin)  and the second stage control 
medium (DMEM/F12 containing 1x B-27 supplement, 2 mM L-glutamine, 100 U/ml : 100 
μg/ml penicillin -  streptomycin) were applied.  The medium was changed every third day. 
After  9  days  the  third  stage  differentiation  medium  (DMEM/F12  containing  1x  B-27 
supplement,  10  mM  nicotinamide  (Sigma-Aldrich,  Germany),  10  nM  exendin-4  (Sigma-
Aldrich, Germany), 1 μM DAPT (Sigma-Aldrich, Germany), 2 mM L-glutamine, 100 U/ml : 
100  μg/ml  penicillin  -  streptomycin)  was  applied.  The  third  stage  control  medium  was 
identical to the second stage control medium. After 21 days in the third stage differentiation 
medium the differentiation protocol was completed.
2.13.4.2. Protocol 2
The ASCs from the donor No.4 after P5 were grown at +370C, 5% CO2 in the cell 
culture medium containing 5% AS until they reached 60% confluence. Before differentiation 
the cells were washed with PBS and grown in a pre-differentiation medium (DMEM/F12 
containing 20 ng/ml recombinant human EGF (Sigma-Aldrich, Germany), 10 ng/ml bFGF, 2 
mM L-glutamine, 100 U/ml : 100 μg/ml penicillin - streptomycin) for 2 days. Afterwards the 
first  stage  differentiation  medium  (DMEM/F12  containing  4  nM  Activin  A,  0,5  mM  2-
mercaptoethanol, 1 mM sodium butyrate, 2 mM L-glutamine, 100 U/ml : 100 μg/ml penicillin 
-  streptomycin) and the control medium (DMEM/F12 containing 2 mM L-glutamine,  100 
U/ml  :  100  μg/ml  penicillin  -  streptomycin)  were  applied  and  the  cells  were  further 
differentiated at +370C, 5% CO2 and 60% O2. To maintain such a high level of oxygen in a 
cell  incubation  chamber,  the  Xvivo  System  (BioSpherix,  USA)  was  used  for  the  whole 
differentiation process.  The control  medium throughout  the Protocol  2  was identical.  The 
medium was changed every third day. After 3 days the second stage differentiation medium 
(DMEM/F12 containing 50 ng/ml recombinant human FGF10, 2 μM retinoic acid, 2 mM L-
glutamine, 100 U/ml : 100 μg/ml penicillin – streptomycin) was applied. After 6 days the third 
stage differentiation medium (DMEM/F12 containing 10 mM nicotinamide, 10 nM exendin-
4, 1  μM DAPT, 2 mM L-glutamine, 100 U/ml : 100 μg/ml penicillin - streptomycin) was 
applied. The cell differentiation in the third stage differentiation medium was discontinued 
after 12 days due to a high rate of cell detachment.
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2.13.4.3. Protocol 3
The differentiation protocol was adapted from Kang et al. 2011. The ASCs from the 
donors No.3 and No.4 after P3 were seeded at a density of 5x104 cells per well (6 well plates) 
and  grown  at  +370C,  5%  CO2 in  the  cell  culture  medium  (DMEM  low  glucose  (Life 
Technologies, UK) containing 10% FBS (Life Technologies, UK), 20 ng/ml bFGF, 100 U/ml : 
100 μg/ml penicillin - streptomycin) until they reached 80% confluence. The cells were grown 
in  the  first  stage  differentiation  medium  (DMEM  high  glucose  (Life  Technologies,  UK) 
containing  4  nM  Activin  A,  20  ng/ml  bFGF, 10  nM  exendin-4,  100  U/ml  :  100  μg/ml 
penicillin - streptomycin) and the first stage control medium (DMEM high glucose containing 
100 U/ml :  100 μg/ml penicillin  -  streptomycin)  for 3 days.  Afterwards the second stage 
differentiation medium and the second stage control medium (both the same as in the first 
stage only each supplemented with 10% FBS) were applied.  After 3 days the third stage 
differentiation  medium  (DMEM  low  glucose  containing  4  nM  Activin  A,  10  mM 
nicotinamide, 10 nM exendin-4, 10% FBS, 100 U/ml : 100 μg/ml penicillin – streptomycin) 
and the third stage control medium (DMEM low glucose containing 10% FBS, 100 U/ml : 
100 μg/ml penicillin – streptomycin) were applied. The medium was changed every third day. 
After  15  days  in  the  third  stage  differentiation  medium  the  differentiation  protocol  was 
completed.
2.13.4.4. Protocol 4
The differentiation protocol was adapted from Chandra et al. 2011. The ASCs from the 
donors No.3 and No.4 after P3 were seeded onto low attachment plates at a density of 7,5x105 
cells per well (6 well plates) and grown at +370C, 5% CO2 in the first stage differentiation 
medium (DMEM/F12 containing 4 nM Activin A, 50 μM 2-mercaptoethanol, 1 mM sodium 
butyrate, 1% BSA (Sigma-Aldrich, Germany), 2 ng/ml bFGF, 5  μg/ml human recombinant 
insulin (Life Technologies, UK), 5 μg/ml human transferrin (Sigma-Aldrich, Germany), 100 
U/ml : 100 μg/ml penicillin – streptomycin) or in the first stage control medium (DMEM/F12 
containing 1% BSA, 100 U/ml : 100 μg/ml penicillin – streptomycin) for 3 days. Afterwards 
the second stage differentiation medium (DMEM/F12 containing 1% BSA, 5  μg/ml human 
recombinant insulin, 5 μg/ml human transferrin, 0,3 mM taurine (Sigma-Aldrich, Germany), 
100  U/ml  :  100  μg/ml  penicillin  –  streptomycin)  was  applied.  The  second  stage  control 
medium  was  identical  to  the  first  stage  control  medium.  After  3  days  the  third  stage 
differentiation  medium (DMEM/F12  containing  1,5% BSA,  5  μg/ml  human  recombinant 
insulin, 5 μg/ml human transferrin, 3 mM taurine, 100 nM exendin-4, 1 mM nicotinamide, 1x 
non-essential  amino  acids  (Life  Technologies,  UK),  100  U/ml  :  100  μg/ml  penicillin  – 
streptomycin) and the third stage control medium (DMEM/F12 containing 1,5% BSA, 100 
U/ml : 100 μg/ml penicillin – streptomycin) were applied. The medium was changed every 
third day. After 15 days in the third stage differentiation medium the differentiation protocol 
was completed.
2.13.4.5. Protocol 9
The ASCs from the donors No.4 and No.8 after P3 were grown at +370C, 5% CO2 in the 
cell culture medium (DMEM/F12 containing 10% FBS, 20 ng/ml bFGF, 2 mM L-glutamine, 
100  U/ml  :  100  μg/ml  penicillin  -  streptomycin)  until  they  reached  80%  confluence. 
Afterwards  the  cells  were  grown  in  the  first  stage  differentiation  medium  (DMEM/F12 
containing 4 nM Activin A, 0,5 mM 2-mercaptoethanol, 1 mM sodium butyrate, 0,2% FBS, 
50 μM LY294002 (Cayman Chemical, USA), 3 μM CHIR99021 (Cayman Chemical, USA), 
100  U/ml  :  100  μg/ml  penicillin  -  streptomycin)  or  the  first  stage  control  medium 
(DMEM/F12 containing 0,2% FBS, 100 U/ml : 100 μg/ml penicillin - streptomycin) for 1 day. 
Then the second stage differentiation medium (DMEM/F12 containing 4 nM Activin A, 0,5 
mM 2-mercaptoethanol, 1 mM sodium butyrate, 2% FBS, 50 μM LY294002, 100 U/ml : 100 
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μg/ml  penicillin  -  streptomycin)  and  the  second  stage  control  medium  (DMEM/F12 
containing  2% FBS,  100 U/ml  :  100 μg/ml  penicillin  –  streptomycin)  were applied.  The 
control medium throughout the next stages of the Protocol 9 was identical to the second stage 
control medium. After 3 days the third stage differentiation medium (DMEM/F12 containing 
1x B-27 supplement, 2  μM retinoic acid, 50 ng/ml FGF10, 2% FBS, 100 U/ml : 100 μg/ml 
penicillin - streptomycin) was applied. The medium was changed every third day. After 5 days 
the fourth stage differentiation medium (DMEM/F12 containing 1x B-27 supplement, 10 mM 
nicotinamide,  10 nM exendin-4,  10  μM dexamethasone,  2% FBS,  100 U/ml :  100 μg/ml 
penicillin  –  streptomycin)  was  applied.  After  12  days  in  the  fourth  stage  differentiation 
medium the differentiation protocol was completed.
2.13.5. Differentiation into cells of endodermal lineage
For the in vitro differentiation of ASCs into cells of endodermal lineage the ASCs from 
the donors No.4 and No.9 after P3 were grown at +370C, 5% CO2 in the cell culture medium 
(DMEM/F12 containing 10% FBS, 20 ng/ml bFGF, 2 mM L-glutamine, 100 U/ml : 100 μg/ml 
penicillin  -  streptomycin)  until  they reached 80% confluence.  Afterwards  the following 4 
protocols were used (for the overview, see Table 2.13.5.1.):
2.13.5.1. Protocol 5
The cells were grown in the first stage differentiation medium (DMEM/F12 containing 
4 nM Activin A,  0,5 mM 2-mercaptoethanol,  1  mM sodium butyrate,  0,2% FBS,  50  μM 
LY294002, 3  μM CHIR99021, 100 U/ml : 100 μg/ml penicillin - streptomycin) or the first 
stage control medium (DMEM/F12 containing 0,2% FBS, 100 U/ml : 100 μg/ml penicillin - 
streptomycin)  for  3  days.  Then  the  second  stage  differentiation  medium  (DMEM/F12 
containing 4 nM Activin A, 0,5 mM 2-mercaptoethanol, 1 mM sodium butyrate, 2% FBS, 50 
μM LY294002, 100 U/ml : 100 μg/ml penicillin - streptomycin) and the second stage control 
medium (DMEM/F12 containing 2% FBS, 100 U/ml : 100 μg/ml penicillin - streptomycin) 
were applied.  After  6  days  in  the  second stage  differentiation  medium the  differentiation 
protocol was completed.
2.13.5.2. Protocol 6
The differentiation protocol was adapted from Buang et al. 2012. The cells were grown 
in the first stage differentiation medium (DMEM high glucose containing 4 nM Activin A, 
0,2% FBS,  10  mM  nicotinamide,  10  nM  exendin-4,  100  U/ml  :  100  μg/ml  penicillin  - 
streptomycin) or the first stage control medium (DMEM/F12 containing 0,2% FBS, 100 U/ml 
:  100  μg/ml  penicillin  -  streptomycin)  for  3  days.  For  the  next  4  days  almost  the  same 
differentiation and control media were applied only 2% FBS was used instead of 0,2% FBS.
2.13.5.3. Protocol 7
The differentiation protocol was adapted from Gao et al. 2008. The cells were grown in 
the first  stage differentiation medium (DMEM high glucose containing 10% FBS, 10  μM 
retinoic acid, 100 U/ml : 100 μg/ml penicillin – streptomycin) or in the first stage control 
medium (DMEM high  glucose  containing  10% FBS,  100  U/ml  :  100  μg/ml  penicillin  - 
streptomycin) for 24 h. For the next 2 days the differentiation medium was replaced with the 
first stage control medium. 
2.13.5.4. Protocol 8
The differentiation protocol was adapted from Sun Y. et al. 2007. The cells were grown 
in  the  first  stage  differentiation  medium  (DMEM  high  glucose  containing  0,5  mM  2-
mercaptoethanol, 100 U/ml : 100 μg/ml penicillin – streptomycin) or in the first stage control 
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medium (DMEM high glucose containing 100 U/ml : 100 μg/ml penicillin - streptomycin) for 
2 days. Then the second stage differentiation medium (DMEM high glucose containing 1x 
non-essential amino acids, 20 ng/ml bFGF, 20 ng/ml EGF, 2x B-27 supplement, 2 mM L-
glutamine,  100  U/ml  :  100  μg/ml  penicillin  –  streptomycin)  or  the  second  stage  control 
medium  (DMEM  high  glucose  containing  2  mM  L-glutamine,  100  U/ml  :  100  μg/ml 
penicillin  -  streptomycin)  were  applied.  After  8  days  in  the  second  stage  differentiation 
medium the differentiation protocol was completed.
Table 2.13.5.1. Overview of experimental protocols used to differentiate ASCs into cells of 
endodermal lineage.
Days 1 2 3 4 5 6 7 8 9 10 Reference
Pr
ot
oc
ol
 5
DMEM/F12
Activin A
LY294002
CHIR99021
FBS
Sodium butyrate
2-Mercaptoethanol
DMEM/F12
Activin A
LY294002
FBS
Sodium butyrate
2-Mercaptoethanol
Pr
ot
oc
ol
 6 DMEM high glucose
Activin A
FBS
Nicotinamide
Exendin-4
Buang et al. 
2012
Pr
ot
oc
ol
 7
DMEM high glucose
FBS
Retinoic acid
DMEM high glucose
FBS
Gao et al. 
2008
Pr
ot
oc
ol
 8
DMEM high glucose
2-Mercaptoethanol
DMEM high glucose
Non-essential amino acids
bFGF
EGF
B-27
Sun Y. et al. 
2007
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3. Results and discussion
3.1. Characterization of ASC morphology and growth aspects
ASCs from fat tissue of the donor No.4 were isolated as described in section “Materials 
and  Methods”.  Plastic-adherent  cell  population  could  be  observed  on  the  next  day  after 
isolation.  Most of the cells  were rounded, but few spindle-shaped cells  with fibroblastoid 
morphology, characteristic to MSCs (Zuk et al. 2001, Romanov et al. 2005, Kern et al. 2006), 
were  observed  (Figure  3.1.1.A).  A day  later  practically  all  cells  exhibited  typical  MSC 
morphology (Figure 3.1.1.B) and after eight days of growth even monolayer of ASCs was 
formed (Figure 3.1.1.C). The first ten days ASCs were grown in a medium supplemented with 
10% AS but this was reduced to 5% afterwards. In our study we substituted a FBS, which is  
routinely used to supplement most of the cell culture media, with an AS. Since ASCs have a 
significant therapeutic potential, all possible threats must be eliminated to ensure the safety of 
ASCs intended for  the  future  clinical  use.  The greatest  concerns  arise  about  FBS.  While 
dangers of prion diseases and zoonoses from the FBS are considered to be minimal (Doerr et 
al. 2003), it has been shown that 108 MSCs grown in the medium supplemented with 20% 
FBS would carry 7-30 mg of FBS proteins leading to possible autoimmune reaction against 
patient's  own stem cells  (Spees  et  al.  2004).  To avoid this  risk,  we used AS instead and 
characterized various aspects of ASCs grown in such medium.
Figure 3.1.1.  Morphology of ASCs from the donor No.4. (A) ASCs on the next day after 
isolation. (B) ASCs 2 days after isolation. (C) Monolayer of ASCs 8 days after isolation. Scale 
bar 100 μm (50 μm for Figure 3.1.1.A).
In order to characterize ASCs at subsequent passages, after the second passage cells 
were frozen and stored in a liquid nitrogen for two months. After thawing, ASCs were seeded 
onto tissue culture flasks (regarded as P3) and cultured as previously (Figure 3.1.2.A). When 
cells reached 80% confluence, they were trypsinized and subcultured, freezing a part of cells 
in parallel. During passaging the cells preserved their fibroblast-like morphology till inspected 
eighth  passage  (Figure  3.1.2.B,  D),  showing  that  ASCs  could  be  easily  and  effectively 
cultured and propagated in the medium supplemented with 5% AS without the loss of their 
typical MSC morphology.
Figure 3.1.2. Morphology of ASCs from the donor No.4 at different passages. (A) ASCs at 
passage 3. (B) ASCs at passage 6. (C) ASCs at passage 8. Scale bar 100 μm.
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To verify that obtained ASCs do not have any genetic abnormalities, karyotype analysis 
was performed after third passage for ASCs of the donor No.4. Karyotype of normal man (46, 
XY) was detected and changes in number or structure of chromosomes were not discovered 
(Figure 3.1.3.).
Figure 3.1.3.  Karyotype of ASCs from the donor No.4 after the third passage. Number of 
metaphases analysed – 16. Author I.Grīviņa.
Under some presumed stress conditions the ASCs from the donor No.4 started to form 
cell  aggregates. During a cultivation of ASCs from this donor we observed four different 
types  of  aggregates.  The  first  and  the  most  common  type  was  plastic-adherent  ASC 
aggregates (Figure 3.1.4.). The cells in a ASC monolayer started to  congregate into clusters 
until all cells were assembled into distinct aggregates. The exact reason provoking this type of 
cell clustering is unknown. We assume that this was an ASC response to a stress caused by 
slight  changes  in  the  culture  medium,  growth environment  or  culture  conditions. Similar 
plastic-adherent ASC aggregates were observed in the ASC cultures from few other donors, 
however, the occurrences and cell aggregate numbers were much lower.
Figure 3.1.4. Plastic-adherent ASC aggregates of donor No.4 (A-C). Scale bar 50 μm.
The second type of ASC aggregates was detected only at early passages (P1-P3). Above 
the monolayer of ASCs, floating cell  bodies were observed in the uppermost layer of the 
medium after each change of the fresh medium that also included a brief wash with a PBS. 
Initially they were detected as faint clumps (Figure 3.1.5.A) resembling dead cells. But the 
ASCs in these clusters continued to divide and grow (Figure 3.1.5.B) and started to form 
compact  structures  (Figure  3.1.5.C).  These  cell  bodies  began  to  congregate  into  clusters 
(Figure 3.1.5.D), eventually forming large aggregates of interconnected ASC bodies (Figure 
3.1.5.E, F). Since the medium was changed every third day and the ASC bodies were removed 
together with the old medium, no more than 72 hours were needed for the formation of the 
observed  large  aggregates.  Floating  ASC aggregates  in  different  sizes  could  be  observed 
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simultaneously in each tissue culture flask. Both single bodies (Figure 3.1.6.A) and smaller or 
larger aggregates of ASC bodies (Figure 3.1.6.B, C) could be seen. Their dense structure and 
size made it possible to easily detect ASC aggregates even with a naked eye.
Figure 3.1.5. Formation  of  floating  aggregates  of  ASC bodies.  (A-F) Different  stages  of 
development of cell aggregates at P1. Scale bar 100 μm (50 μm for Figure 3.1.5.B).
Figure 3.1.6. Types of floating ASC bodies. (A) Single ASC body. (B) Small aggregate of 
ASC bodies.  (C)  Large  aggregate  of  ASC bodies.  Scale  bar  100 μm (50  μm for  Figure 
3.1.6.A).
When individual floating ASC bodies were transferred onto new adherent plastic tissue 
culture flasks, they adhered to the surface within 24 hours. The new ASCs started to migrate 
out of the cell body soon after, ultimately covering the available growth surface and reducing 
the  volume  and  density  of  initial  ASC  body  (Figure  3.1.7.A-C).  Since  the  size  and 
compactness of original ASC bodies differed, it is not possible to precisely define the time 
needed for the ASC body to completely disappear forming new cell monolayer after transfer 
to the new tissue culture flask. Smaller ASC bodies can transform after a week, while bigger 
ASC bodies can still be observed after a month. This experiment showed that such culture 
medium where FBS is substituted with AS not only supports the formation of 3D bodies, but  
also facilitate growth of the new ASC monolayer after the body transfer onto new adherent 
culture flask.
In order to test the influence of medium on above-mentioned process, single floating 
ASC bodies were transferred onto new adherent plastic tissue culture flasks and cultivated in 
three  different  media.  In  one  case  the  commercial  medium  MesenPRO  RS™  (Life 
Technologies,  UK) containing 2% FBS was used.  For  the other  two experiments the cell
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Figure 3.1.7. Cell growth after the transfer of single ASC bodies onto adherent cell culture 
plates. (A) ASC body after 3 days. (B) ASC body after 10 days. (C) ASC body after 30 days. 
Scale bar 100 μm.
growth medium was applied, but AS was substituted with 5% serum from different human 
donors  (donors  No.10 and No.11).  After  48 hours  most  of  the ASC bodies  grown in the 
medium supplemented with human serum were attached to the surface and gradual expansion 
of spindle-shaped ASCs around the ASC body could be observed (Figure 3.1.8.A and D). In 
the MesenPRO RS™ medium none of  the ASC bodies  was adhered to  the flask (Figure 
3.1.8.G). Using commercial medium, four days were needed for few ASC bodies to attach to 
the surface and plastic-adherent cell growth (Figure 3.1.8.H), while in the medium containing 
human serum every ASC body was attached to the flask and dynamic expansion of cells could 
Figure 3.1.8. Cell growth in the different cell culture media after the transfer of ASC bodies 
onto adherent cell  culture plates.  (A-C) ASC body in the medium supplemented with 5% 
serum from donor No.10. (D-F) ASC body in the medium supplemented with 5% serum from 
donor No.11. (G-I) ASC body in the commercial medium MesenPRO RS™. Scale bar 100 
μm.
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be seen (Figure 3.1.8.B and E). After 10 days ASC bodies in the medium with 5% human 
serum were surrounded by extensive cell monolayer (Figure 3.1.8.C and F), whereas in the 
MesenPRO RS™ medium intense migration of ASCs out of the bodies was not observed 
(Figure 3.1.8.I) and few ASC bodies were still floating.
The third type of ASC aggregates was observed when ASCs were grown on an uncoated 
glass surface. In this case ASCs initially formed a monolayer and soon after started to cluster 
(Figure 3.1.9.A). More of the cells were huddled together creating an adherent ASC bodies 
(Figure 3.1.9.B). Eventually most of the ASCs were assembled into dense ASC bodies (Figure 
3.1.9.C) that could remain adhered to the surface or detach and form floating ASC bodies. But 
contrary  to  the  second  type  of  ASC  bodies,  this  type  of  floating  bodies  did  not  form 
aggregates.
Figure  3.1.9. Formation  of  adherent  ASC  bodies  onto  a  glass  surface.  (A)  ASCs  in  a 
monolayer start to gather into clusters (day 2). (B) As more ASCs are congregated in the 
clusters, ASC bodies are formed (day 5). (C) Eventually most of the monolayer ASCs are 
clustered into dense bodies (day 8). Scale bar 100 μm.
The fourth type of ASC aggregates could be obtained when a cell culture medium was 
not  changed  for  a  prolonged  time  (7  –  10  days)  (Figure  3.1.10.).  Such stress  conditions 
facilitated formation of floating ASC bodies, however, they differed from the floating ASC 
bodies observed during the early passages. In this case compact ASC bodies in different sizes 
were recognized in a medium, but different stages of development of cell bodies were not 
detected and they did not congregate into clusters and form large aggregates of interconnected 
ASC bodies. These ASC bodies could be easily collected and transferred onto new adherent 
plastic culture flask (Figure 3.1.11.A). Similarly to the second type of ASC aggregates, they 
rapidly adhered to the surface and within 12 hours new ASCs extensively migrated out of the 
cell body (Figure 3.1.11.B). 24 hours later most of the ASC aggregates had disappeared giving 
rise to a dense monolayer of ASCs (Figure 3.1.11.C).
Figure 3.1.10. Floating ASC bodies formed after extended periods of not changing a cell 
medium. Scale bar 100 μm (50 μm for Figure 3.1.10.C). Author U.Bērziņš. 
After a transfer onto new plastic tissue culture flasks spontaneously formed floating 
ASC bodies (the second and the fourth type), irrespective of their size, were capable to adhere 
to the surface and gradual spread of spindle-shaped ASCs out of the bodies was observed.
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Figure 3.1.11. Cell growth after the transfer of floating ASC bodies onto new adherent cell 
culture plate. (A) ASC bodies immediately after the transfer. (B) ASC bodies after 12 hours. 
(C) ASC bodies after 36 hours. Scale bar 100 μm. Author U.Bērziņš.
This  ability  of three-dimensional  (3D) spheroids  to convert  back to  functional  monolayer 
culture has been also described for MSC aggregates obtained by other methods (Kruse et al. 
2004,  Bartosh  et  al.  2010,  Cheng  N.C.  et  al.  2012).  Our  results  regarding  ASC  bodies 
observed at early passages showed that even the replacement of autologous serum in the cell 
growth medium with allogeneic sera did not impede this process, while commercial medium 
MesenPRO  RS™ delayed the attachment of ASC bodies to the surface and reorganization 
back to 2D culture (based on a visual assessment). It is known that the addition of FBS to 
MSC culture medium is essential for the attachment and proliferation of the cells (Lennon et 
al. 1996). Since the MesenPRO RS™ medium contains only 2% FBS and is adapted to the 
expansion of monolayer MSCs above clonal densities (according to manufacturer), it may not 
be suitable for the analysis of growth properties of ASC bodies. 
When a cell growth after the transfer of ASC body onto new adherent cell culture plate 
is  compared between the  floating  ASC bodies  formed at  early  passages  and ASC bodies 
formed after prolonged periods in an unchanged medium, the difference in time needed to 
reduce the volume of initial ASC body could be observed. The ASC bodies obtained after 
extended periods of not changing a cell medium adhered more quickly to the surface and 
formed uniform monolayer  of ASCs within few days,  while  ASC bodies formed at  early 
passages  could  still  be  detected  after  a  month  following  the  transfer  onto  new  plate. 
Presumably this was related to a size and formation characteristics of the ASC bodies. The 
ASC bodies obtained when a cell culture medium was not changed for a prolonged time were 
comparatively smaller. Visual assessment indicated that a number of cells forming these ASC 
bodies was smaller and their arrangement was less dense when compared to the second type 
of ASC bodies. The organization of ASC bodies from early passages was more condensed, as 
during their assembly the cells were tightly interconnected forming a very solid structure. It is  
possible that compactness and a greater number of cells arranged in these ASC bodies did not 
favor  their  complete  transformation  back to  monolayer  culture  as  quickly  as  in  the  ASC 
bodies obtained after extended periods of unchanged cell medium.
We have obtained and propagated ASCs from 10 different human donors, but only in 
one case (donor No.4) have observed the spontaneous formation of herein described types of 
the ASC bodies (the experiments of ASC growth on a glass surface and without the change of 
a culture medium were not performed on ASCs from other donors). It seems that the cell  
aggregation in ASC bodies was triggered under various stress conditions that could not always 
be precisely determined.  Since donor-to-donor variability in adult stem cell cultures covers 
diverse aspects of their characteristics (Siegel et al. 2013), it is possible that stress tolerance 
also varies between donors and the ASCs of donor No.4 are more sensitive. The first type of 
ASC bodies was most probably formed in the influence of stress caused by slight changes in 
the growth environment. A direct explanation for an aggregation of the second type of ASC 
bodies was not found. They appeared to form at early passages after each change of fresh 
medium that also included a brief wash with a PBS. Presumably a slight wash of ASCs from 
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this particular donor with PBS was sufficient to trigger a stress response in a form of cell 
aggregation. The third type of ASC bodies was apparently assembled in a response to stress 
created by unsuitable growth surface.  Since ASCs are plastic adherent and their growth and 
morphological characteristics can be influenced when expanded on the untreated glass surface 
(Ho et  al.  2006),  it  is  feasible  to  suspect  that  reduced cell  attachment  ability  caused the 
clustering of ASCs and their assembly into the bodies. The fourth type of ASC bodies was 
likely formed as a reaction to stress caused by altered composition of a culture medium due to 
a prolonged periods without a change of fresh medium. 
In the last few years 3D culture method has become progressively acknowledged as a 
tool to increase differentiation properties and therapeutic potential of adult stem cells (Bartosh 
et  al.  2010,  Frith  et  al.  2010,  Baraniak  and  McDevitt  2012,  Cerwinka et  al.  2012).  This 
method has been commonly used in ESC cultures. When cultured in the absence of leukemia 
inhibitory factor or mouse embryonic fibroblasts, a spontaneous differentiation and formation 
of 3D aggregates of ESCs is observed. These aggregates are called embryoid bodies (EBs) 
(Kurosawa 2007). Over time EBs increase in cell number and complexity as they give rise to 
cells of all the three germ layers (Dang et al. 2002). The 3D culture method has also been 
widely exploited in neural stem cell studies to propagate, characterize and assay these cells by 
means of neurosphere system (Jensen, Parmar 2006) and in cancer research to simulate the 
tumor environment (Ivascu, Kubbies 2006). In order to obtain 3D adult stem cell aggregates, 
such methods as  cell  culture onto non-adherent  surfaces,  hanging drop technique,  forced-
aggregation, surface treatment, and microfabrication have been used (for review, see Sart et 
al.  2014).  There  is  evidence  that  3D culture  methods  facilitate  higher  cell-cell  and  cell-
extracellular matrix interactions and are believed to hold a greater promise in mimicking in  
vivo environment than monolayer culture (Frith et al. 2010, Baraniak and  McDevitt 2012). 
Such ASC aggregates show enhanced transdifferentiation capabilities not only into cells of 
mesodermal origin, but also into cells of endodermal and ectodermal origin (Cheng N.C. et al. 
2012).
During our literature search we have not come across similar studies showing various 
types  of  spontaneously  formed  ASC  aggregates.  Cell  aggregates  comparable  to  herein 
described  first  type  of  ASC  bodies  have  been  reported  in  the  course  of  pancreatic 
differentiation  of  MSCs  (Sun  et  al.  2007,  Neshati  et  al.  2010,  Tang  et  al.  2012).  The 
appearance of these aggregates is perceived as a successful sign of MSC differentiation into 
insulin-producing cells, because their morphology is similar to pancreatic islets. These islet-
like  structures  often  stain  positive  for  dithizone  as  well,  which  is  a  selective  stain  for 
pancreatic β cells. However, there is a possibility that reported cell aggregation itself is not an 
evidence of MSC differentiation,  but simply cell  response to stress caused by suboptimal 
conditions of the differentiation.
Regarding  the  stress-caused  aggregation  of  adult  stem cells,  it  has  been  previously 
shown that adult human mesenchymal cell populations contain a specific type of stem cells, 
called Muse cells,  able to form clusters in suspension culture after subjection to different 
stress conditions (Kuroda et al. 2010). It is possible to draw few parallels between our ASCs 
and Muse cells, but the formation of 3D aggregates is antipodal. While enduring and severe 
stress  is  the  main  criteria  to  isolate  Muse  cells  from  overall  cell  culture,  our  ASCs 
spontaneously formed 3D bodies even by a slightest stress that is normally considered routine 
(short wash with PBS between a change of medium). 
3.2. Various marker expression in ASCs
3.2.1. Surface markers
One of the minimal criteria, set for the identification of MSCs, is the expression of such 
surface markers as CD105, CD73, CD90 and the lack of expression of CD45, CD34, CD14, 
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CD19, HLA-DR surface molecules (Dominici et al., 2006). To define ASCs, this list has been 
extended  with  CD9,  CD10,  CD13,  CD29,  CD44,  CD54,  CD55,  CD59,  CD106,  CD146, 
CD166,  HLA I  as  positive and CD31,  CD80,  CD117,  CD133,  CD144,  c-kit,  STRO-1 as 
negative markers (Schäffler and Büchler 2007). Each of above mentioned surface markers 
could be found on different types of cells and neither of them is unique to MSC. Currently 
there is a lack of specific marker that would allow to detect exclusively MSC, therefore a 
group of markers is needed to verify identity of isolated cell population (Lv et al. 2014).
Analysis of MSC surface markers was performed on ASCs of the donor No.4 after P3 
using immunocytochemistry method. The obtained results showed that at least 95% (visual 
assessment) of the ASC population express CD73, CD90, and CD105, but lack expression of 
CD34 and CD45 (Figure 3.2.1.1.) that is consistent with previous reports (Zuk et al. 2002, 
Seo et al. 2005, Fraser et al. 2006, Kern et al. 2006, Taléns-Visconti et al. 2006). To verify that 
the detected MSC markers are indeed on the surface of the cells, a plasma membrane of ASCs 
was  simultaneously  labeled  with  wheat  germ  agglutinin  (WGA)  conjugated  with  Alexa 
Fluor®633. As shown in a Figure 3.2.1.2. the exact colocalization of surface markers and 
WGA can be observed indicating that CD73, CD90 and CD105 are found on the plasma 
membrane.
Figure 3.2.1.1. Expression of typical MSC surface markers on ASCs of the donor No.4 after 
the third passage.  (A) CD34.  (B) CD45.  (C) CD73.  (D) CD90.  (E)  CD105.  (F)  negative 
control, secondary antibody only. Cell nuclei stained with DAPI. Magnification 200x. Author 
R.Brūvere.
In order to obtain more accurate data on the amount of ASCs expressing MSC surface 
markers and their changes during the passages, a flow cytometric analysis was performed on 
ASCs of the donor No.4 cryopreserved after passages 2, 3, 4, 5, 8 and stored for more than 4 
years. Here we have tested ASCs starting from P2. We have chosen this passage because from 
the 5 ml of fat tissue as an initial material we can harvest around 107 cells at the end of P2 that 
are frozen for a long term storage until the clinical necessity for the potential patient may 
arise. Fraction of the cryopreserved cells can be thawed, propagated and used for various 
assays based on potential patient's needs at any moment. We have determined that 5 ml of fat  
tissue yield approximately 109 ASCs at the end of P5 at our culture conditions using 5% AS. It 
is sufficient for 3-4 repeated injections of ASCs for a 90-100 kg patient using therapeutic dose 
of 3x106 cells per kg of body weight. 
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Figure 3.2.1.2. Colocalization of MSC surface markers CD34, CD45, CD73, CD90, CD105, 
and  wheat  germ agglutinin  (WGA)  on  ASCs  of  the  donor  No.4  after  the  third  passage; 
analysis  of  confocal  laser  scanning  microscopy.  Cell  nuclei  stained  with  DAPI. Author 
R.Brūvere. 
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When  clinical  need  for  the  potential  patient  emerges,  ASCs  from  P2  are  thawed, 
expanded till P5 and frozen again. It is important because a) cellular properties must be tested 
again before injection at the given time point; b) the ability of potential patient to receive the 
therapy may not coincide with the time of readiness of ASCs; c) the planned time of injection 
may be delayed; d) preparation of ASC material can be performed remotely from a medical 
institution. We used flow cytometry analysis to determine the changes in cell surface marker 
expression at  different passages of ASCs after  more than 4 years of cryopreservation and 
double  freezing  immediately  after  thawing  as  it  would  be  just  before  stem cell  injection 
therapy.
Cell  viability  test  (Syto  16  staining),  which  was  carried  out  for  each  thawed  vial, 
showed  that  concentration  of  live  cells  in  all  samples  was  at  least  95%.  8-colour  flow 
cytometry was used to test  10 different  cell  surface markers simultaneously on each cell. 
Obtained results  showed that  all  the  cells  were  positive  for  MSC markers  CD29,  CD44, 
CD73, CD90, CD105 and negative for such markers as HLA-DR, CD34 and a cocktail of 
CD14/CD19/CD45.  While  comparing  mean  fluorescence  intensity  of  individual  markers 
through  different  passages  tested,  an  increase  of  marker  fluorescence  intensity  in  each 
subsequent  passage  was  observed,  except  for  a  sharp  decline  in  CD44 expression  at  P5 
(Figure  3.2.1.3.).  Since  the  ASC  population  remained  phenotypically  homogeneous, 
expressing  CD29,  CD44,  CD73,  CD90,  and  CD105  throughout  all  passages  tested,  the 
increase in fluorescence intensity may indicate the accumulation of protein expression with 
subsequent passaging. When fluorescence intensity was compared between markers, it can be 
seen that CD90 was the most abundant marker on the surface of ASCs followed by CD29 and 
CD73, but CD105 showed the lowest level of expression throughout all passages. Collected 
data suggest that the peak of protein expression for CD73 and CD44 markers can be observed 
at P5 or P4 respectively, but in case of CD29, CD90 and CD105 the increase until P8 can be 
detected.
Figure 3.2.1.3. Fluorescence intensity analysis of cell surface marker expression on ASCs of 
the donor No.4 at different passages. Results are shown as box plots with median value (line), 
25th and 75th percentiles as box and 10th and 90th percentiles as whiskers. Data analysis by 
Infinicyt  software  (v1.5.0).  Asterisks  at  passage  with  the  highest  fluorescence  intensity 
indicate statistically significant increase when compared to P2. *** p < 0.001. IC – isotype 
control; P – passage; a.u. - arbitrary units. Author S.Ņikuļšins.
To complement the flow cytometry data, the expression of positive MSC surface marker 
genes was analysed with real-time RT-PCR (Figure 3.2.1.4.). Obtained results showed that the 
expression of  CD29,  CD44,  CD73, and  CD90 genes increased until P4 or P5 and reduced 
afterwards, but the highest level of  CD105 gene expression was detected at P2 followed by 
decline in subsequent passages.
The immunocytochemistry method gave us an insight into overall expression of each of 
the positive surface markers tested, but the 8-colour flow cytometry analysis allowed us to 
detect 10 cell surface markers simultaneously on each cell. The results showed that all ASCs, 
cultured in the medium containing AS, express typical MSC markers CD29, CD44, CD73, 
CD90, and CD105 concurrently irrespective of passage, demonstrating a very homogeneous
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Figure 3.2.1.4. Comparison of  relative  expression  level  of  positive  MSC surface  marker 
genes CD29, CD44, CD73, CD90, and CD105 in ASCs of different passages by real-time RT-
PCR (data normalized to β-Actin). Data represent the mean ± SD of triplicates. An asterisk at 
passage with the highest expression indicates statistically significant increase when compared 
to P2; *p < 0.05, **p < 0.01. P – passage.
cell  population  as  of  P2.  However, median fluorescence  intensity  of  positive cell  surface 
markers increased with each subsequent passage. Negative markers such as HLA-DR, CD34, 
CD14,  CD19,  and  CD45  were  not  detected.  Other  reports  have  demonstrated  the 
incrementation  of  expression  pattern  of  positive  MSC  surface  markers  with  passages 
(Mitchell et al. 2006, Varma et al. 2007, Park and Patel 2010), while others have not detected 
the difference from P3 to P12 (Yang et al. 2011). The greatest disagreements exist over the 
expression of CD34 in ASCs. Few studies failed to detect CD34 (Zuk et al. 2002, Zhu et al. 
2008), but others reported high levels of CD34 expression (Gronthos et al. 2001, Festy et al. 
2005). It has been recently shown that cells in the SVF and early passages of ASCs express 
CD34, but the level of expression diminishes with further cell culturing (Mitchell et al. 2006, 
Astori  et  al.  2007,  Varma et  al.  2007),  although  contrary  data  have  also  been  published 
showing not only increase of CD34 in later passages, but also accumulation of haematopoietic 
marker  CD45 in  ASCs (Park and Patel  2010).  As possible reasons to  these discrepancies 
researchers suggest factors secreted by adjacent cells in the early passages (Chamberlain et al. 
2007), different cell culture conditions, donor-specific variability, choice in antibody labeling 
(Baer et  al.  2013),  and individual gating strategies used for flow cytometry (Astori  et  al. 
2007). Since we have not tested the expression of the above mentioned surface markers at P0 
or P1, we cannot speculate of whether ASCs, cultured in the presence of AS, express CD34 or 
CD45 at very early passages. But starting from P2, the cultured cells were homogeneously 
CD29, CD44, CD73, CD90, and CD105 positive demonstrating that culturing ASCs in the 
presence of AS do not influence the expression of characteristic MSC markers.
Since immunophenotype profile of MSCs is similar to fibroblasts and pericytes (Covas 
et  al.  2008)  and above-mentioned markers  could  not  discriminate  between those  three,  a 
possibility  that  tested  cell  population  contains  not  only  ASCs,  but  also  fibroblasts  and 
pericytes can not be entirely excluded. It has been long believed that successive passaging 
purifies MSC culture from other types of cells that can be present in the initial cell population 
immediately after isolation (Horwitz et al. 2006). However, some researchers question this 
theory, as well as the general assumption that MSCs are unique type of cells distinct from 
fibroblasts (Haniffa et al. 2009, Hematti 2012) and pericytes (Crisan et al. 2008). 
Some evidence indicates that MSCs are different from fibroblasts and more similar to 
pericytes (Blasi et al. 2011). The hypothesis that MSCs are actually pericytes has also been 
postulated (Crisan et al. 2008, da Silva Meirelles et al. 2008). Additional research suggests 
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that both MSCs and pericytes express CD146 and it could be used as a marker to segregate 
them  from  fibroblasts  which  show  no  expression  of  this  antigen  (Covas  et  al.  2008). 
However, the current opinion is still in a disagreement as to whether ASCs express CD146, 
making it problematic to use it as a reliable marker and to claim that ASCs and pericytes are 
the same. Similarly, the lack of smooth muscle actin, which is a known pericyte marker, in 
most  of  the  isolated  ASC  populations  also  argues  against  this  hypothesis  (Zuk  2013). 
Recently, CD106 and integrin alpha 11 were suggested as markers distinguishing BM MSCs 
from fibroblasts (Halfon et al. 2011), and different expression levels of CD10 and CD26 could 
also help to discriminate between BM MSCs and fibroblasts (Cappellesso-Fleury et al. 2010). 
Since no analogous studies have been published using ASCs, it is not clear whether these 
markers  could be used for  somatic  SC populations  isolated from fat  tissue.  Although the 
origin and true identity of ASCs is  not absolutely understood, from a clinical perspective 
knowledge that such multipotent cells can be obtained from adipose tissue and exploited for 
the  treatment  of  patients  may  be  more  important  (Zuk  2013).  While  additional  markers 
helping to separate ASCs from fibroblasts and pericytes were not included in this study, there 
is a great deal of evidence suggesting for their incorporation in our future work.
3.2.2. Pluripotency markers
One of the main criteria that allow to define pluripotent cells,  such as ESCs, is  the 
expression  of  specific  pluripotency markers.  That  signifies  their  ability  to  self  renew and 
differentiate into each cell type within the organism, except extraembryonic tissues. In the 
field of ESC research it is a well-established practice to characterize ESCs by the expression 
of OCT4, NANOG and SOX2 markers, as they are regarded as the central transcriptional 
regulators maintaining the pluripotency of ESCs (Boyer et al. 2005). 
In the last decade numerous studies have detected OCT4 and other pluripotency markers 
in adult stem cells as well (Tai et al. 2005, Izadpanah et al. 2006, Greco et al. 2007, Kucia et 
al. 2007, Roche et al. 2007, Trivanović et al. 2015). To find out whether ASC culture of the 
donor No.4 also displays such pluripotency markers, polyclonal anti-OCT4 and anti-NANOG 
antibodies were used. Immunocytochemistry revealed the expression of OCT4 in most of the 
ASCs (Figure 3.2.2.1.). Although OCT4 is a transcription factor (Nichols et al.  1998) that 
must be expressed only in the nucleus, it was detected throughout the cell. More prominent 
granular nuclear staining was observed in some ASCs. 
A  transcription  factor  NANOG  was  mostly  detected  in  the  nuclei,  but  granular 
cytoplasmic staining was also observed and few ASCs demonstrated pronounced expression 
of NANOG in the nucleoli (Figure 3.2.2.2.). Since a polyclonal antibody (sc-33759) was used 
in this experiment, it may have caused some of the unspecific staining. The ASCs from two 
other donors, not described in this study, have also been tested for the expression of NANOG 
using the same antibody. These ASC cultures displayed predominant cytoplasmic staining and 
very weak nuclear staining (data not shown).
In  the  scientific  literature,  where  similar  experiments  have  been  conducted,  a 
cytoplasmic staining of pluripotency defining transcription factors can be also found (Tai et 
al. 2005, Carlin et al. 2006), but usually authors focus only on the nuclear staining and do not 
interpret the rest. Increasing amount of research tends to classify the ASCs (Izadpanah et al. 
2006), BM MSCs (Moriscot et al. 2005, Tai et al. 2005), and umbilical cord blood MSCs 
(Tondreau et al. 2005) as pluripotent, based on the methods of immunofluorescence or PCR, 
where an expression of OCT4, NANOG or SOX2 is determined. Inaccurate conclusions may 
arise  from the  antibody used to  determine  the  expression  of  pluripotency markers  at  the 
protein level. It has been shown that the intracellular distribution of these markers in adult 
stem cells  varies  significantly  depending on the  commercial  antibody used.  For  example, 
different  commercial  anti-OCT4,  anti-NANOG,  and  anti-SOX2  antibodies  display
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Figure 3.2.2.1. Expression of OCT4 in ASC culture of the donor No.4. Negative control – 
secondary antibody only. Cell nuclei stained with DAPI. Author R.Brūvere.
Figure 3.2.2.2. Expression of NANOG in ASC culture of the donor No.4. Negative control – 
secondary antibody only. Cell nuclei stained with DAPI. Author R.Brūvere.
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cytoplasmic, nuclear or nucleolar staining respectively, or alternatively, no staining at all in 
ASCs and BM MSCs (Zuk 2009). Similarly, it is always a higher risk to obtain an unspecific 
staining  when  polyclonal  antibodies  are  used,  thus  leading  to  incorrect  interpretation  of 
obtained data. Equally, a background staining from secondary antibody must be constantly 
taken into account.
There  is  one  more  factor  that  must  be  taken  into  consideration  when  anti-OCT4 
antibodies are used. The alternative splicing of  OCT4 gene results in three different protein 
isoforms termed OCT4A, OCT4B (Takeda et al. 1992), and OCT4B1 (Atlasi et al. 2008). The 
OCT4A isoform  is  localized  in  a  nucleus,  but  OCT4B  is  mainly  found  in  a  cytoplasm 
(Cauffman et al. 2006, Lee et al. 2006). The localization of OCT4B1 is not known, as the 
protein product of OCT4B1 has not been identified yet (Wang, Dai 2010). It is believed that 
only  OCT4A is  responsible  for  maintenance  of  pluripotency and  self-renewal  (Lee  et  al. 
2006), but biological function of OCT4B is still unclear (Gao et al. 2012). Research shows 
that OCT4B could be alternatively translated into three additional protein isoforms termed 
OCT4B-265,  OCT4B-190,  and OCT4B-164 (Wang X.  et  al.  2009).  The OCT4B-190 and 
OCT4B-265 are both involved in a cell stress response (Wang X. et al. 2009, Gao et al. 2012), 
but a role of the OCT4B-164 has not yet been discovered. A very little is known about the 
biological function of the OCT4B1 isoform, but it has a probable role in stress response and 
apoptosis (Yazd et al. 2011). Most of the commercially available anti-OCT4 antibodies do not 
discriminate between isoforms of OCT4, as they are generated against C-terminus of OCT4 
protein  that  is  identical  to  all  isoforms.  This  may  explain  the  observed  nuclear  and 
cytoplasmic staining (Liedtke et al. 2008). Few antibodies, specific to only OCT4A isoform, 
are also available in the market, but they show only weak staining both in the nucleus and 
cytoplasm (Zuk 2009).
The anti-OCT4 antibody used in this study was a goat polyclonal antibody (sc-8630) 
that recognizes OCT4B isoform, but not the OCT4A isoform, according to manufacturer. This 
explains the staining pattern observed in our ASC culture, as OCT4B localizes mostly in a 
cytoplasm (Lee  et  al.  2006).  The  anti-OCT4 antibody  that  helps  to  identify  the  OCT4A 
isoform was also tested in our ASC culture. It was a mouse monoclonal antibody (sc-5279), 
raised against amino acids 1-134 of human origin, hence, non cross-reactive with OCT4B 
(according to manufacturer). Unfortunately, no expression was detected in the ASC culture 
(data not shown). This antibody has previously produced a weak staining in a nucleus and in a 
cytoplasm of ASCs and MSCs (Zuk 2009), but in our ASCs neither of them stained positive.
To test  whether  ASC aggregates  also  expressed  pluripotency markers  NANOG and 
OCT4,  immunocytochemistry  with  monoclonal  anti-NANOG  and  anti-OCT4A antibodies 
was employed on glass adherent ASC bodies. The obtained results showed the expression of 
NANOG  in  ASC  bodies  (Figure  3.2.2.3.A-C)  and  prominent  NANOG  positive  nuclear 
staining was also observed in clustered ASCs where the formation of ASC bodies is initiated 
(Figure 3.2.2.3.D-F). Some cytoplasmic staining was also detected. The few monolayer ASCs 
neighbouring  ASC  bodies  were  NANOG  negative.  Similarly  to  monolayer  ASCs  tested 
previously,  no  positive  signal  was  detected  in  ASC bodies  using  anti-OCT4A antibodies 
against N-terminus of OCT4 of human origin (data not shown).
The RT-PCR method was used to test an expression of pluripotency markers at the gene 
level. The expression of genes OCT4A, NANOG, and SOX2 was detected in ASCs and plastic-
adherent ASC aggregates (Figure 3.1.4.) of the donor No.4. Commercially available cDNA of 
ESCs was used as positive control (Figure 3.2.2.4.). The ASC aggregates were included in this 
analysis to test whether they differ from the monolayer ASCs in a way that may indicate a 
more primitive cell state. The expression of a  housekeeping gene β-Actin was tested first to 
ascertain the same level of expression in all  three samples to be compared.  The obtained 
results regarding all three pluripotency marker genes showed a very weak expression in ASCs 
when compared to ESCs.
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Figure 3.2.2.3. Expression of NANOG in adherent ASC bodies of the donor No.4 formed 
onto  a  glass  surface  at  day  5.  (A-C)  Immunocytochemical  localization  of  NANOG  in 
completely organized ASC body. (D-F) Detection of NANOG in ASCs gathered into cluster 
triggering  the  first  stage  of  ASC body formation.  Cell  nuclei  stained with  DAPI.  Author 
D.Pjanova.
Figure  3.2.2.4. Expression  of  pluripotency  marker  genes  OCT4A,  NANOG,  SOX2 and 
housekeeping gene β-Actin in ASCs and ASC aggregates (ASC aggr.) of the donor No.4, and 
ESCs by RT-PCR. Analysis of RT-PCR products in 3% TAE agarose gel. NANOG_1 and 
NANOG_2 represent two different primer pairs tested. M – DNA ladder. bp – base pairs. 
ESCs – embryonic stem cells.
In the case of OCT4 gene, the target was a mRNA of OCT4A, since only this isoform is 
involved in the maintenance of pluripotency (Lee et al. 2006). To detect exclusively OCT4A, 
the primers must lie in the 5' part of the OCT4 sequence, as the exon 1 is not found in other 
splice  variants  (Figure 1.6.1.1.).  Furthermore,  the  unique  polymorphisms  are  located  at 
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positions 48,  234, and 353 within exon 1,  starting at  the transcriptional start  codon ATG, 
allowing  to  avoid  amplification  of  false  positive  products  derived  from pseudogenes  and 
OCT4-like sequences as well (Liedtke et al. 2008). In total, four different primer pairs were 
tested, but only the results obtained by one are shown herein. The exact primer sequences and 
a comparison of  OCT4A gene product  sequence,  amplified with this  primer pair, to three 
OCT4 pseudogene sequences that closely resemble parental OCT4A  gene can be found in the 
Appendix 1. All the primer pairs tested showed very low level of OCT4A expression both in 
ASCs and ASC aggregates of the donor No.4. No significant differences were found between 
the OCT4A expression in monolayer ASCs and ASC aggregates (Figure 3.2.2.4.). In contrast, 
the expression of OCT4A in the ESCs was very pronounced, verifying their pluripotent state. 
It must to be mentioned that the quantity of cDNA from both ASC samples used in a RT-PCR 
was  twice  the  amount  of  ESC cDNA,  emphasizing  an  even  more  modest  expression  of 
OCT4A in adult stem cells. 
Similarly to  OCT4A, detecting the expression of  NANOG at the gene level is a tricky 
task. It is known that there are 11 human  NANOG pseudogenes from whom  NANOGP8 is 
highly  similar  to  the  original  NANOG,  bearing  only  two  fixed  and  twelve  polymorphic 
nucleotide alternations within the ORF (Appendix 4) (Fairbanks et al. 2012). We have tested 
four  different  primer  pairs  for  the  detection  of  NANOG gene,  but  only  two of  them are 
described in this work. A comparison of NANOG gene product sequence, amplified with the 
two primer pairs, to 11 NANOG pseudogene sequences can be found in the Appendices 2 and 
3. A higher expression level of NANOG in all samples was detected when NANOG_1 primer 
pair was used (Figure 3.2.2.4.). Similarly to OCT4A case, the level of NANOG expression in 
ASCs and ASC aggregates of the donor No.4 was much lower than that of ESCs, irrespective 
of the primer pair that was used. A difference in the amount of NANOG between ASCs and 
ASC aggregates was inconclusive, since the results for each primer pair were opposite.
Since there are no known pseudogenes or isoforms of SOX2 (Ståhlberg et al. 2009), the 
detection of its expression by RT-PCR was more conclusive than that of OCT4A and NANOG. 
Similarly  to  the  above-mentioned  pluripotency  markers,  the  level  of  SOX2 expression  in 
ASCs and ASC aggregates was equally low when compared to ESCs (Figure 3.2.2.4.).
A careful design of primers to specifically detect  OCT4A isoform and  NANOG gene 
does not fully guarantee the exclusion of false positive results. For this reason it is necessary 
to sequence the obtained RT-PCR products to make sure, that no amplification of pseudogenes 
has occurred. The same primer pairs used for the RT-PCR method were employed for the 
sequencing. Sequencing of RT-PCR products, amplified using OCT4A primer pair, confirmed 
the expression of OCT4A isoform both in adult stem cells of the donor No.4 and in ESCs. A 
comparison between original OCT4A gene fragment and sequencing result of respective RT-
PCR products  is  shown in  the  Appendices  5,  6,  7,  and 8.  The sequencing with  OCT4A 
forward primer has not been successful in the samples of ASCs and ASC aggregates, probably 
due to a improper sample quality caused by a very low level of OCT4A expression.
The obtained results from sequencing of RT-PCR products, amplified using NANOG_1 
and NANOG_2 primer pairs, are summarized in Table 3.2.2.1. Within a sequence, amplified 
using NANOG_1 primer pair, are 5 positions that could help to distinguish  NANOG from 
NANOGP8.  Unfortunately, all  of them are modern polymorphisms and not fixed variants. 
Nevertheless, sequencing results showed that ASCs of the donor No.4 express NANOGP8 and 
not the original NANOG gene. From the sample of monolayer ASCs of the donor No.4 clear 
answer could not be obtained, as the critical nucleotides could indicate expression of both 
NANOG and NANOGP8. However, the results from aggregates of the same ASCs showed a 
variant  T  at  the  position  190,  indicating  the  amplification  of  NANOGP8.  In  ESCs  the 
expression of original NANOG was detected based on variants at the positions 276 and 363. A 
comparison between original NANOG gene fragment, amplified using NANOG_1 primer pair, 
and sequencing result of respective RT-PCR products is shown in the Appendices 9, 10, 11, 
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and 12. 
Table 3.2.2.1.  The sequencing results of RT-PCR products of ASCs and ASC aggregates of 
the donor No.4,  and ESCs,  amplified using NANOG_1 and NANOG_2 primer pairs.  a  - 
nucleotides in the reading frame are numbered relative to the first  nucleotide in the ATG 
initiation codon; b – information based on Fairbanks et  al.  2012; c – in order to make a 
comparison easier, the nucleotides  on a  reverse strand are  converted into  their  respective 
complementary counterparts; NANOGP8 – NANOG pseudogene 8; F – forward primer; R – 
reverse primer; “-” - not applicable; X –  sequence could not be determined at the respective 
position.
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No.4 
(F)
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(R)c
ESCs 
(F)
ESCs 
(R)c
ASCs 
No.4 
(F)
ASCs 
No.4 
(R)c
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(F)
ASC 
aggr. 
(R)c
ESCs 
(F)
ESCs 
(R)c
47. C C/A - - - - X C X C X C
126. T T/C - - - - T T T T T T
144. G A - - - - X A X X G G
165. T/C T X T X T T T T T C C
190. G G/T X T X G T T T X G G
246. T/G T T T T T T X T X T X
276. G/A G X G A A G X G X G X
363. C/T C C C T T - - - - - -
Within a sequence, amplified using NANOG_2 primer pair, are  7 positions (one fixed 
variant  at  the  position  144  and  6  modern  polymorphisms)  distinguishing NANOG from 
NANOGP8. The same as using NANOG_1 primer pair, the expression of parent NANOG was 
detected in ESCs, according to observed variants at the positions 144 and 165. Unfortunately, 
the data regarding ASCs of the donor No.4 were inconclusive. In accordance with the variant 
T, detected at the position 190, these cells express  NANOGP8. This conclusion was further 
supported by an identification of the variant A at the position 144 in one case out of four. The  
rest  of  three  sequences  were  ambiguous  due  to  sequencing  artefacts  near  this  position. 
Repeated efforts did not result in more precise data and for this reason it is likely that the very 
low  level  of  the  initial  sample  caused  these  artefacts.  Within  these  sequencing 
chromatograms, around the position 144, specific peaks could not be observed, but two signal 
lines, representing the nucleotides G and A (as in NANOG and NANOGP8 respectively), were 
always present. As the position 144 is of utmost importance, since it represents one of only 
two  fixed  variants  that  could  help  to  distinguish  NANOG from  NANOGP8,  it  could 
undoubtedly prove the expression of one or another in ASCs of the particular donor. It is 
tempting to speculate that there is a possibility that ASCs of the donor No.4 express both 
NANOG and NANOGP8, as it has been a case in other types of cells (Ambady et al. 2010). It  
is probable that they dominantly express NANOGP8 at low level and the expression of parent 
NANOG gene,  at  even more modest level,  is  also existent.  Although the current evidence 
regarding NANOG expression in ASCs is questionable, the expression of NANOGP8 in these 
cells  has been clearly detected by both primer pairs  used. A comparison between original 
NANOG gene fragment,  amplified using NANOG_2 primer pair, and sequencing result of 
respective RT-PCR products is shown in the Appendices 13, 14, 15, 16, 17, and 18.
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If  the  expression  of  NANOGP8 was  detected  in  ASCs  of  the  donor  No.4  and  the 
expression of NANOG was doubtful, then a protein detected by anti-NANOG antibody most 
likely was NANOGP8, not NANOG. This leads to a conclusion that NANOGP8 in ASCs of 
this donor is not only transcribed, but also translated into protein. Since the proteins encoded 
by NANOG and NANOGP8 differ by only one fixed aa substitution and possibly few other, 
depending on modern polymorphisms in each individual  (Table 1.6.2.1.)  (Fairbanks et  al. 
2012),  the  anti-NANOG  antibodies  can  not  distinguish  between  the  two.  Therefore,  the 
presence of positive signal detected by anti-NANOG antibodies could be due to translation of 
NANOG, NANOGP8, or both. 
The NANOGP8 protein has been also detected in human smooth muscle cells, where it 
exhibits predominantly nuclear localization. Other cell types that express exclusively NANOG 
or transcripts of both NANOG and NANOGP8, show various staining patterns within the same 
cell  culture  (Ambady et  al.  2010).  The  ASCs of  the  donor  No.4  showed mainly  nuclear 
staining and less prominent granular cytoplasmic staining. This was observed in monolayer 
ASC  culture,  as  well  as  in  ASC  aggregates,  using  two  different  antibodies.  The  main 
difference between the two was a lack of any staining in ASCs adjacent to adherent ASC 
bodies or clustered ASCs. The results regarding the expression of  NANOGP8 in monolayer 
ASCs and their aggregates were obtained from cells grown on adherent plastic cell culture 
plates. The ASC aggregates, stained with anti-NANOG antibody, were formed on an uncoated 
glass surface. Therefore, we can not exclude the possibility, that different growth conditions 
have an influence on gene expression, leading to distinct expression patterns. We do not have 
a direct proof that ASCs grown on the glass surface also express NANOGP8. It is possible that 
such growth conditions facilitate the expression of parent  NANOG,  caused by more rapid 
clustering of ASCs, thus providing higher and more effective cell-cell and cell-extracellular 
matrix  interactions.  Furthermore,  the  monoclonal  anti-NANOG  antibody  used  on  glass-
adherent ASC aggregates may be more specific than polyclonal antibody used on monolayer 
ASCs.
The monolayer ASCs of the donor No.4 were also tested for an alkaline phosphatase 
(AP) activity using naphthol AS phosphate/Fast Blue BB solution.  High activity of AP in 
human adult can be observed in small intestine, kidney, liver, placenta, bone and neutrophils 
(Butterworth  1983),  but  in  embryo all  tissues  show strong AP activity  at  early  stages  of 
development (Bernstine 1973). Four isozymes of AP are discriminated in the humans: tissue-
nonspecific (liver/bone/kidney), intestinal, placental and germ cell (Millán 2006). The tissue-
nonspecific  AP  (TNAP)  expression  is  a  known  marker  for  embryonic  stem  cells  and 
osteoblast differentiation, but it has also been observed in undifferentiated BM MSCs (Kim et 
al. 2012). Separate ASCs in monolayer showed the AP activity detected by two types of blue 
colouring. Most of the cells, positive for AS, displayed uniform staining (Figure 3.2.2.5.A), 
while in the others granular staining was observed (Figure 3.2.2.5.B). Addition of levamisole
Figure 3.2.2.5. Detection of the alkaline phosphatase activity in ASCs of the donor No.4 at P3 
using  naphthol  AS  phosphate/Fast  Blue  BB  solution.  (A-B)  ASCs  positive  for  alkaline 
phosphatase activity (blue) demonstrating uniform and granular staining.  (C) Inhibition of 
alkaline phosphatase activity by levamisole. Scale bar 50 μm. Author R.Brūvere.
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to the naphthol AS phosphate/Fast Blue BB solution served as an evidence for the specificity 
of reaction, since the levamisole inhibits the AP activity (Van Belle 1976), resulting in a lack 
of blue colouring (Figure 3.2.2.5.C).
When ASC bodies, after the transfer to a new adherent plastic culture flasks (Figure 
3.1.7.), were tested for an AP activity, the ASCs, assembled into bodies, did not stain positive 
for AP irrespective of their size. However, a large fraction of cells migrating out of the ASC 
bodies exhibited AP activity detected by blue staining (Figure 3.2.2.6.). 
Figure 3.2.2.6. Detection of the alkaline phosphatase activity in ASC bodies of the donor 
No.4  9  days  after  the  transfer  onto  adherent  cell  culture  plates  using  naphthol  AS 
phosphate/Fast Blue BB solution. (A) Absence of AP activity in large ASC body. (B) Lack of 
AP activity in small ASC body and evident AP activity (blue) in the cells surrounding the 
ASC body. (C) AP activity (blue) in the cells migrating out of the ASC body. Scale bar 100 
μm (50 μm for Figure 3.2.2.6.C).
Few ASCs in monolayer and substantial part of cells migrating out of the ASC bodies 
after their transfer to a new adherent culture flask displayed AP activity. It has been previously 
shown that TNAP positive (TNAP+) BM MSCs possess lower multipotentiality than TNAP 
negative (TNAP-) cells and are prone to differentiate into osteoblasts more often than into 
adipocytes  or  chondrocytes.  TNAP+  BM  MSCs  also  show  lower  proliferation  rates  and 
diminished expression of pluripotency marker genes NANOG and REX-1 when compared to 
TNAP- BM MSCs (Kim et al. 2012). Since ASCs share most of their characteristics with BM 
MSCs, it  could be possible that ASCs in monolayer, staining positive for AP, represented 
more mature cells, while the major part of the monolayer ASCs were AP negative, hence 
illustrating their multipotentiality. As ASC bodies after the transfer onto new adherent surface 
did not show the AP activity, but significant part of the surrounding cells were AP positive, 
the ASCs forming 3D bodies may indicate more primitive cells than ASCs migrating out of 
the  bodies. These observations  suggest  that  particular  stress  conditions  can  cause  the 
spontaneous formation of 3D ASC bodies (described in section 3.1.) that may represent more 
primitive cell subpopulation within the individual ASC culture.
Numerous studies have detected OCT4 and other pluripotency markers in adult stem 
cells in the last decade (Tai et al. 2005, Izadpanah et al. 2006, Ambady et al. 2010, Trivanović 
et  al.  2015).  These findings have led to speculations that somatic stem cells may possess 
greater  similarities  to  ESCs in terms of  regulatory networks  and potency than  previously 
thought (Greco et al. 2007). However, additional scientific research contrasts this hypothesis 
by evidence that OCT4 is not essential for maintaining potency and self-renewal in the adult  
mammalian stem cells (Lengner et al. 2007). It is thought that albeit pluripotency markers can 
be  observed at  a  basal  level  in  adult  stem cells,  they  may not  have  the  same biological  
functions as in ESCs (Lengner et al. 2008). Indeed, our results showed the expression of all 
three pluripotency determining key transcription factors OCT4, NANOG, and SOX2 in ASCs, 
but the detected level of expression was much lower than that of ESCs. It turned out that the 
detected expression of NANOG in ASCs was not the expression of parental NANOG gene, but 
its pseudogene 8. The data showed that a sequencing of RT-PCR products is the only reliable 
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method to distinguish NANOG from NANOGP8. Despite of the numerous NANOG, as well as 
OCT4 pseudogenes  (Booth,  Holland  2004,  Liedtke  et  al.  2007)  that  can  easily  confuse 
researchers and result into misleading conclusions regarding pluripotency of adult stem cells 
(Lengner et al. 2008), part of the published research still overlooks this aspect.
3.3. Differentiation ability of ASCs
3.3.1. Differentiation of ASCs into cells of mesodermal lineage
To  test  whether  ASCs  cultured  in  the  medium  supplemented  with  AS  exhibit 
multilineage potential, they were differentiated into adipocytes, osteocytes, and chondrocytes 
using a lineage-specific induction factors. At first, the ASCs from the donor No.4 at P3 were 
subjected  to  the  differentiation  into  cells  of  above-mentioned  mesodermal  lineages.  After 
more than 4 years of cryopreservation these cells were examined for ability to maintain their 
potential of differentiation in even later passages such as P6.
When  ASCs  were  treated  with  adipogenic  induction  medium,  the  fibroblastoid 
morphology in the fraction of cells changed already during the first week of differentiation. 
These  cells  flattened  and  broadened  and  a  significant  accumulation  of  intracellular  lipid 
droplets was also observed. Throughout the differentiation the amount of such cells and the 
size  and  the  quantity  of  intracellular  lipid-filled  vacuoles  increased  rapidly.  Adipogenic 
differentiation was confirmed after 28 (for P3) or 16 (for P6) days by Oil Red O staining 
(Figure 3.3.1.1.A and G). The Oil Red O staining was also performed on differentiated cells of 
P3 after 14 days of differentiation, but since the amount of mature adipocytes was modest, the 
process  of  differentiation  was continued.  Intracellular  lipid droplets  of  differentiated cells 
accumulated Oil Red O indicating the phenotype of mature adipocytes. Cells cultivated in a 
control medium did not show the signs of adipogenic differentiation (Figure 3.3.1.1.D and J). 
To differentiate ASCs into osteocytes, the cells were cultivated in osteogenic medium 
for 28 days.  No visible  signs of the differentiation could be observed without  the use of 
specific dye. Osteogenic induction of ASCs was assessed by Alizarin Red S. It is a dye that 
stains calcium deposits within mineralized extracellular matrix produced by osteoblasts (Tapp 
et al. 2009). A red staining was detected around a small portion of differentiated ASCs from 
P3 (Figure 3.3.1.1.B) and only in few spots of differentiated cells from P6 (Figure 3.3.1.1.H). 
Two types of Alizarin Red S staining were observed in differentiated cells from P3. One part 
of the cells  had lighter  and smoother  staining,  but  other  cells  were surrounded by dense, 
intensive and circular stain. This difference may point to distinct stages of differentiation. In 
the control cells from both passages red staining was not observed (Figure 3.3.1.1.E and K). 
Chondrogenic differentiation was induced using  micromass  culture  technique.  High-
density micromass culture ensures effective condensation of cells, considered to be a critical 
stage in  the initiation of  chondrogenic differentiation (Handschel  et  al.  2007).  Micromass 
culture of ASCs resulted in the formation of a dense aggregate of cells. After an incubation for 
three days in a chondrogenic medium, new cells started to grow out of the initially formed 
nodule. During the chondrogenic differentiation these cells proliferated rapidly and started to 
condense, forming new, smaller cell aggregates. After 28 days of differentiation the cells were 
stained with Alcian Blue under acidic conditions to detect sulphated glycosaminoglycans that 
are characteristic to extracellular matrix of chondrocytes (Lev and Spicer 1964, Zuk et al. 
2001).
Differentiated aggregates of cells from P3 were fixed and stained with 1% Alcian Blue 
(pH 2,5) directly in the cell culture dish (Figure 3.3.1.1.C). The initial and newly formed cell 
aggregates in the chondrogenic medium were Alcian Blue positive, indicating the presence of 
sulfated proteoglycans within the extracellular matrix. However, the Alcian Blue staining of 
the  initial  cell  aggregate  was  comparatively  weak.  It  was  most  probably  due  to  the 
compactness and size of the aggregate. The dense structure of the nodule possibly hindered a
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Figure 3.3.1.1. ASCs of the donor No.4 from the third and the sixth passages differentiated 
towards adipogenic, osteogenic, and chondrogenic lineages. (A, D, G, J) Oil Red O staining 
of differentiated and control cells. (B, E, H, K) Alizarin Red S staining of differentiated and 
control cells. (C, F, I, L) Alcian Blue staining of differentiated and control cells. In the Figures 
3.3.1.1. A and D the cells are counterstained with hematoxylin. Scale bar 100 μm.
penetration of the Alcian Blue during a relatively short dyeing time. Different approach was 
used  to  confirm  chondrogenic  differentiation  of  the  ASCs  from  P6.  The  formed  cell 
aggregates were collected, fixed, embedded in paraffin, sectioned, and only then stained with 
1% Alcian Blue (pH 1,3) (Figure 3.3.1.1.I). The lower pH of the dyeing solution was also 
introduced,  since  at  pH  2,5  not  only  sulphated,  but  also  carboxyl  groups  containing 
glycosaminoglycans stain with Alcian Blue (Lev and Spicer, 1964). 
In a control medium cells from P3 did not form aggregates and intense cell growth and 
condensation was not detected. Weak Alcian Blue staining was also observed in the control 
medium although the morphology of the cells radically differed from the cells subjected to the 
chondrogenic differentiation (Figure 3.3.1.1.F). The ASCs from P6 initially formed the cell 
aggregate in the control medium. Similarly to the differentiation samples, new cells started to 
grow out  of  the  initially  formed  nodule  and  a  formation  of  smaller  cell  aggregates  was 
observed. But in contrast to the differentiation samples, reduction of the volume and density 
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of the initial cell aggregate was detected. The paraffin-embedded sections of control samples 
were stained with Alcian Blue, but in spite of low pH of the dyeing solution, a light blue 
staining was also detected in the control (Figure 3.3.1.1.L).
ASC ability  to  differentiate  into other  cell  types of  mesodermal  origin is  a key for 
verifying their identity. Obtained results showed that ASCs cultured in the presence of AS can 
be effectively differentiated into adipocytes and chondrocytes not only at P3, but also at P6. 
However ASC differentiation into osteocytes was weak at P3 and obtained data suggest that it 
may have decreased even more at P6. Comparison of the differentiation samples from P3 and 
P6 was done by visual assessment, and the aim of in vitro differentiation was to evaluate the 
potency of ASCs from various passages to differentiate into other cell types of mesodermal 
origin as such, not to directly compare the extent of each differentiation between P3 and P6. 
In the case of osteogenic differentiation the weak formation of calcified extracellular matrix 
was observed in all triplicates at P3, but Alizarin Red S staining was detected only in one 
triplicate at P6. As this most likely represents a characteristic of the  ASC donor, since the 
same protocol of differentiation has yielded reliable results with ASCs from different donors, 
for example, the donor No.5 (Figure 3.3.1.2.), it is impossible to state that the ability of ASCs, 
cultured in AS, to differentiate into osteogenic lineage diminishes in later passages. Others 
show that differential capacity of  ASCs, when cultured in the standard media, is preserved 
through 10 to 13 passages (Wall et al. 2007, Gruber et al. 2012), but decreases at P25 (Zhu et 
al. 2008).
Figure 3.3.1.2. ASCs of the donor No.5 at P4 differentiated towards adipogenic, osteogenic, 
and chondrogenic lineages. (A) Detection of lipids with Oil Red O. (B) Detection of calcified 
extracellular matrix with Alizarin Red S. (C) Detection of sulfated proteoglycans with Alcian 
Blue. In the Figure 3.3.1.2. A the cells are counterstained with hematoxylin. Scale bar 100 
μm.
One  could  argue  that  the  observed  differentiation  could  represent  the  presence  of 
various lineage-committed progenitor cells or other multipotent cells, such as pericytes or BM 
MSCs from peripheral blood, and not the multipotentiality of ASCs (Zuk et al. 2001). Since 
SVF contains preadipocytes that can differentiate into mature fat cells, it would be feasible to 
suspect  their  possible  contribution  to  adipogenic  differentiation.  However,  only  0,02% of 
human adipose tissue are adipocyte precursor cells (Pettersson et al. 1984) and such a low 
overall occurrence could not constitute for the detected level of adipogenic differentiation. 
The possibility that osteogenic or chondrogenic progenitor cells could be found in SVF due to 
disruption of blood vessels in adipose tissue is very low as well. Even if circulating blood 
carries such progenitor cells, their amount in peripheral blood is likely negligible. The same 
could be said about BM MSCs, as there is not enough evidence supporting their presence in 
peripheral blood (Zuk et al. 2001). And since  only 0,001 to 0,01% of all nucleated cells of 
BM are MSCs (Pittenger et al. 1999), their amount in circulating blood is bound to be even 
lower,  thus  making  their  possible  contamination  of  SVF insignificant  (Zuk  et  al.  2001). 
However, the possibility that fibroblasts and pericytes could be present in SVF may not be 
entirely excluded. Since their immunophenotype profile is very similar to ASCs (Covas et al. 
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2008) and the surface markers exploited in this study could not discriminate between them 
and ASCs, and considering the ability of both fibroblasts (Lorenz et al.  2008, Blasi et  al. 
2011) and pericytes  (Covas et al. 2008, Crisan et al. 2008) to differentiate into  adipocytes, 
osteocytes, and chondrocytes, it is probable that observed differentiation is partly due to their 
presence in ASC culture. 
3.3.2.Differentiation of ASCs into insulin-producing cells
3.3.2.1. Protocol 1
The ASCs from the donor No.4 at P5 were subjected to the differentiation Protocol 1. 
This protocol was composed from analysis of literature covering production of pancreatic 
hormone-expressing cells from ESCs, since these differentiation protocols are more detailed 
than those described for somatic SCs and majority of the extrinsic factors added to induction 
media is identical in both cases. For the first 3 days the cells were deprived of serum, as an 
absence or low concentrations of serum in the presence of high concentrations of activin A 
facilitates the differentiation of human ESCs into definitive endoderm (D'Amour et al. 2005). 
After  the first  stage of  differentiation the cells  started to  enlarge and an accumulation of 
intracellular granules as well as clustering of ASCs were observed (Figure 3.3.2.1.1.).
Figure 3.3.2.1.1. Morphological changes in ASCs during their  differentiation into insulin-
producing cells using the Protocol 1. Scale bar 100 μm.
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During the second stage of differentiation the cells lost their intracellular granules, but 
the  clustering  became  more  prominent.  At  the  end  of  this  stage  few  rounded  granules, 
attached to a cell surface, were detected. The amount of these granules increased during the 
third stage of differentiation. The granules were considered cell debris or dead cells although 
they could not be effectively removed by washing with PBS. Since the cell death became 
more pronounced, the DAPT was omitted from the third stage differentiation medium after 
few days to exclude a possible cell death by elevated DMSO (used as a solvent for DAPT) 
concentration in the medium. At the end of the differentiation the remaining monolayer cells 
were gathered into clusters and covered with cell debris. In the control medium discrete cell 
clustering and slight amount of cell debris were observed.
To test the course of differentiation, an immunocytochemistry method was used. After 
the first stage of differentiation the cells in differentiation and control media were stained 
using anti-SOX17 antibody. As the SOX17 is a transcription factor, it should be located in a 
nucleus. The results revealed notable nuclear staining as well as slight cytoplasmic staining in 
both differentiation and control  samples  (Figure 3.3.2.1.2.).  No substantial  difference was 
found between these two samples tested. 
Figure  3.3.2.1.2. Expression of SOX17 in ASCs after the first stage of differentiation  into 
insulin-producing cells using the Protocol 1. Analysis of confocal laser scanning microscopy. 
Author R.Brūvere.
After the second stage of differentiation the differentiation and control samples were 
stained using anti-PDX1 antibody. Likewise SOX17, PDX1 is also the transcription factor and 
should  be  expressed in  a  nucleus.  Obtained immunocytochemistry data  showed exclusive 
staining of nucleoli and an other cell organelle, likely a Golgi complex (Figure 3.3.2.1.3.). No 
prominent  difference  in  a  staining  pattern  was  found between  differentiation  and  control 
samples,  however the staining intensity in the control sample was reduced in comparison to 
the differentiation sample (based on a visual assessment).
Figure 3.3.2.1.3. Expression of PDX1 in ASCs after the second stage of differentiation into 
insulin-producing cells using the Protocol 1. Cell nuclei stained with DAPI. Magnification 
1000x for the differentiation image and 630x for the control image. Author R.Brūvere.
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At the end of the differentiation Protocol  1 a double staining immunocytochemistry 
method  was  used  on the  differentiation  samples.  Anti-C-PEPT, anti-NGN3,  and  anti-SST 
antibodies  were  co-stained  with  anti-INS  or  anti-GCG  antibodies  which  were  tested  on 
cryosections  of  mouse  pancreas  beforehand to  verify  their  reactivity  (Appendix  27).  The 
obtained  results  from  the  differentiation  Protocol  1  demonstrated that  INS  was  weakly 
expressed in a cytoplasm and, although it is a cytoplasmic protein, distinctly found in the 
nuclei  (Figure 3.3.2.1.4.).  The C-PEPT was found only in the cytoplasm and it  showed a 
colocalization with cytoplasmic staining of INS. The NGN3, which is the transcription factor, 
was mainly detected in the nuclei and probably the Golgi complex, as the staining pattern of 
this  organelle  was  similar  to  that  observed  using  the  anti-PDX1  antibody.  The  exact 
colocalization was found between INS and SST. Even though the SST is the cytoplasmic 
protein, an apparent nuclear staining was also discovered likewise in the case of INS. The 
GCG  was  expressed  in  the  cytoplasm  and  showed  colocalization  with  C-PEPT  and 
cytoplasmic parts of staining of NGN3 and SST (Figure 3.3.2.1.5.).
Figure  3.3.2.1.4. Expression  of  INS,  C-PEPT,  NGN3  and  SST  in  ASCs  after  their 
differentiation  into  insulin-producing  cells  using  the  Protocol  1.  Cell  nuclei  stained  with 
DAPI. Magnification 1000x. Author R.Brūvere.
The dead cells,  broadly observed during the third stage of differentiation,  were also 
detected after the immunocytochemical analysis (Figure 3.3.2.1.4. in the INS/NGN3 image 
and Figure 3.3.2.1.5. in the GCG/NGN3 and GCG/SST images). They were recognized as 
small, rounded cells with very bright staining of DAPI and all the antibodies tested, probably 
caused by an unspecific binding due to the damaged membranes.
After each stage of differentiation part of the cells was collected in order to obtain total 
RNA and perform quantitative real-time RT-PCR analysis. Unfortunately a yield of RNA from
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Figure  3.3.2.1.5. Expression  of  GCG,  C-PEPT,  NGN3  and  SST  in  ASCs  after  their 
differentiation  into  insulin-producing  cells  using  the  Protocol  1.  Cell  nuclei  stained  with 
DAPI.  Magnification 400x for the GCG/C-PEPT and GCG/SST images and 630x for the 
GCG/NGN3 image. Author R.Brūvere.
all gathered samples was very low due to a chosen extraction method and resulting RNA was 
not suitable for effective PCR analysis. We were able to perform an initial analysis of the 
expression of genes PDX1, MNX1, and INS using a cDNA synthesised from the scarce RNA 
samples.  None  of  the  samples  from  all  stages  of  differentiation  or  control  showed  the 
expression of above-mentioned genes (data not shown).
Since the expression of genes PDX1 and INS was not detected and the observed staining 
pattern of respective antibodies was also inconclusive, it is likely that ASCs were not able to 
differentiate  into  insulin-producing  cells  using  above-tested  protocol.  Firstly,  their  initial 
differentiation  into  DE was  uncertain,  as  immunocytochemistry  results  using  anti-SOX17 
antibody showed no difference between the differentiation and control samples. It is doubtful 
that undifferentiated ASCs express SOX17 which is a marker of endoderm (Grapin-Botton 
2008). Even if so, it could not be much higher than a background level and there should be 
considerable  upregulation  visible  in  the  differentiation  sample  after  the  first  stage  of  the 
Protocol 1. Activin A, which was used during the first stage of differentiation, is known to 
facilitate the differentiation of human ESCs into DE (D'Amour et al. 2005). It has also been 
successfully used in the differentiation protocols of MSCs (Sun Y. et al. 2007, Chandra et al. 
2011), although other research has showed that the use of activin A is insufficient to induce 
differentiation of DE from UC blood SCs (Filby et al. 2011). Secondly, the posterior foregut 
marker PDX1 was not detected after the second stage of differentiation at  gene level and 
immunocytochemistry data did not show its expected staining pattern. It inclines to suggest 
that even if the detected positive signal of SOX17 represented the cells that were prone to 
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endodermal  differentiation,  the  further  process  of  differentiation  has  been  hampered. 
However, immunocytochemical analysis at the end of the differentiation demonstrated that the 
cells stained positive for INS, GCG, C-PEPT, NGN3, and SST. Nevertheless, their staining 
pattern did not entirely match the staining of positive control (mouse pancreas). Additionally, 
the transition states of ASCs were not detected neither using SOX17 nor PDX1 antibodies, 
and it  is  highly  unlikely  that  such differentiation  would  happen directly, without  gradual 
transformation that could be followed. The lack of INS gene detection by real-time RT-PCR 
analysis  is  in  further  support  of  unspecific  binding  of  used  antibodies  rather  than  actual 
expression  of  tested  antigens.  Together  these  results  suggest  that  ASCs were  not  able  to 
differentiate into insulin-producing cells using Protocol 1.
3.3.2.2. Protocol 2
The ASCs from the donor No.4 at P6 were subjected to the differentiation Protocol 2. 
This  protocol  was  based  on  the  Protocol  1,  but  with  few  alterations.  First,  before  the 
differentiation the ASCs were grown in the serum-free pre-differentiation medium containing 
EGF and bFGF for 2 days. This step has been successfully used in hepatogenic differentiation 
protocol (Taléns-Visconti et al.  2006). Since it  is believed that pancreas and liver share a 
common precursor (Zaret 2001), this step could facilitate the chosen differentiation protocol. 
Second, starting from the first stage of differentiation the cells were grown at 60% O2 level, as 
elevated levels of oxygen could favor the pancreatic differentiation (Fraker et al. 2009, Heinis 
et al. 2010). Third, B-27 supplement was omitted from the differentiation protocol, since it 
contains  human  recombinant  insulin  that  can  give  false  positive  result  in  the 
immunocytochemical analysis with anti-INS antibody (Hansson et al. 2004).
The ASCs, used for the experiment, showed an accumulation of intracellular granules 
from the beginning of differentiation probably due to a late cell passage and became more 
prominent during the course of differentiation (Figure 3.3.2.2.1.). Until the end of the second 
stage no difference between the control and experimental samples was observed. Part of the 
cells lost their spindle-shaped appearance and shifted to more rounded and flattened look. At 
the third stage of differentiation the cells in the differentiation medium started to detach from 
the surface due to apoptosis or necrosis. After the twelfth day in the third stage differentiation 
medium the experiment was discontinued due to the high rate of cell death. In the control 
medium the detachment of the cells was also detected, but not in such a great scale as in the  
differentiation medium.
The  cells  in  the  differentiation  medium  after  the  first  and  second  stages  of 
differentiation were stained with anti-SOX17 and anti-PDX1 antibodies respectively (Figure 
3.3.2.2.2.).  Obtained results  revealed similarities with the staining pattern observed in the 
cells  differentiated using the Protocol 1.  The SOX17 was detected in the nuclei  and only 
slightly in the cytoplasm. The PDX1 was identified for the most part  in the nucleoli,  but 
distinct staining of probable Golgi complex, as in the cells differentiated after the Protocol 1, 
was  not  observed.  Instead,  a  weak  cytoplasmic  staining  could  be  seen  throughout  the 
cytoplasm.
At the end of the differentiation Protocol  2 a double staining immunocytochemistry 
method was also tried on the differentiation samples. Since most of the cells were lost during 
the last  stage of  differentiation  and in  a  fraction  of  remaining cells  a  fragmentation of  a 
nucleus was observed (from DAPI staining; data not shown) signalling of undergoing necrosis 
or apoptosis, the obtained results could not be considered reliable. This makes a competent 
analysis  of  tested  markers  impossible.  The examples  of  acquired  INS,  C-PEPT and SST 
staining are given in the Figure 3.3.2.2.3.
The same concern applies to an extraction of total RNA. The cells from the third stage 
of differentiation do not represent a healthy cell culture hence rendering the gene analysis 
meaningless.  The  real-time  RT-PCR  analysis  was  carried  out  on  the  cDNA samples  of 
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differentiation and control cells from the first and second stages, but no expression of genes 
PDX1, MNX1, HNF4A, NKX6-1, and INS was detected (data not shown).
Figure 3.3.2.2.1. Morphological changes in ASCs during their  differentiation into insulin-
producing cells using the Protocol 2. Scale bar 100 μm.
Because of the prominent loss of cells during the last stage of differentiation rendering 
any possible further analysis unnecessary, the Protocol 2 was considered unsuccessful. The 
exact cause of cell necrosis or apoptosis was not fully identified. Since this differentiation 
protocol  was  very  similar  to  the  Protocol  1,  but  cell  detachment  at  such  scale  was  not 
observed during the differentiation Protocol 1, it is plausible to suspect that the cell death was 
caused by few novelties introduced in the Protocol 2. The pre-differentiation stage could not 
have induced the cell necrosis or apoptosis, as the cell death was not detected until the third
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Figure 3.3.2.2.2. Expression of SOX17 and PDX1 in ASCs after the first (for SOX17) and the 
second (for PDX1) stages of differentiation into insulin-producing cells using the Protocol 2. 
Cell nuclei stained with DAPI. Magnification 400x.
Figure 3.3.2.2.3. Expression of INS, C-PEPT, and SST in ASCs after their differentiation into 
insulin-producing cells using the Protocol 2. Cell nuclei stained with DAPI. Magnification 
400x. 
stage. Similarly, discontinued use of B-27 supplement can not have any impact on the survival 
of cells. That leaves the change of growth conditions, since the differentiation Protocol 2 was 
performed at 60% O2 instead of 21% O2, as usually accepted. Although oxygen is critical for 
the normal growth of mammalian cells, concentrations higher than 200 μM have been shown 
to obstruct the growth and metabolism of various types of cells. Normally cells are cultured at 
21% gas-phase O2 where they are exposed to dissolved O2 concentrations of 200 μM or less 
(saturation  of  the  air  with  water  vapor  at  370C  reduces  the  concentration  of  oxygen  to 
approximately 190 μM). Research shows that a human β cell line TK6 can grow normally at 
40% O2 (approximately 380 μM dissolved oxygen) and continued exponential cell growth can 
be observed up to O2 concentration of 540 μM (Oller et al. 1989). Mouse ESCs and human 
iPSCs can be more efficiently differentiated into insulin-producing cells at 60% O2 (Hakim et 
al.  2014),  and  murine  pancreatic  buds  cultured  at  80%  O2 show  much  higher  β  cell 
differentiation  when compared  to  cultures  at  21% O2 (Heinis  et  al.  2010).  Since,  to  our 
knowledge, there have not been any published data about impact of high levels of oxygen on 
the growth, differentiation, or survival of MSCs, one can only speculate about its influence 
during the differentiation Protocol 2. As ASCs in a control medium were cultured under the 
same conditions, but exhibited much lower cell death rate, the elevated level of O2 could not 
be the only cause of observed cell  necrosis or apoptosis. However, the cells in the control 
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medium at the end of differentiation were more flattened and their spindle-shaped appearance 
was partly lost, not speaking in favor of ASC cultivation at 60% O2 for prolonged periods. 
Experiments with mouse ESCs have shown that culturing at high levels of  O2 starting from 
the first day of their differentiation into insulin-producing cells diminishes survival of cells. 
To  avoid  this,  mouse  ESCs  are  subjected  to  60%  O2 starting  from  the  third  day  of 
differentiation. Additionally, their culturing at  high levels of  O2 during the early stages of 
differentiation has the biggest effect on the efficiency of differentiation (Hakim et al. 2014). It 
is  possible  that  similar  approach  to  use  60% O2 only  during  the  first  two  stages  of 
differentiation  and  to  apply  it  few days  after  the  initiation  of  differentiation  would  have 
yielded better results and reduced the cell death. There is also a slight probability that a later  
cell passage used for this differentiation has influenced the failure of this protocol. It is hard to 
say why, because the ASCs from the donor No.4 at P6 have been successfully differentiated 
into  adipocytes,  osteocytes,  and  chondrocytes.  Since  no  data  is  available  on  MSC 
differentiation  or  survival  under  high  levels  of  oxygen  depending  on  cell  passage,  this 
possibility can not be entirely excluded.
3.3.2.3. Protocol 3
The ASCs from the donors No.3 and No.4 at P4 were subjected to the differentiation 
Protocol  3.  Since differentiation  of  ASCs into insulin-producing cells  using previous  two 
protocols  composed by ourselves  was not  successful,  we chose  to  test  the  differentiation 
protocol described by Kang et al. 2011. We incorporated small changes into their protocol by 
substituting a glucagon-like peptide 1 (GLP-1) by an exendin-4 and excluding a FBS for the 
first 3 days. Since natural GLP-1 is rapidly degraded, it is possible to use its long-acting 
analogue exendin-4 (Suen et al. 2006). And since activin A stimulates the differentiation more 
effectively  when  the  FBS is  absent  or  in  low concentrations  (D'Amour  et  al.  2005),  we 
decided to eliminate it at the beginning of the differentiation.
Throughout the differentiation ASCs from both donors preserved their spindle-shaped 
appearance  and  no  morphological  changes  were  detected  in  differentiated  cells  when 
compared to control cells (Figure 3.3.2.3.1.). In the course of the differentiation a formation 
of cell clusters was observed both in differentiation and control cells, but it was caused by a 
rapid cell growth in the differentiation and control media and a limited growth space rather 
than a ASC differentiation itself. Since a cell growth of both donors was practically identical, 
only morphology of ASCs of the donor No. 3 during the differentiation is presented herein.
Figure  3.3.2.3.1. Morphological  changes  in  ASCs  of  the  donor  No.3  during  their 
differentiation into insulin-producing cells using the Protocol 3. Scale bar 100 μm.
80
For this protocol immunocytochemistry method was not performed. After the first stage 
and at the end of differentiation the cells were collected for total RNA isolation. A reversely 
transcribed cDNA was used to detect expression of housekeeping genes GUSB and YWHAZ as 
well as genes SOX17, FOXA2, CK19, PDX1, INS, SST, PPY, ISL1, and GCG involved in the 
differentiation into insulin-producing cells by quantitative real-time RT-PCR analysis. After 
the initial screening of the genes critical to successful differentiation, only  SOX17,  FOXA2, 
CK19, SST, and PPY were detected in some of the examined samples (data not shown). Since 
those genes were detected both in differentiation and control samples from both donors, but 
no  visible  trend  was  detected  throughout  tested  samples,  the  differentiation  into  insulin-
producing cells using Protocol 3 was considered unsuccessful. This protocol has been used to 
differentiate  ASCs  from  human  eyelid  into  insulin-secreting  cells  with  considerable 
achievement.  Even without extra  addition of insulin-like growth factor  2 to the induction 
medium, after three weeks of differentiation the cells expressed such genes as ISL1,  NGN3, 
NKX2.2,  PDX1,  NKX6.1,  and  INS among others  β cell-related genes,  as  well  as  secreted 
insulin  in  a  glucose-dependent  manner  (Kang  et  al.  2011).  As  probable  reasons  for  the 
inability of used protocol to induce differentiation of herein studied ASCs could be suggested 
different  source of ASCs, donor-to-donor variability, or alterations made to differentiation 
medium.
 
3.3.2.4. Protocol 4
In parallel with the Protocol 3 the ASCs from the donors No.3 and No.4 at P4 were also 
subjected to the differentiation protocol published by Chandra et al. 2011. This study used low 
adherence cell culture dishes to achieve cell differentiation via aggregation. The same as in 
the Protocol 3, a GLP-1 was replaced with an exendin-4. In addition, sodium selenite was 
omitted. 
The  use  of  low  attachment  cell  culture  plates  resulted  in  the  formation  of  ASC 
aggregates soon after the beginning of the differentiation Protocol 4. On the next day the 
ASCs were congregated into irregular aggregates of different sizes that freely floated into a 
medium  (Figure  3.3.2.4.1.).  After  the  first  stage  of  the  differentiation  most  of  the  cell 
aggregates became rounded in shape, but their size still differed greatly. After the second stage 
a considerable part of smaller aggregates had disappeared, and this pattern was observed also 
throughout the third stage of the differentiation. The main reason for the cell loss during the 
differentiation process was disintegration of formed ASC aggregates. It seemed that cell to 
cell  interactions  within  the  small-scale  aggregates  were  not  strong  enough,  causing  their 
decomposition. Towards the end of the differentiation, even the larger aggregates started to 
disintegrate. The cells at the outer edge of aggregates became swollen and gradually loosened. 
This process together with a mechanical loss of the cells during the medium changes, that 
included  collection  and  centrifugation  of  ASC aggregates,  resulted  in  a  very  few   large 
aggregates at the end of the differentiation Protocol 4.
After the first stage and at the end of differentiation a total RNA was isolated and the 
same set of gene expression as after the Protocol 3 was tested by quantitative real-time RT-
PCR. Similarly to that protocol, only SOX17, CK19, SST, and PPY were detected in some of 
the  examined  samples,  but  without  a  coherent  trend  (data  not  shown).  Although  cell 
aggregation  into  3D  clusters  has  been  successfully  employed  on  ASCs  leading  to  their 
differentiation into physiologically functional islet-like cell aggregates (Chandra et al. 2011), 
this  method  was  not  effective  in  our  experience.  Observations  during  the  differentiation 
process suggested that ASCs cultivation on low adherence cell culture plates did not give the 
expected result. Quite the opposite, disintegration of 3D aggregates and subsequent loss of 
cells gave no opportunity to evaluate the efficiency of the tested protocol itself, since such 
culture conditions were not optimal for ASCs survival, let alone differentiation.
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Figure  3.3.2.4.1. Morphological  changes  in  ASCs  of  the  donor  No.3  during  their 
differentiation into insulin-producing cells using the Protocol 4. Scale bar 100 μm.
3.3.2.5. Protocols 5-8
Since previously examined 4 protocols did not result in a successful differentiation of 
ASCs into  insulin-producing  cells,  we decided  to  test  whether  ASCs are  at  least  able  to 
differentiate into cells of endodermal origin. This is usually achieved after the second stage of 
differentiation  into  insulin-producing  cells  and is  the  most  important  turning-point  in  the 
process of this differentiation. We chose three previously published studies that have shown 
notable differentiation of MSCs into insulin-producing cells and followed the first two stages 
of  their  differentiation  protocols  that  should  result  into  the  differentiation  of  cells  with 
endodermal  characteristics  according to  their  results.  Additionally  we included  the  fourth 
protocol to test a role of small molecules in the differentiation process. The ASCs from the 
donors No.4 and No.9 at P4 were subjected to the differentiation. The ASCs from both donors 
showed morphological differences before a start of the differentiation. ASCs of the donor 
No.4 were spindle-shaped like classical MSCs (Figure 3.3.2.5.1.) whereas part of the ASCs of 
the  donor  No.9  were  larger,  more  flattened,  and  exhibited  more  rounded  shape  (Figure 
3.3.2.5.2.). 
 Protocol 5 was based on the observations that two small  molecules LY294002 and 
CHIR99021  can  facilitate  differentiation  into  endodermal  lineage  (McLean  et  al.  2007, 
Kunisada et al. 2012).  After the first stage of the differentiation the cells from both donors 
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were finely spindle-shaped (Figures 3.3.2.5.1. and 3.3.2.5.2.), but the cells of the donor No.9 
showed elevated cell death rate. At the end of the differentiation protocol almost all cells of 
the donor No.9 were lost.  The cells  of the donor No.4 turned out to be more tolerant  as 
approximately 50% of the cells remained after the differentiation has been finished. The ASCs 
of both donors in a control medium did not show any changes throughout the differentiation. 
Figure  3.3.2.5.1. Morphological  changes  in  ASCs  of  the  donor  No.4  during  their 
differentiation into cells of endodermal lineage using the Protocol 5. Scale bar 100 μm.
Figure  3.3.2.5.2. Morphological  changes  in  ASCs  of  the  donor  No.9  during  their 
differentiation into cells of endodermal lineage using the Protocol 5. Scale bar 100 μm.
Since all the components of the differentiation medium used in the Protocol 5, except 
LY294002 and CHIR99021, have been tested previously and have not shown such cell death 
rate, it is feasible to suspect the role of those two small molecules in the observed process. 
CHIR99021 is a highly selective inhibitor of GSK3β and GSK3α and its effect on other cell 
signalling processes would be very low (Kunisada et al. 2012), thus diminishing its potential 
effect on  observed cell death. Although there is no information about its influence on ASC 
cultures, it has been shown that UC blood SCs can be cultured in the presence of CHIR99021 
at least  for a week with increasing cell  numbers (Huang et  al.  2012). On the other hand,  
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LY294002 is not only a strong inhibitor of PI3K signalling, but also a potent inhibitor of other 
proteins.  And  considering  the  crucial  role  of  PI3K  signalling  in  growth,  proliferation, 
metabolism, and survival of cells (Gharbi et al. 2007), its long-term inhibition alone could 
lead to elevated cell death.  It is known that LY294002 at higher concentrations than 50 μM 
causes human ESC death in a concentration-dependent manner, but its action in DE formation 
is safe and effective at concentrations between 20 and 50 μM (McLean et al. 2007). Although 
in this protocol LY294002 was used at 50 μM concentration that should be safe for ESCs, its 
influence on ASCs is unknown. As observed during this differentiation Protocol 5, there was a 
significant  difference  between ASCs from both  donors  regarding  their  tolerance  for  used 
induction  protocol,  most  likely  caused  by  impact  of  LY294002.  The  exposure  time  of 
LY294002 is another crucial  issue in ESC differentiation into DE. Sustained inhibition of 
PI3K for 4 to 5 days is necessary for successful differentiation of ESCs (McLean et al. 2007),  
and since differentiation potential of somatic SCs is considered lower than that of ESCs, the 
treatment  with  LY294002 was  prolonged in  our  protocol.  It  is  possible  that  the  detected 
increase in cell death was due to a role of PI3K in cell survival processes, and blockade of its 
signalling for more than 5 days turned out to be critical for examined ASC cultures. However, 
ASCs of the donor No.9 were more susceptible and even 3 days in the presence of LY294002 
caused their death. The observed change in cell morphology of both donors was also likely 
the result of LY294002 action, as it has been observed in human ESCs and is associated with 
downregulation of the cell adhesion molecule E-cadherin (McLean et al. 2007).
Protocol 6 was based on the manuscript by Buang et al. 2012. The original manuscript 
described  a  generation  of  insulin-producing  cells  from human  ASCs in  three  weeks.  We 
repeated the first stage of their protocol substituting only a glucagon-like peptide 1 (GLP-1) 
by an exendin-4 and changing a concentration of FBS. The authors used 10% FBS for the 
differentiation medium, but we applied 0,2% FBS for the first 3 days and 2% FBS afterwards. 
We decided to reduce the concentration of FBS, as their protocol included addition of activin 
A and  it  is  known  to  be  more  effective  in  the  presence  of  low  concentrations  of  FBS 
(D'Amour et al. 2005). During the differentiation ASCs did not change their morphology and 
no difference was observed between differentiation and control  cells  in  neither  of donors 
(Figures 3.3.2.5.3. and 3.3.2.5.4.). A transformation of cell growth pattern of both donors was
Figure  3.3.2.5.3. Morphological  changes  in  ASCs  of  the  donor  No.4  during  their 
differentiation into cells of endodermal lineage using the Protocol 6. Scale bar 100 μm.
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Figure  3.3.2.5.4. Morphological  changes  in  ASCs  of  the  donor  No.9  during  their 
differentiation into cells of endodermal lineage using the Protocol 6. Scale bar 100 μm.
detected, as active cell  growth continued throughout the differentiation process. This is in 
compliance with published data, since during the first stage of differentiation continuous cell 
expansion  is  observed  and  morphological  changes  could  be  detected  only  during  the 
following stage (Buang et al. 2012). 
Protocol  7 was based on the manuscript by Gao et  al.  2008. The first  stage of this 
differentiation protocol lasts only three days during which UC blood SCs show no changes in 
their morphology, but the expression of  NGN3 and  PDX1 genes could be already detected 
according to the authors (Gao et al. 2008). During these three days of differentiation the ASCs 
continued  to  actively  proliferate  and  no  significant  changes  in  a  cell  morphology  were
Figure  3.3.2.5.5. Morphological  changes  in  ASCs  of  the  donor  No.4  during  their 
differentiation into cells of endodermal lineage using the Protocol 7. Scale bar 100 μm.
Figure  3.3.2.5.6. Morphological  changes  in  ASCs  of  the  donor  No.9  during  their 
differentiation into cells of endodermal lineage using the Protocol 7. Scale bar 100 μm.
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observed  in  both  donors  (Figures  3.3.2.5.5.  and  3.3.2.5.6.).  Similarly  no  difference  was 
detected between differentiation and control samples.
Protocol  8  was  based  on the  manuscript  by  Sun  Y. et  al.  2007.  After  a  two  stage 
differentiation  protocol  lasting  for  10  days  authors  observed  changes  in  BM  MSC 
morphology and formation of cell  aggregates,  as well  as showed the expression of genes 
Nestin, PDX1, NGN3, PAX4, INS, and GCG (Sun Y. et al. 2007). Likewise using the Protocol 
7,  no  transformations  in  ASC  morphology  were  noticed  in  the  course  of  differentiation 
Protocol 8 in the cells of both donors, and the cells under differentiation conditions did not 
differ from the control cells (Figures 3.3.2.5.7. and 3.3.2.5.8.).
Figure  3.3.2.5.7. Morphological  changes  in  ASCs  of  the  donor  No.4  during  their 
differentiation into cells of endodermal lineage using the Protocol 8. Scale bar 100 μm.
Figure  3.3.2.5.8. Morphological  changes  in  ASCs  of  the  donor  No.9  during  their 
differentiation into cells of endodermal lineage using the Protocol 8. Scale bar 100 μm.
At the end of the every differentiation the cells were stained with anti-SOX17 and anti-
PDX1  antibodies  to  detect  pancreatic  progenitors.  The  nuclear  staining  of  SOX17  was 
identified along with cytoplasmic staining in both the differentiated and control cells using the 
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Protocols  6,  7,  and 8  (Appendices  20,  21,  22).  When the  Protocol  5  was  employed,  the 
SOX17 was observed throughout the differentiated cells, but distinct staining of the nuclei 
was  not  recognized,  although  control  cells  displayed  more  pronounced  nuclear  staining 
(Appendix 19). The staining intensity of SOX17 antibody was weak in all cases, except in the 
differentiated cells of the Protocol 5. This increase was most likely caused by the evident cell 
death in these samples and hence compromised cell membranes leading to more unspecific 
antibody binding. The PDX1 staining was observed in the same pattern as in the Protocols 1 
and 2. The definite staining of nucleoli and probable Golgi complex was detected both in the 
differentiated cells and in the control cells using all four differentiation protocols (Appendices 
23,  24,  25,  26).  No significant differences in  the SOX17 or PDX1 staining manner were 
observed between the cells of both donors, although the definite motive of the PDX1 staining 
in some protocols was less marked in the cells of the donor No.4 due to the smaller and more 
spindle-shaped cells.
After the differentiation the cells were collected and total RNA was obtained. Suitable 
RNA sample from the differentiated cells of donor No.9 from Protocol 5 was not acquired due 
to  a  high  cell  death  during the  differentiation  protocol.  The obtained RNA samples  were 
reversely transcribed into cDNA and real-time RT-PCR was performed to detect expression of 
genes  GUSB, YWHAZ,  β-Actin (housekeeping genes),  SOX17,  FOXA2,  PDX1, and  CXCR4. 
For the genes SOX17 and FOXA2 two primer pairs were tested. The human pancreas served 
as a positive control.  Additionally  a sample of ASCs of donor No.4 before a  start  of the 
differentiation was analysed. The initial screening of the above-mentioned genes showed no 
expression  of  the  genes  FOXA2 and  PDX1 in  any  of  the  samples  examined,  except  the 
positive control (data not shown). The genes SOX17 and CXCR4 were detected both in few 
differentiation and some control samples from both donors, but no apparent coherence was 
observed between those two (Figure 3.3.2.5.9.). No similar pattern was also found between 
the  expression  of  SOX17 gene  detected  by  two  different  primer  sets.  Since  the  initial 
screening showed no visible difference among all four differentiation protocols tested, nor 
between differentiation and control samples or both donors, further and more extensive gene 
analysis was not performed.
Figure 3.3.2.5.9. Comparison of relative expression level of genes SOX17 and CXCR4 in the 
differentiated  and  control  cells  of  donors  No.4  and  No.9  by  real-time  RT-PCR  (data 
normalized to  GUSB). For the detection of  SOX17 gene expression two primer pairs were 
used: SOX17_C and SOX17. Protocols 5-8 - different protocols used to differentiate ASCs 
into cells of endodermal lineage. No.4 – donor No.4; No.9 – donor No.9; ASCs – adipose-
derived stem cells before the differentiation; Differ. - differentiated cells; Contr. - cells grown 
in a control medium.
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The overall results from four above-described protocols showed  no solid evidence of 
tested  ASC ability to differentiate into cells of endodermal origin. It is unclear whether the 
chosen protocols have been unsuitable for the tested ASC cultures, the ASCs of both donors 
are incapable of differentiation into types of cells that do not have mesodermal origin,  or 
published protocols for MSC differentiation into endodermal cells are not universal and can 
not be successfully repeated in a slightly altered setting.
3.3.2.6. Protocol 9
The ASCs from the donors No.4 and No.8 (diabetic donor) at P4 were subjected to the 
differentiation Protocol 9. The first two stages were identical to the Protocol 5 followed by 
two  additional  stages  of  differentiation.  Although  a  differentiation  of  ASCs  into  cells  of 
endodermal origin using the Protocol 5 was not successful and high rate of cell death was 
observed, we decided to test the effects of CHIR99021 and LY294002 by reducing the time of 
differentiation in the presence of these small molecules. 
After  the first  stage of differentiation the cells  of both donors in  the differentiation 
medium started to gather into clusters (Figures 3.3.2.6.1. and 3.3.2.6.2.). During the second
Figure  3.3.2.6.1. Morphological  changes  in  ASCs  of  the  donor  No.4  during  their 
differentiation into insulin-producing cells using the Protocol 9. Scale bar 100 μm.
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Figure  3.3.2.6.2. Morphological  changes  in  ASCs  of  the  donor  No.8  during  their 
differentiation into insulin-producing cells using the Protocol 9. Scale bar 100 μm.
stage of differentiation further clustering was not observed although the previously formed 
groups  of  cells  were still  evident.  In  the  course  of  the  first  two stages  of  differentiation 
slightly elevated cell death was detected, but it did not impede the differentiation. Throughout 
the  third  stage  of  differentiation  part  of  the  cells  started  to  lose  their  spindle-shaped 
appearance and became more flattened. These cells were usually clustered together in small 
groups. Furthermore, accumulation of intracellular granules was identified in the altered cells. 
During the last stage of differentiation cell flattening became more apparent and  was also 
observed in small  amounts in the control cells.  Similarly, the small  clusters of cells were 
detected in the control samples at the end of differentiation. No difference was discovered 
between the cells of both donors throughout the differentiation process.
At the end of the differentiation Protocol  9 a double staining immunocytochemistry 
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method was used on both the differentiation and control samples. Anti-C-PEPT, anti-NGN3, 
anti-PDX1, and anti-SST antibodies were co-stained with anti-INS and anti-GCG antibodies 
in the same manner as for the differentiated samples in the Protocols 1 and 2. Although the 
expression  of  PDX1  is  usually  tested  earlier  in  the  course  of  differentiation  to  detect 
pancreatic precursors, it can still be found in restricted parts of adult pancreas (Stoffers et al. 
1997). Our obtained results demonstrated that a staining pattern of PDX1 is practically the 
same as in all previous protocols tested. The distinct staining of nucleoli and probable Golgi 
complex was detected both in the differentiated cells and in the control cells, but more marked 
nuclear staining was observed in part of the cells when compared to former protocols (Figure 
3.3.2.6.3.).
Figure  3.3.2.6.3. Expression  of  INS  and  PDX1  in  ASCs  of  donor  No.8  after  their 
differentiation  into  insulin-producing  cells  using  the  Protocol  9.  Cell  nuclei  stained  with 
DAPI. Magnification 200x.
The INS staining pattern was also almost identical to earlier protocols – distinct staining 
of nuclei and weak expression in a cytoplasm (Figures 3.3.2.6.3. - 3.3.2.6.6.). However, few 
cells with more pronounced cytoplasmic staining were observed in the differentiation samples 
(Figure  3.3.2.6.4.).  The  C-PEPT  was  found  only  in  the  cytoplasm  and  it  showed  a 
colocalization with cytoplasmic staining of INS, but no difference was detected between the 
differentiation and control sample (Figure 3.3.2.6.4.).
The  staining  of  NGN3  was  very  weakly  identified  solely  in  the  nuclei  of  both 
differentiated and control cells (Figure 3.3.2.6.5.). The observed expression of SST in the cell 
nuclei  was almost at  the background level and could not be considered as positive signal 
(Figure  3.3.2.6.6.).  The  expected  cytoplasmic  staining  was  not  observed,  although  it  is 
impossible to distinguish the exact staining pattern of the examined protein in a cluster of 
cells.  Most likely the visible colouring in the centre of cell clusters shown in the Figures 
3.3.2.6.3., 3.3.2.6.5., and 3.3.2.6.6. is a staining artefact because no actual cells could be seen 
amidst of these clusters.
The double immunocytochemistry staining with GCG antibodies is not presented in this 
work because a GCG signal was only slightly above the background level in all  samples 
tested and therefore was not considered as positive. Other antibody staining showed identical 
results to those presented above. The same applies to the immunocytochemistry results from 
the cells of donor No.4. Since obtained data from both donors were indistinguishable, only 
one set of the results was described herein.
90
Figure  3.3.2.6.4. Expression  of  INS  and  C-PEPT  in  ASCs  of  donor  No.8  after  their 
differentiation  into  insulin-producing  cells  using  the  Protocol  9.  Cell  nuclei  stained  with 
DAPI. Magnification 200x.
Figure  3.3.2.6.5. Expression  of  INS  and  NGN3  in  ASCs  of  donor  No.8  after  their 
differentiation  into  insulin-producing  cells  using  the  Protocol  9.  Cell  nuclei  stained  with 
DAPI. Magnification 200x.
The total RNA was obtained from differentiation and control samples after the second 
stage of differentiation and at the end of the Protocol 9. The RNA samples were reversely 
transcribed into cDNA and real-time RT-PCR was performed to detect expression of genes 
GUSB,  β-Actin (housekeeping genes),  SOX17,  FOXA2,  PDX1,  WNT3,  CXCR4,  CK19,  INS, 
PPY, SST, HNF1A, HNF1B, HNF4A, GCG, PAX6, NKX6-1, MNX1, and PTF1A. The human 
pancreas served as a positive control.  The initial  screening of the above-mentioned genes 
showed no expression of the genes PDX1, HNF1A, HNF1B, PTF1A, INS and GCG in any of 
the samples examined, except the positive control (data not shown). The expression of the 
genes SOX17, FOXA2, WNT3, CK19, PPY, SST, PAX6, and NKX6-1 was found in most of the 
samples tested, both in differentiation and control, but no visible trend of increase or decrease 
of the gene expression during the differentiation was observed (data not shown). Only the 
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expression of the genes CXCR4 and MNX1 followed a detectable trend (Figure 3.3.2.6.7.).
Figure 3.3.2.6.6. Expression of INS and SST in ASCs of donor No.8 after their differentiation 
into  insulin-producing  cells  using  the  Protocol  9.  Cell  nuclei  stained  with  DAPI. 
Magnification 200x.
 
The expression of the gene CXCR4 was detected only in the samples of the donor No.8. 
It was found at a low level already in undifferentiated ASCs. After the second stage of the 
differentiation,  the  expression  of  CXCR4 in  the  differentiation  sample  was tenfold higher 
when compared to ASCs before the differentiation.  The expression in control sample was 
almost doubled. At the end of the differentiation the CXCR4 was not detected in any of the 
samples tested. The expression of the gene MNX1 was observed at a very low level only after 
the second stage of the differentiation, both in differentiation samples of the donors No.4 and 
the donor No.8. The expression of both above-mentioned genes was much lower than in a 
human  pancreas,  indicating  a  modest  degree  of  efficiency  of  the  chosen  differentiation 
protocol or a low level of ASCs submitted to this differentiation.
Figure 3.3.2.6.7. Comparison of relative expression level of genes CXCR4 and MNX1 in the 
differentiated and control cells of donors No.4 and No.8 after the second stage (2nd stage) of 
the  differentiation  Protocol  9  and  at  the  end  of  it  (Final)  by  real-time  RT-PCR  (data 
normalized to GUSB). No.4 – donor No.4; No.8 – donor No.8; ASCs – adipose-derived stem 
cells before the differentiation; Differ. - differentiated cells; Contr. - cells grown in a control 
medium.
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CXCR4 (chemokine (C-X-C motif) receptor 4) is a chemokine receptor, and together 
with its ligand, stromal derived factor 1α, is critical for differentiation of numerous tissues 
during  development.  It  is  an  essential  component  of  pancreatic  ductal  cell  survival, 
proliferation,  and  migration  throughout  pancreatic  organogenesis,  as  well  as  regeneration 
(Kayali et al. 2003). It has been used as a marker of pancreatic endocrine progenitors and has 
been suggested as one of the possible markers that could help to identify putative pancreatic 
SCs (Koblas et al. 2007). In the course of  in vitro pancreatic cell differentiation CXCR4 is 
considered as a marker of definitive endoderm (D'Amour et al. 2005, D'Amour et al. 2006, 
Jiang et al. 2007, Zhang et al. 2009).
MNX1  (motor  neuron  and  pancreas  homeobox  1)  (also  known  as  HLXB9)  is  a 
transcription factor which is expressed at the early stages of pancreatic development and also 
later in differentiated β cells (Riley and Gannon 2014). It is required for dorsal pancreatic bud 
development  and  differentiation  of  endocrine  cell  types  (Grapin-Botton  et  al.  2001).  In 
zebrafish model loss of  Mnx1 provokes the differentiation of β cell precursors into α cells, 
suggesting that Mnx1 promotes β and suppresses α cell fate (Dalgin et al. 2011). Its expression 
coincide with such gut endoderm patterning genes as PDX1 and PTF1A (Riley and Gannon 
2014).
Since only initial screening of samples was performed, meaning that PCR efficiencies 
for each primer pair were not determined and no replicates were run, no definite conclusions 
can be drawn from the obtained results. However, it gives an insight into success of used 
differentiation protocol. One could speculate that a combination of activin A, sodium butyrate, 
LY294002, and CHIR99021 has stimulated differentiation of ASCs into DE and further into 
the posterior foregut, indicated by the detection of an increase in  CXCR4 expression in the 
samples  of  donor  No.8,  as  well  as  expression  of  MNX1 in  both  donors.  All  of  these 
components  and  their  combinations  have  been  previously  shown  to  effectively  induce 
endoderm differentiation in ESCs and iPSCs (D'Amour et al. 2005, Jiang et al. 2007, McLean 
et al. 2007, Kunisada et al. 2012) and may have proven useful in the setting of adult SCs as  
well. At this stage of pancreatic differentiation PDX1 expression is regarded as a turning point 
of successful differentiation as PDX1-positive cells will give rise to the islets, exocrine cells, 
and ductal cells (Gu et al. 2002).  PDX1 expression usually coincide with the expression of 
PTF1A and  MNX1 genes (Riley and Gannon 2014).  Since only expression of  MNX1 was 
detected,  but PDX1 was not  observed neither at  gene nor at  protein level,  it  may not be 
enough to suggest efficient ASC differentiation into posterior foregut. Even if ASCs of both 
donors have been able to transdifferentiate into endodermal cells at some level, their further 
differentiation into insulin-producing cells has been impeded as no solid evidence has been 
collected to suggest otherwise.
Published results show that not only ASCs (Timper et al. 2006, Lee et al. 2008, Okura et 
al. 2009, Chandra et al. 2011, Kang et al. 2011, Buang et al. 2012), but also SCs isolated from 
human UC blood (Sun B. et al. 2007, Hu et al. 2010), placenta (Chang et al. 2007), and BM 
(Sun Y. et  al.  2007,  Tang et  al.  2012)  can  be  differentiated  into  insulin-producing  cells. 
Unfortunately, we have not been able to differentiate any of our tested ASC cultures into 
insulin-positive cells. Even attempts to obtain cells expressing endodermal markers have not 
produced any reliable results. Since the lack of an efficient standard method for functional 
insulin-producing  cell  generation  in  vitro forces  every  researcher  to  create  individual 
differentiation protocol, it does not come as a surprise that part of those protocols can not be 
reproduced neither by us, nor by others (Oishi et al. 2009). An optimization of the  timing and 
combination of chemical factors to activate or suppress the key signalling pathways during 
pancreatic  development  is  critical  to  positive  outcome.  However,  the  mechanisms  and 
pathways that govern the required changes in cell phenotype to reach the desired cell type are 
not fully understood. This makes a controlled and highly reproducible differentiation much 
harder to design. We do believe that ASC differentiation into insulin-producing cell can be 
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achieved and our lack of success is only due to unsuitable protocols. Our results suggest that 
herein  used  protocols  that  have  been originally  designed for  BM MSC or  UC blood SC 
differentiation can not be directly employed on ASCs. Even those that have been tested on 
ASCs can probably produce non-identical results if the site of adipose tissue or the method of 
their  acquirement  differs.  During  our  work  we  have  seen  diversity  of  ASC morphology, 
proliferative capacity, and differential capacity among various donors (unpublished results). In 
this work morphological differences were observed between ASCs of the donors No.4 and 
No.9. Differentiation ability into osteocytes was also unequal in ASCs of the donors No.4 and 
No.5. Also the 3D aggregate formation in the ASC culture of the donor No.4 was likewise 
unique. This donor-to-donor variability is another problem hampering the design of effective 
differentiation  protocols.  Nevertheless,  the  further  exploration  of  chemical,  as  well  as 
physiological and mechanical factors regulating the process of differentiation is continuing, 
and it will require a great deal of scientific efforts before somatic SCs can be effectively 
differentiated into insulin-producing cells for diabetes treatment.
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4. Conclusions
1. Human ASCs can be effectively cultured and expanded in the medium supplemented with 
autologous serum. Such culture conditions do not influence their morphology, expression 
of  characteristic  MSC surface  markers  and the  ability  to  differentiate  into  adipocytes, 
osteocytes, and chondrocytes.
2. ASCs  from  the  second  passage  to  the  eighth  passage,  cultured  in  the  presence  of 
autologous serum, represent a highly homogeneous cell population showing simultaneous 
expression of such surface markers as CD29, CD44, CD73, CD90, and CD105, but lacking 
the expression of HLA-DR, CD14, CD19, CD34, and CD45. The accumulation of positive 
surface proteins increases with each subsequent passage and is preserved after double cell 
freezing and more than 4 years of cryopreservation. 
3. The observed ASC aggregation into three-dimensional bodies may represent a response 
mechanism  triggered  by  various  stress  conditions,  such  as  alterations  in  the  culture 
medium, growth environment, culture conditions, or growth surface, since the formation of 
different types of bodies was detected after changes in one or more of these factors.
4. The floating ASC bodies that have spontaneously formed at early passages may represent 
more primitive cell subpopulation within the individual ASC culture due to their ability to 
form such three-dimensional aggregates and lack of alkaline phosphatase activity.
5. The expression of pluripotency marker genes OCT4A and SOX2 is very low in ASCs. The 
OCT4A protein can not be detected neither in monolayer culture of ASCs nor in glass 
adherent ASC bodies.
6. ASCs show the expression of NANOG pseudogene 8, but the level of transcription is very 
modest.  The  parental  NANOG gene  is  detected  in  ESCs,  but  its  presence  in  ASCs  is 
inconclusive.
7. It is possible that NANOG pseudogene 8 is translated into protein in the tested ASCs and 
the  presence  of  positive  signal  detected  by  anti-NANOG  antibodies  could  be  due  to 
translation of NANOG pseudogene 8, NANOG, or both.
8. ASCs  cultured  in  the  medium  containing  autologous  serum  can  differentiate  into 
adipocytes,  osteocytes,  and  chondrocytes  at  least  until  the  sixth  passage.  ASCs  from 
different donors show various degree of differentiation towards osteogenic lineage.
9. ASC cultures of four donors could not be differentiated into cells of endodermal lineage or 
insulin-producing cells employing the nine differentiation protocols tested in this study.
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5. Theses for defence
1. The fetal bovine serum in a conventional adult stem cell culture medium can be substituted 
with the autologous serum without affecting the characteristics and abilities of the cells.
2. To avoid false positive results that lead to attribution of pluripotent cell characteristics to 
adult stem cells, an accurate and complex approach is required to confirm the expression of 
pluripotency markers OCT4 and NANOG in human stem cells.
3. NANOG pseudogene 8 is not only transcribed in the tested ASC culture, but it may also be 
translated into protein.
4. The differentiation  of  ASC into  cells  of  endodermal  lineage or  insulin-producing cells 
could  not  be  achieved  using  the  commonly  described  protocols  for  adult  stem  cells, 
because  the  chemical,  as  well  as  physiological  and  mechanical  factors  regulating  the 
process  of  such  differentiation  are  weakly  understood and  each  published  protocol  is 
highly adapted for individual case.
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Appendix
Appendix 1
Comparison  of  OCT4A  gene  product  sequence,  amplified  with  OCT4  primers,  to  OCT4 
pseudogene 3 (OCT4P3), pseudogene 4 (OCT4P4), and pseudogene 1 (OCT4P1) sequences 
of current primary reference assembly (GRCh38) (using Clustal Omega software). Sequences 
of primers used in the assay are underlined and written in bold. Distinct nucleotides found in 
the pseudogenes, but not in the original OCT4A gene, are marked in yellow. Unique sites of 
OCT4A gene are marked in green. The corresponding sequences of pseudogenes 2, 5, 6, 7, 
and 8 are not shown, since they display no similarity to the region of interest.
OCT4A    TGAGGTGTGGGGGATTCCCCCATGCCCCCCGCCGTATGAGTTCTGTGGGGGGATGGCGTA 
OCT4P3   TGAGGAGTGGGGGATTCCCCCATGTCCCCCGCCGTATGAGTTCTGCGGGGGGATGGCGTA 
OCT4P4   TGAGGTGTGGGGGATTCCCCCATGCCCCCCGCTGTATGAGTTCTGTGGGGGGATGGCGTA 
OCT4P1   TGAGGTGTGGGGGATTCCCCCTTGCCCCCCGCCGTATGAGTTATGTGGGGGGATGGCGTA 
         ***** *************** ** ******* ********* ** ************** 
OCT4A    CTGTGGGCC  CCAGGTTGGAGTGGGGCTAGTGCCCCAAGGCGGCTTGGAGACCTCTCAGCC 
OCT4P3   CTGTGGGCCTCAGACTGGAGTGGGGCTAGTGCCCCAAGACGGCTTGGAGACCTCTCAGCC 
OCT4P4   CTGTGGGCCTCAGGTTGGAGTGCGGCTAGTGCCCCAAGGCGGCTTGGAGACCTCTCAGCC 
OCT4P1   CTGTGGGCCTCAGGTTGGAGTGGGGCTAGTGCCCCAAGGCGGCTTGGAGACCTCTCAGCC 
         ********* ***  ******* *************** ********************* 
OCT4A    TGAGGGCGAAGCAGGAGTCGGGGTGGAGAGCAACTCCGATGGGGCCTCCCCGGAGCCCTG 
OCT4P3   TGAGGGCGAAGCAGGAGTCGGGGTGGAGAGCAACTCCGATGGGGCCTCCCCGGAGCCCTG 
OCT4P4   TGAGGGCGAAGCAGGAGTCAGGGTGGAGAGCAACTCCGATGGCACCTCCCTGGAGCCCTG 
OCT4P1   TGAGAGCGAAGCAGGAGTCGGGGTGGAGAGCAACTCCAATGGGGCCTCCCCGGAACCCTG 
         **** ************** ***************** ****  ****** *** ***** 
OCT4A    CACCGTCACCCCTGGTGCCGTGAAGCTGGAGAAGGAGAAGCTGGAGCAAAACCCGGAGGA 
OCT4P3   CACCGTCCCCTCTGGTGCCGTGAAGCTGGAGAAGGAGAAGCTGGAGCAAAACCCGGAGGA 
OCT4P4   CACCGTCCCCCCTGGTGCCGTGAAACTGGAGAAGGAGAAGCTGGAGCAAAACCCGCAGGA 
OCT4P1   CACCGTCCCCCCTGGTGCCGTGAAGCTGGAGAAGGAGAAGCTAGAGCAAAACCCGGAGAA 
         ******* ** ************* ***************** ************ ** * 
OCT4A    GTCCCAGGACATCAAAGCTCTGCAGAAAGAACTCGAGCAATTTGCCAAGCTCCTGAAGCA 
OCT4P3   GTCCCAGGACATCAAAGCTCTGCAGAAAGAACTCGAGCAATTTGCCAAGCTCCTGAAGCA 
OCT4P4   GTCCCAGAACATCAAAGCTCTGCAGAAAGAACTCGAACAATTTGCCAAGCTCCTGAAGCA 
OCT4P1   GTCCCAGGACATCAAAGCTCTGCAGAAAGAACTCGAGCAATTTGCCAAGCTCCTGAAGCA 
        ******* **************************** ***********************
Appendix 2-1
Comparison  of  NANOG  gene  product  sequence,  amplified  with  NANOG_1  primers,  to 
NANOGP1-NANOGP11  pseudogene  sequences  of  current  primary  reference  assembly 
(GRCh38)  (using  Clustal  Omega software).  Sequences  of  primers  used  in  the  assay  are 
underlined and written in bold. Distinct nucleotides found in the pseudogenes, but not in the 
original  NANOG gene,  are marked in yellow. The site that distinguishes  NANOGP8 from 
NANOG is marked in green. 
NANOG        ---------GTCTCTCCTCTTCCTTCCTCCATGGATCTGCTTATTCAGGACAGCCCTGAT 
NANOGP8      ---------GTCTCTCCTCTTCCTTCCTCCATGGATCTGCTTATTCAGGACAGCCCTGAT 
NANOGP1      TTTCCAACAGTCTCTCCTCTTCCTTCCTCCATGGATCTGCCTATTCAGGACAGCCATGAT 
NANOGP2      ---------GTCTCTCCTCTTCCTTCCTCCATGGATCTG-------AGGATAGTCCTGAT 
NANOGP4      ---------GTCTCTCCTCTTC-TTCCTCCATGGATCTGCTTATTCAGGACAGCCCTGAT 
NANOGP7      ---------GTCTCTCCTCTTCCTTCCTCCGTGGATCTGCTTATTTAGGACAGCCCTGAT 
NANOGP9      ---------GTCTCTCCTCTTCCTTCCTCCATGGATCTGCTTATTCAGGACAGCCCTGAT 
NANOGP10     ---------GTCTCTCCTCTTCCTTCCGCCATGGATCTGCTTATCCAGGACAGCCCTGAT 
NANOGP11     ------------------------------------------------------------ 
NANOGP6      ---------CTCTCTCATCTTCCTTCCTCCGTGGATCTATTTATTCAGGAAAGCTCTAAT 
NANOGP5      ------------------------------------------------GACAGCTCTAAT 
NANOGP3      ------------------------------------------------------------ 
  
NANOG        TCTTCCACCAGTCCCAAAGGCAAACAACCCACTTCTGCAGAGAAGAGTGTCGCAAAA-AA 
NANOGP8      TCTTCCACCAGTCCCAAAGGCAAACAACCCACTTCTGCAGAGAATAGTGTCGCAAAA-AA 
NANOGP1      TCTTCCACCAGTCCCAAAGGCAAACAACCCACTACTGCAGAGAAGAGTGCCACAAAA-AA 
NANOGP2      TCTCCTACCAGTCCCAAAGGCAAACAACCCACTGCTGCAGAGAATAGCGCCACAAAAGAA 
NANOGP4      TCTTCCACCAGTCCCAAAGGCAAACAACCCATTGCTGCAGAGAATAATGCCCCAAAA-AA 
NANOGP7      TCTTCCACCCCTCCCAAAGGCAAACAACCCACTTCTGCAGAGAAGAGTGCCAGAAAA-AA 
NANOGP9      TCTTCCACCAGTCCCAAAGGCAAGCAACCCACTTCTGCAGAGAAGAGTGCCACAAAA-AA 
NANOGP10     TCTTCTACCAGTCCTAAAGGCAAAAAACCCACTTCTGCAGAGAAGAGCACCACAAAA-AA 
NANOGP11     ------------------------------------------------------------ 
NANOGP6      TCTTCCACTAGTCCCAGAGTAAAACTACACATTTCTGCAGAGAAGAGCACAGTG-AAGAA 
NANOGP5      TCTTTCACGAGTCCCAAAGGCAGACAACTCACTTCTGCAGAGAAGAGCACCGCAAAA-AA 
NANOGP3      ------------------------------------------------------------ 
  
NANOG        GGAAGACAAGGTCCCGGTCAAGAAACAGAAGACCAGAACTGTGTTCTCTTCCACCCAGCT 
NANOGP8      GGAAGACAAGGTCCCGGTCAAGAAACAGAAGACCAGAACTGTGTTCTCTTCCACCCAGCT 
NANOGP1      GGAAGACAAGGTCCCGGTCAAGAAACAGAAGACCAGAACTGTGTTCTCTTCCACCCAGCT 
NANOGP2      GGAAGACAAGGTCCCAGTCAAGAAACAGAAGACCAGAACTGTGTTCTCTTCCACCCAGCT 
NANOGP4      GGGAGACGAGGTCCCAGTCAAGAAACAGAAGACCAGAACTGTGTTTTCTTCCACCCAGCT 
NANOGP7      GGAAGACAAGGTCCCATTCAAGAAACAGAAGACCAGAACTGTGTTCTCTTCCACACAGCT 
NANOGP9      GGAAAACAAGGTCCCAGTCAAGAAACAGAAGACCAGAACTCTGTTCTCTTCCAACCAGCT 
NANOGP10     GGAAGACAAGGTCCTGGTCAAGAAACAGAAGACCAGAACTGTGTTCCGTTCCACCCAGCT 
NANOGP11     ------------------------------------------------------------ 
NANOGP6      TGAAGATAAGATCCAGGAGAAGAAACAGAAGACCAGAATCATGTTCTCTCCGGCCCAGCT 
NANOGP5      GGAAGACAAAGTCCTGGTCAAGAAACAGATGACCAGAACTGTGTTCTCTTCCACCCAGCT 
NANOGP3      ------------------------------------------------------------ 
  
NANOG        GTGTGTACTCAATGATAGATTTCAGAGACAGAAATACCTCAGCCTCCAGCAGATGCAAGA 
NANOGP8      GTGTGTACTCAATGATAGATTTCAGAGACAGAAATACCTCAGCCTCCAGCAGATGCAAGA 
NANOGP1      GTGTGTACTCAATGATAGATTTCAGAGACAGAAATACCTCAGCCTCCAGCAGATGCAAGA 
NANOGP2      GTGTGTACTCAATGATAGATTTCAGAGACAGAAATACCTCAGCCTTCAACAGATGCAAGA 
NANOGP4      GTGTGTACTCAATGATAGATTTCAGAGACAGAAATACCTTAGCCTCCAGCAGATGCAAGA 
NANOGP7      GTTTGTACTCAATGATAGATTTCAGGGACAGAAATACTTCAGCCTCCAGCAGATGCAAGA 
NANOGP9      GTGTGTACTCAATGATAGATTGCAGAGACAGAAATACTTCAGCCTCCAGCAGATGCAAGA 
NANOGP10     GTGTGTACTCAATGATAGATTTCACGGACAGAAATACCTCAGCCTCCAGCAGATGCAAGA 
NANOGP11     ------------------------------------------------------------ 
NANOGP6      GTGTGTAATTAATGATGGATTTCAGAGACAGAAACACCGCAGCCTCCAGCAGCTGCAAGA 
NANOGP5      GTGTGTACTCAGTGATAGATTTCAGAGACAGAAATACCTCAGCCTCCAGCAGATGCAAGA 
NANOGP3      ------------------------------------------------------------ 
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NANOG        ACTCTCCAACATCCTGAACCTCAGCTACAAACAGGTGAAGACC-----TGGTTCCA-GAA 
NANOGP8      ACTCTCCAACATCCTGAACCTCAGCTACAAACAGGTGAAGACC-----TGGTTCCA-GAA 
NANOGP1      ACTTTCCAACATCCTGAACCTCAGCTACAAACAGGTAGGCTTATTTTGTCGTTGCAATAA 
NANOGP2      ACTTTCCAATATCCTGAACCTTAGCTACAAACAGGTGAAGACC-----TGGTTCCA-GAA 
NANOGP4      ACTCTCCAATATCTGGAACCTCAGCTACAAACAGGTGAAGACC-----TGGTTCTA-GAA 
NANOGP7      ACTTTCCAACATCCTGAACCTCAGCTACAAACAGGTTAAGACG-----TGGTTCCA-GAA 
NANOGP9      ACTTTCCAACATCCTGAACCTCAGCTACAA--AGGTGAAGACC-----TGGTTCCA-GAA 
NANOGP10     ACTTTCCAACATCCTGAACCTTAGCTACAAACAGGTTAAGACC-----TGGTTCCA-GAA 
NANOGP11     ------------------------------------------------------------ 
NANOGP6      ACTTTCCAATACCCTGAATCTTAGCTACAAACAGCATACAAGC-----TAGTTACA---- 
NANOGP5      ACTTTACAGCATCCTGAATCTTAGCTACAAACAGGTTAAGACT-----TGGTTCCA-GAA 
NANOGP3      ------------------------------------------------------------ 
Appendix 3-1
Comparison  of  NANOG  gene  product  sequence,  amplified  with  NANOG_2  primers,  to 
NANOGP1-NANOGP11  pseudogene  sequences  of  current  primary  reference  assembly 
(GRCh38) (using MAFFT software). Sequences of primers used in the assay are underlined 
and written in bold. Distinct nucleotides found in the pseudogenes, but not in the original 
NANOG gene, are marked in yellow. The sites that distinguish NANOGP8 from NANOG are 
marked in green. ! sign means that a part of the certain pseudogene sequence, not similar to 
the original gene, is not shown.
NANOG        CCAGCTTGTCCCCAAAGCTTGCCTTGCTTTGAAGCATCCGACTGTAAAGAATCT-TCACC 
NANOGP8      CCAGCTTGTCCCCAAAGCTTGCCTTGCTTTGAAGAATCCGACTGTAAAGAATCT-TCACC 
NANOGP1      CCAGCTTGTCCATAAAGCCTGCCTTGCTCCAAAGCATCTGACTGTAAAGACTGG-TCACC 
NANOGP2      CCAGCTTGTCCCCAA-ACCTGCCTGGCTTCAAAGCATCTGATTGTAAAGAATCT-TCACC 
NANOGP4      CTGGCTTGTCTGCAAAGCTTGCCTTGCTTCGAAGCATCCGACTGTAAAGAATCT-TAACC 
NANOGP7      CCAGCTTGTTCACAAAGCCTGCCTTGCTCCAACGCATCCGTCTGTAAAGACTCT-TCACT 
NANOGP9      TCAGCTTGTTCACAAAGCCTGCCTTTCTCTGAAGCATCCGACTGTAAAGACTTT-TCACC 
NANOGP10     CCAACCTATGCCCAAAGCCTGCCTTGTTCTGAAGCATCCAACTGTAAAGAATCT-TCACC 
NANOGP11     ------------------------------------------------------------ 
NANOGP6      CCAGCTTGTCTCCAAAGCCTGCCTTATTCTAAAGCATCCAATTCTAGGGACTCTTTCACC 
NANOGP5      CCAGCTTGTCCCCAAAACCTGCCTTGCTCTGAAGCATCCAACTGTAAAGACTCT-TTGCC 
NANOGP3      ------------------------------------------------------------ 
  
NANOG        TATGCCTGTGATTTGTGGGCCTGAAGAAAACTATCCATCCTTGCAAATGTCTTCTGCTGA 
NANOGP8      TATGCCTGTGATTTGTGGGCCTGAAGAAAACTATCCATCCTTGCAAATGTCTTCTGCTGA 
NANOGP1      TATACCTGTGATTTGTGGGCCTGAAGAAAACCATCCATCCTTGCAAATGTCTTCTGCTGA 
NANOGP2      TATGCCTGTCATTTGTGGGCCTGAAGA-AACTATCCATCCTTGCAAATGTCTCCTGCTGA 
NANOGP4      TATGGCTGTGATTTGTGGGCCTGAAGAAAACTATCCATCCTTGCAAATGTCTTCTGCTGA 
NANOGP7      TACACCTGTGATTTGTGGGCCTGAAGAAAACTATCCATCCTTGCAAATGTCTTCTGCTGA 
NANOGP9      TACACCTGTAATTTGTGGGCCTGAAGAAAACTATCCATCCTTGCAAATGTCTTCTGCTGA 
NANOGP10     TACGCCGGTGACTTGTGGGCCTGAAGAAAACTATCCATCCCTGCAAATGTCTTCTGCTGA 
NANOGP11     ------------------------------------------------------------ 
NANOGP6      AATGCCTGTGACTCGTGGCCCTGATGAAAGTTATCCATCCTTGCAAATGACATATGAGGA 
NANOGP5      AATGTCTGTGATTTGTGGGCCCAAAACAAACTATCCATCCTTGCATATATCTTCTGCTGA 
NANOGP3      ------------------------------------------------------------ 
  
NANOG        GATGCCTCACACGGAGACT----------------------------------------- 
NANOGP8      GATGCCTCACACAGAGACT----------------------------------------- 
NANOGP1      GATGCCTCACACAGAGACTGGTAAGAAAGAAATTTATCCTTGAAAGAAAGGCCTTATTTG!
NANOGP2      GATGCCTCACACTGCGACT----------------------------------------- 
NANOGP4      GATGCCTCACACGGAGACT----------------------------------------- 
NANOGP7      GATGCCTCACATGGAGACT----------------------------------------- 
NANOGP9      GATGCCTCACACAGAGACT----------------------------------------- 
NANOGP10     GATGCCTCACTCAGAGACT----------------------------------------- 
NANOGP11     ------------------------------------------------------------ 
NANOGP6      GGTGTCCCACTCAGAGG------------------------------------------- 
NANOGP5      GATGCCTCACACAGAGTCTG---------------------------------------- 
NANOGP3      ------------------------------------------------------------ 
  
NANOG        ---------GTCTCTCCTCTTCCTTCCTCCATGGATCTGCTTATTCAGGACAGCCCTGAT 
NANOGP8      ---------GTCTCTCCTCTTCCTTCCTCCATGGATCTGCTTATTCAGGACAGCCCTGAT 
NANOGP1      TTTCCAACAGTCTCTCCTCTTCCTTCCTCCATGGATCTGCCTATTCAGGACAGCCATGAT 
NANOGP2      ---------GTCTCTCCTCTTCCTTCCTCCATGGATCTG-------AGGATAGTCCTGAT 
NANOGP4      ---------GTCTCTCCTCTTC-TTCCTCCATGGATCTGCTTATTCAGGACAGCCCTGAT 
NANOGP7      ---------GTCTCTCCTCTTCCTTCCTCCGTGGATCTGCTTATTTAGGACAGCCCTGAT 
NANOGP9      ---------GTCTCTCCTCTTCCTTCCTCCATGGATCTGCTTATTCAGGACAGCCCTGAT 
NANOGP10     ---------GTCTCTCCTCTTCCTTCCGCCATGGATCTGCTTATCCAGGACAGCCCTGAT 
NANOGP11     ------------------------------------------------------------ 
NANOGP6      ---------CTCTCTCATCTTCCTTCCTCCGTGGATCTATTTATTCAGGAAAGCTCTAAT 
NANOGP5      ------------------------------------------------GACAGCTCTAAT 
NANOGP3      ------------------------------------------------------------ 
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NANOG        TCTTCCACCAGTCCCAAAGGCAAACAACCCACTTCTGCAGAGAAGAGTGTCGCAAAA-AA 
NANOGP8      TCTTCCACCAGTCCCAAAGGCAAACAACCCACTTCTGCAGAGAATAGTGTCGCAAAA-AA 
NANOGP1      TCTTCCACCAGTCCCAAAGGCAAACAACCCACTACTGCAGAGAAGAGTGCCACAAAA-AA 
NANOGP2      TCTCCTACCAGTCCCAAAGGCAAACAACCCACTGCTGCAGAGAATAGCGCCACAAAAGAA 
NANOGP4      TCTTCCACCAGTCCCAAAGGCAAACAACCCATTGCTGCAGAGAATAATGCCCCAAAA-AA 
NANOGP7      TCTTCCACCCCTCCCAAAGGCAAACAACCCACTTCTGCAGAGAAGAGTGCCAGAAAA-AA 
NANOGP9      TCTTCCACCAGTCCCAAAGGCAAGCAACCCACTTCTGCAGAGAAGAGTGCCACAAAA-AA 
NANOGP10     TCTTCTACCAGTCCTAAAGGCAAAAAACCCACTTCTGCAGAGAAGAGCACCACAAAA-AA 
NANOGP11     ------------------------------------------------------------ 
NANOGP6      TCTTCCACTAGTCCCAGAGTAAAACTACACATTTCTGCAGAGAAGAGCACAGTG-AAGAA 
NANOGP5      TCTTTCACGAGTCCCAAAGGCAGACAACTCACTTCTGCAGAGAAGAGCACCGCAAAA-AA 
NANOGP3      ------------------------------------------------------------ 
  
NANOG        GGAAGACAAGGTCCCGGTCAAGAAACAGAAGACCAGAACTGTGTTCTCTTCCACCCAGCT 
NANOGP8      GGAAGACAAGGTCCCGGTCAAGAAACAGAAGACCAGAACTGTGTTCTCTTCCACCCAGCT 
NANOGP1      GGAAGACAAGGTCCCGGTCAAGAAACAGAAGACCAGAACTGTGTTCTCTTCCACCCAGCT 
NANOGP2      GGAAGACAAGGTCCCAGTCAAGAAACAGAAGACCAGAACTGTGTTCTCTTCCACCCAGCT 
NANOGP4      GGGAGACGAGGTCCCAGTCAAGAAACAGAAGACCAGAACTGTGTTTTCTTCCACCCAGCT 
NANOGP7      GGAAGACAAGGTCCCATTCAAGAAACAGAAGACCAGAACTGTGTTCTCTTCCACACAGCT 
NANOGP9      GGAAAACAAGGTCCCAGTCAAGAAACAGAAGACCAGAACTCTGTTCTCTTCCAACCAGCT 
NANOGP10     GGAAGACAAGGTCCTGGTCAAGAAACAGAAGACCAGAACTGTGTTCCGTTCCACCCAGCT 
NANOGP11     ------------------------------------------------------------ 
NANOGP6      TGAAGATAAGATCCAGGAGAAGAAACAGAAGACCAGAATCATGTTCTCTCCGGCCCAGCT 
NANOGP5      GGAAGACAAAGTCCTGGTCAAGAAACAGATGACCAGAACTGTGTTCTCTTCCACCCAGCT 
NANOGP3      ------------------------------------------------------------ 
Appendix 4-1
Sequence alignment of current primary reference assembly (GRCh38) of the open reading 
frames  (ORFs)  of  human  NANOG and  NANOGP8 sequences  (using  EMBOSS  Needle 
software). Sequences of NANOG_1 primer pair used in the study are coloured in purple and 
written in bold. Sequences of NANOG_2 primer pair used in the study are coloured in orange 
and  written  in  bold.  14  coloured  nucleotides  represent  variants  between  NANOG and 
NANOGP8 ORF sequences. Two fixed variants detected by comparison of current primary 
and alternate reference assemblies are marked in red. Eight polymorphic variants detected by 
comparison of current primary and alternate reference assemblies are marked in green. Four 
polymorphic  variants  not  present  in  the  comparison  of  primary  and  alternate  reference 
assemblies  of  NANOGP8 or  in  other  studies,  but  observed in  at  least  two individuals by 
Fairbanks et al. 2012 are marked in blue.  The numbers above coloured nucleotides depicts 
their position in the reading frame, relative to the first nucleotide in the ATG initiation codon. 
The letters above (for NANOG) or under (for NANOGP8) coloured nucleotides represent the 
polymorphic variants at this site.
                                                                                                                                                                                    
                                                                                                                                                                 47 
NANOG_ORF       1 ATGAGTGTGGATCCAGCTTGTCCCCAAAGCTTGCCTTGCTTTGAAGCATC     50
                  ||||||||||||||||||||||||||||||||||||||||||||||.|||
NANOGP8_ORF     1 ATGAGTGTGGATCCAGCTTGTCCCCAAAGCTTGCCTTGCTTTGAAGAATC     50
                                                                                                                                                                                    C/A
NANOG_ORF      51 CGACTGTAAAGAATCTTCACCTATGCCTGTGATTTGTGGGCCTGAAGAAA    100
                  ||||||||||||||||||||||||||||||||||||||||||||||||||
NANOGP8_ORF    51 CGACTGTAAAGAATCTTCACCTATGCCTGTGATTTGTGGGCCTGAAGAAA    100
                                                                                                           126                                       144
NANOG_ORF     101 ACTATCCATCCTTGCAAATGTCTTCTGCTGAGATGCCTCACACGGAGACT    150
                  |||||||||||||||||||||||||||||||||||||||||||.||||||
NANOGP8_ORF   101 ACTATCCATCCTTGCAAATGTCTTCTGCTGAGATGCCTCACACAGAGACT    150
                                                                                         T/C                         T/C
                                                                               165                                                         190
NANOG_ORF     151 GTCTCTCCTCTTCCTTCCTCCATGGATCTGCTTATTCAGGACAGCCCTGA    200
                  ||||||||||||||||||||||||||||||||||||||||||||||||||
NANOGP8_ORF   151 GTCTCTCCTCTTCCTTCCTCCATGGATCTGCTTATTCAGGACAGCCCTGA    200
                                                                                                                                                                G/T          T/G
                                                                                                                                                             246
NANOG_ORF     201 TTCTTCCACCAGTCCCAAAGGCAAACAACCCACTTCTGCAGAGAAGAGTG    250
                  |||||||||||||||||||||||||||||||||||||||||||||.||||
ENANOGP8_ORF  201 TTCTTCCACCAGTCCCAAAGGCAAACAACCCACTTCTGCAGAGAATAGTG    250
                                                                                                                        G/A
                                                                                                           276
NANOG_ORF     251 TCGCAAAAAAGGAAGACAAGGTCCCGGTCAAGAAACAGAAGACCAGAACT    300
                  ||||||||||||||||||||||||||||||||||||||||||||||||||
NANOGP8_ORF   251 TCGCAAAAAAGGAAGACAAGGTCCCGGTCAAGAAACAGAAGACCAGAACT    300
NANOG_ORF     301 GTGTTCTCTTCCACCCAGCTGTGTGTACTCAATGATAGATTTCAGAGACA    350
                  ||||||||||||||||||||||||||||||||||||||||||||||||||
NANOGP8_ORF   301 GTGTTCTCTTCCACCCAGCTGTGTGTACTCAATGATAGATTTCAGAGACA    350
                                                                                   C/T
                                                                          363
NANOG_ORF     351 GAAATACCTCAGCCTCCAGCAGATGCAAGAACTCTCCAACATCCTGAACC    400
                  ||||||||||||||||||||||||||||||||||||||||||||||||||
NANOGP8_ORF   351 GAAATACCTCAGCCTCCAGCAGATGCAAGAACTCTCCAACATCCTGAACC    400
NANOG_ORF     401 TCAGCTACAAACAGGTGAAGACCTGGTTCCAGAACCAGAGAATGAAATCT    450
                  ||||||||||||||||||||||||||||||||||||||||||||||||||
NANOGP8_ORF   401 TCAGCTACAAACAGGTGAAGACCTGGTTCCAGAACCAGAGAATGAAATCT    450
NANOG_ORF     451 AAGAGGTGGCAGAAAAACAACTGGCCGAAGAATAGCAATGGTGTGACGCA    500
                  ||||||||||||||||||||||||||||||||||||||||||||||||||
NANOGP8_ORF   451 AAGAGGTGGCAGAAAAACAACTGGCCGAAGAATAGCAATGGTGTGACGCA    500
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                                                                                                                                       C/T
                                                                                                                        531
NANOG_ORF     501 GAAGGCCTCAGCACCTACCTACCCCAGCCTTTACTCTTCCTACCACCAGG    550
                  ||||||||||||||||||||||||||||||.|||||||||||||||||||
NANOGP8_ORF   501 GAAGGCCTCAGCACCTACCTACCCCAGCCTCTACTCTTCCTACCACCAGG    550
                                              552
NANOG_ORF     551 GATGCCTGGTGAACCCGACTGGGAACCTTCCAATGTGGAGCAACCAGACC    600
                  ||||||||||||||||||||||||||||||||||||||||||||||||||
ENANOGP8_ORF  551 GATGCCTGGTGAACCCGACTGGGAACCTTCCAATGTGGAGCAACCAGACC    600
                                                    A/T
                                                                                                                  629
NANOG_ORF     601 TGGAACAATTCAACCTGGAGCAACCAGACCCAGAACATCCAGTCCTGGAG    650
                  ||||||||||||||||||||||||||||||||||||||||||||||||||
NANOGP8_ORF   601 TGGAACAATTCAACCTGGAGCAACCAGACCCAGAACATCCAGTCCTGGAG    650
                                                                                                                                 C/T
NANOG_ORF     651 CAACCACTCCTGGAACACTCAGACCTGGTGCACCCAATCCTGGAACAATC    700
                  ||||||||||||||||||||||||||||||||||||||||||||||||||
NANOGP8_ORF   651 CAACCACTCCTGGAACACTCAGACCTGGTGCACCCAATCCTGGAACAATC    700
NANOG_ORF     701 AGGCCTGGAACAGTCCCTTCTATAACTGTGGAGAGGAATCTCTGCAGTCC    750
                  ||||||||||||||||||||||||||||||||||||||||||||||||||
NANOGP8_ORF   701 AGGCCTGGAACAGTCCCTTCTATAACTGTGGAGAGGAATCTCTGCAGTCC    750
                                                                                                                                                                                       C/T
                                                   754       759                                                                                             798
NANOG_ORF     751 TGCATGCAGTTCCAGCCAAATTCTCCTGCCAGTGACTTGGAGGCTGCCTT    800
                  ||||||||.|||||||||||||||||||||||||||||||||||||||||
NANOGP8_ORF   751 TGCATGCACTTCCAGCCAAATTCTCCTGCCAGTGACTTGGAGGCTGCCTT    800
                                                          A/C
NANOG_ORF     801 GGAAGCTGCTGGGGAAGGCCTTAATGTAATACAGCAGACCACTAGGTATT    850
                  ||||||||||||||||||||||||||||||||||||||||||||||||||
NANOGP8_ORF   801 GGAAGCTGCTGGGGAAGGCCTTAATGTAATACAGCAGACCACTAGGTATT    850
NANOG_ORF     851 TTAGTACTCCACAAACCATGGATTTATTCCTAAACTACTCCATGAACATG    900
                  ||||||||||||||||||||||||||||||||||||||||||||||||||
NANOGP8_ORF   851 TTAGTACTCCACAAACCATGGATTTATTCCTAAACTACTCCATGAACATG    900
NANOG_ORF     901 CAACCTGAAGACGTGTGA    918
                  ||||||||||||||||  
NANOGP8_ORF   901 CAACCTGAAGACGTGT--    916
Appendix 5
Comparison  between  OCT4A gene fragment and sequencing result  of RT-PCR product  of 
ASCs from the donor No.4, amplified with OCT4 reverse (R) primer (using EMBOSS Needle 
software). Unique sites of OCT4A gene are marked in green.
OCT4A R              1 TGGGACTCCTCCGGGTTTTGCTCCAGCTTCTCCTTCTCCAGCTTCACGGC   50
                                                                       
OCT4A ASCs No.4      1 --------------------------------------------------    0
OCT4A R             51 ACCAGGGGTGACGGTGCAGGGCTCCGGGGAGGCCCCATCGGAGTTGCTCT  100
                                ....|||||.||||||||||||||||||||||.||||||..
OCT4A ASCs No.4      1 ---------NNNTGTGCANGGCTCCGGGGAGGCCCCATCGGNGTTGCTNN   41
OCT4A R            101 CCACCCCGACTCCTGCTTCGCCCTCAGGCTGAGAGGTCTCCAAGCCGCCT  150
                       ..........||||||||||||||||.||||||||||||..||......|
OCT4A ASCs No.4     42 NNNNNNNNNNTCCTGCTTCGCCCTCANGCTGAGAGGTCTNNAANNNNNNT   91
OCT4A R            151 TGGGGCACTAGCCCCACTCCAACCTGGGGCCCACAGTACGCCATC-  195
                       ||||||||||.|||||||||||||||||||||||||||||||||| 
OCT4A ASCs No.4     92 TGGGGCACTANCCCCACTCCAACCTGGGGCCCACAGTACGCCATCA  137
Appendix 6
Comparison  between  OCT4A gene fragment and sequencing result  of RT-PCR product  of 
ASC aggregates (aggr.) from the donor No.4, amplified with OCT4 reverse (R) primer (using 
EMBOSS Needle software). Unique sites of OCT4A gene are marked in green.
OCT4A R              1 TGGGACTCCTCCGGGTTTTGCTCCAGCTTCTCCTTCTCCAGCTTCACGGC   50
                                                                       
OCT4 ASC aggr.       0 --------------------------------------------------   0
OCT4A R             51 ACCAGGGGTGACGGTGCAGGGCTCCGGGGAGGCCCCATCGGAGTTGCTCT  100
                                  ..||||..|||||.|||||||||||||||||||||....
OCT4 ASC aggr.       1 -----------NNGTGCNNGGCTCNGGGGAGGCCCCATCGGAGTTGNNNN   39
OCT4A R            101 CCACCCCGACTCCTGCTTCGCCCTCAGGCTGAGAGGTCTCCAAGCCGCCT  150
                       .........|||||||||||||||||||||||||||........|||||| 
OCT4 ASC aggr.      40 NNNNNNNNNCTCCTGCTTCGCCCTCAGGCTGAGAGGNNNNNNNNCCGCCT   89
OCT4A R            151 TGGGGCACTAGCCCCACTCCAACCTGGGGCCCACAGTACGCCATC-  195
                       ||||||||||||||||||||||||||||||||||||||||||||| 
OCT4 ASC aggr.      90 TGGGGCACTAGCCCCACTCCAACCTGGGGCCCACAGTACGCCATCN  135
Appendix 7
Comparison  between  OCT4A gene fragment and sequencing result  of RT-PCR product  of 
ESCs, amplified with OCT4 forward (F) primer (using EMBOSS Needle software).  Unique 
sites of OCT4A gene are marked in green.
OCT4A F              1 GATGGCGTACTGTGGGCCCCAGGTTGGAGTGGGGCTAGTGCCCCAAGGCG   50
                                                                  ....|||
OCT4A ESCs           1 -------------------------------------------NNNNGCG    7
OCT4A F             51 GCTTGGAGACCTCTCAGCCTGAGGGCGAAGCAGGAGTCGGGGTGGAGAGC  100
                       ||||||.|||||||||||||||||||||||||||||||||||||||...|
OCT4A ESCs           8 GCTTGGNGACCTCTCAGCCTGAGGGCGAAGCAGGAGTCGGGGTGGANNNC   57
OCT4A F            101 AACTCCGATGGGGCCTCCCCGGAGCCCTGCACCGTCACCCCTGGTGCCGT  150
                       ||||||||||||||||||||||||||||||||||||||||||||||||||
OCT4A ESCs          58 AACTCCGATGGGGCCTCCCCGGAGCCCTGCACCGTCACCCCTGGTGCCGT  107
OCT4A F            151 GAAGCTGGAGAAGGAGAAGCTGGAGCAAAACCCGGAGGAGTCCCA  195
                       |||||||||||||||||||||||||||||||||||||||||||||
OCT4A ESCs         108 GAAGCTGGAGAAGGAGAAGCTGGAGCAAAACCCGGAGGAGTCCCA  152
Appendix 8
Comparison  between  OCT4A gene fragment and sequencing result  of RT-PCR product  of 
ESCs, amplified with  OCT4 reverse (R) primer (using EMBOSS Needle software).  Unique 
sites of OCT4A gene are marked in green.
OCT4A R              1 TGGGACTCCTCCGGGTTTTGCTCCAGCTTCTCCTTCTCCAGCTTCACGGC   50
                                                                 ....||||
OCT4A ESCs           1 ------------------------------------------NNNNCGGC    8
OCT4A R             51 ACCAGGGGTGACGGTGCAGGGCTCCGGGGAGGCCCCATCGGAGTTGCTCT  100
                       .|||||||||||||||||||||||||||||||||||||||||||||||||
OCT4A ESCs           9 NCCAGGGGTGACGGTGCAGGGCTCCGGGGAGGCCCCATCGGAGTTGCTCT   58
OCT4A R            101 CCACCCCGACTCCTGCTTCGCCCTCAGGCTGAGAGGTCTCCAAGCCGCCT  150
                       .........||||||||||||||||||||||||||||||||.........
OCT4A ESCs          59 NNNNNNNNNCTCCTGCTTCGCCCTCAGGCTGAGAGGTCTCCNNNNNNNNN  108
OCT4A R            151 TGGGGCACTAGCCCCACTCCAACCTGGGGCCCACAGTACGCCATC-  195
                       .|||||||||.|||||||||||||||||||||||||||||||||| 
OCT4A ESCs         109 NGGGGCACTANCCCCACTCCAACCTGGGGCCCACAGTACGCCATCA  154
Appendix 9
Comparison  between  NANOG gene fragment and sequencing result of RT-PCR product of 
ASCs from the donor No.4, amplified with NANOG_1 forward (F) primer (using EMBOSS 
Needle software). The nucleotides representing polymorphic variants that allow to distinguish 
NANOG gene from NANOGP8 are marked in green.
NANOG_1 F            1 CTTCCTCCATGGATCTGCTTATTCAGGACAGCCCTGATTCTTCCACCAGT   50
                                                                       
NANOG_1 ASCs No.4    0 --------------------------------------------------    0
NANOG_1 F           51 CCCAAAGGCAAACAACCCACTTCTGCAGAGAAGAGTGTCGCAAAAAAGGA  100
                                ...||||||||||||||||||||.|||||||||||||||||
NANOG_1 ASCs No.4    1 ---------NNNCAACCCACTTCTGCAGAGAATAGTGTCGCAAAAAAGGA   41
NANOG_1 F          101 AGACAAGGTCCCGGTCAAGAAACAGAAGACCAGAACTGTGTTCTCTTCCA  150
                       |.|..........|||||||||||||||||||||||||||||.....||.
NANOG_1 ASCs No.4   42 ANANNNNNNNNNNGTCAAGAAACAGAAGACCAGAACTGTGTTNNNNNCCN   91
NANOG_1 F          151 CCCAGCTGTGTGTACTCAATGATAGATTTCAGAGACAGAAATACCTCAGC  200
                       |||.|||||||||.||||||||||||||||||||||||||||||||||||
NANOG_1 ASCs No.4   92 CCCNGCTGTGTGTNCTCAATGATAGATTTCAGAGACAGAAATACCTCAGC  141
NANOG_1 F          201 CTCCAGCAGATGCAAGAACTCTCCAACATCCTGAACCTCAGCTACAAACA  250
                       ||||||||||||||||||||||||||||||||||||||||||||||||||
NANOG_1 ASCs No.4  142 CTCCAGCAGATGCAAGAACTCTCCAACATCCTGAACCTCAGCTACAAACA  191
NANOG_1 F          251 GGTGAAGACCTG-  262
                       |||||||||||| 
NANOG_1 ASCs No.4  192 GGTGAAGACCTGA  204
Appendix 10
Comparison  between  NANOG gene fragment and sequencing result of RT-PCR product of 
ASC aggregates (aggr.) from the donor No.4, amplified with NANOG_1 reverse (R) primer 
(using EMBOSS Needle software).  The nucleotides representing polymorphic variants that 
allow to distinguish NANOG gene from NANOGP8 are marked in green.
NANOG_1 R            1 CAGGTCTTCACCTGTTTGTAGCTGAGGTTCAGGATGTTGGAGAGTTCTTG   50
                                                                       
NANOG_1 ASC aggr.    0 --------------------------------------------------    0
NANOG_1 R           51 CATCTGCTGGAGGCTGAGGTATTTCTGTCTCTGAAATCTATCATTGAGTA  100
                           .||||||||..|||||||||||||||||||||||||||.||||...
NANOG_1 ASC aggr.    1 ----NGCTGGAGGNNGAGGTATTTCTGTCTCTGAAATCTATCNTTGANNN   46
NANOG_1 R          101 CACACAGCTGGGTGGAAGAGAACACAGTTCTGGTCTTCTGTTTCTTGACC  150
                       ............|||||||||||||||||||||||||...........||
NANOG_1 ASC aggr.   47 NNNNNNNNNNNNTGGAAGAGAACACAGTTCTGGTCTTNNNNNNNNNNNCC   96
NANOG_1 R          151 GGGACCTTGTCTTCCTTTTTTGCGACACTCTTCTCTGCAGAAGTGGGTTG  200
                       |||||||||||||||||||||||||||||.||||||||||||||||||||
NANOG_1 ASC aggr.   97 GGGACCTTGTCTTCCTTTTTTGCGACACTATTCTCTGCAGAAGTGGGTTG  146
NANOG_1 R          201 TTTGCCTTTGGGACTGGTGGAAGAATCAGGGCTGTCCTGAATAAGCAGAT  250
                       ||||||................|||||||||||||.||||||||||.|||
NANOG_1 ASC aggr.  147 TTTGCCNNNNNNNNNNNNNNNNGAATCAGGGCTGTACTGAATAAGCNGAT  196
NANOG_1 R          251 CCATGGAGGAAG--  262
                       ||.|||||||||  
NANOG_1 ASC aggr.  197 CCNTGGAGGAAGAN  210
Appendix 11
Comparison  between  NANOG gene fragment and sequencing result of RT-PCR product of 
ESCs, amplified with NANOG_1 forward (F) primer (using EMBOSS Needle software). The 
nucleotides representing polymorphic variants that allow to distinguish  NANOG  gene from 
NANOGP8 are marked in green.
NANOG_1 F            1 CTTCCTCCATGGATCTGCTTATTCAGGACAGCCCTGATTCTTCCACCAGT   50
                                                                   .|||||
NANOG_1 ESCs         1 --------------------------------------------NCCAGT    6
NANOG_1 F           51 CCCAAAGGCAAACAACCCACTTCTGCAGAGAAGAGTGTCGCAAAAAAGGA  100
                       ||||||||||||||||||||||||||||||||.|||||||||||||||||
NANOG_1 ESCs         7 CCCAAAGGCAAACAACCCACTTCTGCAGAGAATAGTGTCGCAAAAAAGGA   56
                                         
NANOG_1 F          101 AGACAAGGTCCCGGTCAAGAAACAGAAGACCAGAACTGTGTTCTCTTCCA  150
                       ||||||||||||.|||||||||||||||||||||||||||||||||||||
NANOG_1 ESCs        57 AGACAAGGTCCCAGTCAAGAAACAGAAGACCAGAACTGTGTTCTCTTCCA  106
                                                                                     
NANOG_1 F          151 CCCAGCTGTGTGTACTCAATGATAGATTTCAGAGACAGAAATACCTCAGC  200
                       |||||||||||||||||||||||||||||||||||||||||||||||||.
NANOG_1 ESCs       107 CCCAGCTGTGTGTACTCAATGATAGATTTCAGAGACAGAAATACCTCAGT  156
NANOG_1 F          201 CTCCAGCAGATGCAAGAACTCTCCAACATCCTGAACCTCAGCTACAAACA  250
                       ||||||||||||||||||||||||||||||||||||||||||||||||||
NANOG_1 ESCs       157 CTCCAGCAGATGCAAGAACTCTCCAACATCCTGAACCTCAGCTACAAACA  206
NANOG_1 F          251 GGTGAAGACCTG-  262
                       |||||||||||| 
NANOG_1 ESCs       207 GGTGAAGACCTGA  219
Appendix 12
Comparison  between  NANOG gene fragment and sequencing result of RT-PCR product of 
ESCs, amplified with NANOG_1 reverse (R) primer (using EMBOSS Needle software). The 
nucleotides representing polymorphic variants that allow to distinguish  NANOG  gene from 
NANOGP8 are marked in green.
NANOG_1 R            1 CAGGTCTTCACCTGTTTGTAGCTGAGGTTCAGGATGTTGGAGAGTTCTTG   50
                                                                  ..|||||
NANOG_1 ESCs         1 -------------------------------------------NNTCTTG    7
                                       
NANOG_1 R           51 CATCTGCTGGAGGCTGAGGTATTTCTGTCTCTGAAATCTATCATTGAGTA  100
                       ||||||||||||.|||||||||||||||||||||||||||||||||||..
NANOG_1 ESCs         8 CATCTGCTGGAGACTGAGGTATTTCTGTCTCTGAAATCTATCATTGAGNN   57
               
NANOG_1 R          101 CACACAGCTGGGTGGAAGAGAACACAGTTCTGGTCTTCTGTTTCTTGACC  150
                       ......|||||||||||||||||||||||||||||||||||||||||||.
NANOG_1 ESCs        58 NNNNNNGCTGGGTGGAAGAGAACACAGTTCTGGTCTTCTGTTTCTTGACT  107
NANOG_1 R          151 GGGACCTTGTCTTCCTTTTTTGCGACACTCTTCTCTGCAGAAGTGGGTTG  200
                       |||||||||||||||||||||||||||||.||||||||||||||||||||
NANOG_1 ESCs       108 GGGACCTTGTCTTCCTTTTTTGCGACACTATTCTCTGCAGAAGTGGGTTG  157
NANOG_1 R          201 TTTGCCTTTGGGACTGGTGGAAGAATCAGGGCTGTCCTGAATAAGCAGAT  250
                       ||||||||||||||||||||||||||||||||||||||||||||||||||
NANOG_1 ESCs       158 TTTGCCTTTGGGACTGGTGGAAGAATCAGGGCTGTCCTGAATAAGCAGAT  207
NANOG_1 R          251 CCATGGAGGAAG-  262
                       |||||||||||| 
NANOG_1 ESCs       208 CCATGGAGGAAGA  220
Appendix 13
Comparison  between  NANOG gene fragment and sequencing result of RT-PCR product of 
ASCs from the donor No.4, amplified with NANOG_2 forward (F) primer (using EMBOSS 
Needle software). The nucleotides representing polymorphic variants that allow to distinguish 
NANOG gene from NANOGP8 are marked in green. The letters in green under the unique site 
represent the nucleotides detected in a sequencing graph.
NANOG_2 F            1 GCTTGCCTTGCTTTGAAGCATCCGACTGTAAAGAATCTTCACCTATGCCT   50
                                                                       
NANOG_2 ASCs No.4    1 --------------------------------------------------    0
NANOG_2 F           51 GTGATTTGTGGGCCTGAAGAAAACTATCCATCCTTGCAAATGTCTTCTGC  100
                                ...|||||||||||||||||||||||||||||||||||||| 
NANOG_2 ASCs No.4    1 ---------NNNCCTGAAGAAAACTATCCATCCTTGCAAATGTCTTCTGC   41
NANOG_2 F          101 TGAGATGCCTCACACGGAGACTGTCTCTCCTCTTCCTTCCTCCATGGATC  150
                       |||||...........||||||||||||||||||||||||||||||||||
NANOG_2 ASCs No.4   42 TGAGANNNNNNNNNNNGAGACTGTCTCTCCTCTTCCTTCCTCCATGGATC   91
                                            A/G
NANOG_2 F          151 TGCTTATTCAGGACAGCCCTGATTCTTCCACCAGTCCCAAAGGCAAACAA  200
                       |||||||||||.||||||||||||||||||||||||||||||||.|||||
NANOG_2 ASCs No.4   92 TGCTTATTCAGTACAGCCCTGATTCTTCCACCAGTCCCAAAGGCNAACAA  141
NANOG_2 F          201 CCCACTTCTGCAGAGAAGAGTGTCGCAAAAAAGGAAGACAAGGTCCCGGT  250
                       |||||||||||||||||.||||||||||||||||||||||||||||||||
NANOG_2 ASCs No.4  142 CCCACTTCTGCAGAGAATAGTGTCGCAAAAAAGGAAGACAAGGTCCCGGT  191
NANOG_2 F          251 CAAGAA--  256
                       ||||||  
NANOG_2 ASCs No.4  192 CAAGAAAA  199
Appendix 14
Comparison  between  NANOG gene fragment and sequencing result of RT-PCR product of 
ASCs from the donor No.4, amplified with NANOG_2 reverse (R) primer (using EMBOSS 
Needle software). The nucleotides representing polymorphic variants that allow to distinguish 
NANOG gene from NANOGP8 are marked in green.
NANOG_2 R            1 TTCTTGACCGGGACCTTGTCTTCCTTTTTTGCGACACTCTTCTCTGCAGA   50
                                                                       
NANOG_2 ASCs No.4    1 --------------------------------------------------    0
NANOG_2 R           51 AGTGGGTTGTTTGCCTTTGGGACTGGTGGAAGAATCAGGGCTGTCCTGAA  100
                                ...|||||||||||.|||||||||||.||||.|||.|||||
NANOG_2 ASCs No.4    1 ---------NNNGCCTTTGGGACNGGTGGAAGAATNAGGGNTGTACTGAA   41
NANOG_2 R          101 TAAGCAGATCCATGGAGGAAGGAAGAGGAGAGACAGTCTCCGTGTGAGGC  150
                       ||||...........|.||||||.||||||||||||||||.|||.||||.
NANOG_2 ASCs No.4   42 TAAGNNNNNNNNNNNANGAAGGANGAGGAGAGACAGTCTCTGTGNGAGGN   91
NANOG_2 R          151 ATCTCAGCAGAAGACATTTGCAAGGATGGATAGTTTTCTTCAGGCCCACA  200
                       |||||||.|||||||||||||||||.|||||||||||||||||||||.|.
NANOG_2 ASCs No.4   92 ATCTCAGNAGAAGACATTTGCAAGGNTGGATAGTTTTCTTCAGGCCCNCN  141
NANOG_2 R          201 AATCACAGGCATAGGTGAAGATTCTTTACAGTCGGATGCTTCAAAGCAAG  250
                       ||||||.|||||||||||||||||||||||||||||||||||.||||..|
NANOG_2 ASCs No.4  142 AATCACNGGCATAGGTGAAGATTCTTTACAGTCGGATGCTTCTAAGCNNG  191
NANOG_2 R          251 GCAAGC-  256
                       |||||| 
NANOG_2 ASCs No.4  192 GCAAGCA  198
Appendix 15
Comparison  between  NANOG gene fragment and sequencing result of RT-PCR product of 
ASC aggregates (aggr.) from the donor No.4, amplified with NANOG_2 forward (F) primer 
(using EMBOSS Needle software).  The nucleotides representing polymorphic variants that 
allow to distinguish NANOG gene from NANOGP8 are marked in green. The letters in green 
under the unique site represent the nucleotides detected in a sequencing graph.
NANOG_2 F            1 GCTTGCCTTGCTTTGAAGCATCCGACTGTAAAGAATCTTCACCTATGCCT   50
                                                                      ...
NANOG_2 ASC aggr.    1 -----------------------------------------------NNN    3
NANOG_2 F           51 GTGATTTGTGGGCCTGAAGAAAACTATCCATCCTTGCAAATGTCTTCTGC  100
                       |.||||||||||||||||||||||||||||||||||||.|||||||||||
NANOG_2 ASC aggr.    4 GNGATTTGTGGGCCTGAAGAAAACTATCCATCCTTGCANATGTCTTCTGC   53
NANOG_2 F          101 TGAGATGCCTCACACGGAGACTGTCTCTCCTCTTCCTTCCTCCATGGATC  150
                       |||.........|||.||||||||||||||||||||||||||||.|||||
NANOG_2 ASC aggr.   54 TGANNNNNNNNNCACNGAGACTGTCTCTCCTCTTCCTTCCTCCANGGATC  103
                                     A/G
NANOG_2 F          151 TGCTTATTCAGGACAGCCCTGATTCTTCCACCAGTCCCAAAGGCAAACAA  200
                       |||||||||||.||||||||||||||||||.|||||||||||||||||||
NANOG_2 ASC aggr.  104 TGCTTATTCAGTACAGCCCTGATTCTTCCANCAGTCCCAAAGGCAAACAA  153
NANOG_2 F          201 CCCACTTCTGCAGAGAAGAGTGTCGCAAAAAAGGAAGACAAGGTCCCGGT  250
                       |||||||||||||||||...|||||.||||||||||||||||||||||||
NANOG_2 ASC aggr.  154 CCCACTTCTGCAGAGAATNNTGTCGNAAAAAAGGAAGACAAGGTCCCGGT  203
NANOG_2 F          251 CAAGAA-  256
                       |||||| 
NANOG_2 ASC aggr.  204 CAAGAAA  210
Appendix 16
Comparison  between  NANOG gene fragment and sequencing result of RT-PCR product of 
ASC aggregates (aggr.) from the donor No.4, amplified with NANOG_2 reverse (R) primer 
(using EMBOSS Needle software).  The nucleotides representing polymorphic variants that 
allow to distinguish NANOG gene from NANOGP8 are marked in green.
NANOG_2 R            1 TTCTTGACCGGGACCTTGTCTTCCTTTTTTGCGACACTCTTCTCTGCAGA   50
                                                                       
NANOG_2 ASC aggr.    1 --------------------------------------------------    0
NANOG_2 R           51 AGTGGGTTGTTTGCCTTTGGGACTGGTGGAAGAATCAGGGCTGTCCTGAA  100
                             ...|||||||||||||||||||||||||||||||||||......
NANOG_2 ASC aggr.    1 ------NNNTTTGCCTTTGGGACTGGTGGAAGAATCAGGGCTGTNNNNNN   44
NANOG_2 R          101 TAAGCAGATCCATGGAGGAAGGAAGAGGAGAGACAGTCTCCGTGTGAGGC  150
                       .......||||.|||||||||||||||||||||||||....|||||||||
NANOG_2 ASC aggr.   45 NNNNNNNATCCNTGGAGGAAGGAAGAGGAGAGACAGTNNNNGTGTGAGGC   94
NANOG_2 R          151 ATCTCAGCAGAAGACATTTGCAAGGATGGATAGTTTTCTTCAGGCCCACA  200
                       ||||||||||||||||||||||||||||||||||||||||||||||||||
NANOG_2 ASC aggr.   95 ATCTCAGCAGAAGACATTTGCAAGGATGGATAGTTTTCTTCAGGCCCACA  144
NANOG_2 R          201 AATCACAGGCATAGGTGAAGATTCTTTACAGTCGGATGCTTCAAAGCAAG  250
                       ||||||||||||||||||||||||||||||||||||||||||||||||||
NANOG_2 ASC aggr.  145 AATCACAGGCATAGGTGAAGATTCTTTACAGTCGGATGCTTCAAAGCAAG  194
NANOG_2 R          251 GCAAGC-  256
                       ||||||  
NANOG_2 ASC aggr.  195 GCAAGCA  202
Appendix 17
Comparison  between  NANOG gene fragment and sequencing result of RT-PCR product of 
ESCs, amplified with NANOG_2 forward (F) primer (using EMBOSS Needle software). The 
nucleotides representing polymorphic variants that allow to distinguish  NANOG  gene from 
NANOGP8 are marked in green.
NANOG_2 F            1 GCTTGCCTTGCTTTGAAGCATCCGACTGTAAAGAATCTTCACCTATGCCT   50
                                                                    ...||
NANOG_2 ESCs         1 ---------------------------------------------NNNCT    5
NANOG_2 F           51 GTGATTTGTGGGCCTGAAGAAAACTATCCATCCTTGCAAATGTCTTCTGC  100
                       ||||||||||||||||||||||||||||||||||||||||||||||||||
NANOG_2 ESCs         6 GTGATTTGTGGGCCTGAAGAAAACTATCCATCCTTGCAAATGTCTTCTGC   55
NANOG_2 F          101 TGAGATGCCTCACACGGAGACTGTCTCTCCTCTTCCTTCCTCCATGGATC  150
                       |||||......|||||||||||||||||||||||||.|||||||||||||
NANOG_2 ESCs        56 TGAGANNNNNNACACGGAGACTGTCTCTCCTCTTCCCTCCTCCATGGATC  105
                                             
NANOG_2 F          151 TGCTTATTCAGGACAGCCCTGATTCTTCCACCAGTCCCAAAGGCAAACAA  200
                       ||||||||||||||||||||||||||||||||||||||||||||||||||
NANOG_2 ESCs       106 TGCTTATTCAGGACAGCCCTGATTCTTCCACCAGTCCCAAAGGCAAACAA  155
NANOG_2 F          201 CCCACTTCTGCAGAGAAGAGTGTCGCAAAAAAGGAAGACAAGGTCCCGGT  250
                       |||||||||||||||||.||||||||||||||||||||||||||||||||
NANOG_2 ESCs       156 CCCACTTCTGCAGAGAATAGTGTCGCAAAAAAGGAAGACAAGGTCCCGGT  205
 
NANOG_2 F          251 CAAGAA-  256
                       |||||| 
NANOG_2 ESCs       206 CAAGAAA  212
Appendix 18
Comparison  between  NANOG gene fragment and sequencing result of RT-PCR product of 
ESCs, amplified with NANOG_2 reverse (R) primer (using EMBOSS Needle software). The 
nucleotides representing polymorphic variants that allow to distinguish  NANOG  gene from 
NANOGP8 are marked in green.
NANOG_2 R            1 TTCTTGACCGGGACCTTGTCTTCCTTTTTTGCGACACTCTTCTCTGCAGA   50
                                                                     ...|
NANOG_2 ESCs         1 ----------------------------------------------NNNA    4
NANOG_2 R           51 AGTGGGTTGTTTGCCTTTGGGACTGGTGGAAGAATCAGGGCTGTCCTGAA  100
                       ||||||||||||||||||||||||||||||||||||||||||||||||||
NANOG_2 ESCs         5 AGTGGGTTGTTTGCCTTTGGGACTGGTGGAAGAATCAGGGCTGTCCTGAA   54
NANOG_2 R          101 TAAGCAGATCCATGGAGGAAGGAAGAGGAGAGACAGTCTCCGTGTGAGGC  150
                       |||......||||||||||.||||||||||||||||||||||||.....|
NANOG_2 ESCs        55 TAANNNNNNCCATGGAGGAGGGAAGAGGAGAGACAGTCTCCGTGNNNNNC  104
NANOG_2 R          151 ATCTCAGCAGAAGACATTTGCAAGGATGGATAGTTTTCTTCAGGCCCACA  200
                       ||||||||||||||||||||||||||||||||||||||||||||||||||
NANOG_2 ESCs       105 ATCTCAGCAGAAGACATTTGCAAGGATGGATAGTTTTCTTCAGGCCCACA  154
NANOG_2 R          201 AATCACAGGCATAGGTGAAGATTCTTTACAGTCGGATGCTTCAAAGCAAG  250
                       ||||||||||||||||||||||||||||||||||||||||||..||||||
NANOG_2 ESCs       155 AATCACAGGCATAGGTGAAGATTCTTTACAGTCGGATGCTTCNNAGCAAG  204
NANOG_2 R          251 GCAAGC-  256
                       |||||| 
NANOG_2 ESCs       205 GCAAGCA  211
Appendix 19
Expression of SOX17 in ASCs of the donors No.4 and No.9 after their differentiation into 
cells  of  endodermal  lineage  using  the  Protocol  5.  Cell  nuclei  counterstained  with  DAPI. 
Magnification 200x.
Appendix 20
Expression of SOX17 in ASCs of the donors No.4 and No.9 after their differentiation into 
cells  of  endodermal  lineage  using  the  Protocol  6.  Cell  nuclei  counterstained  with  DAPI. 
Magnification 200x.
Appendix 21
Expression of SOX17 in ASCs of the donors No.4 and No.9 after their differentiation into 
cells  of  endodermal  lineage  using  the  Protocol  7.  Cell  nuclei  counterstained  with  DAPI. 
Magnification 200x.
Appendix 22
Expression of SOX17 in ASCs of the donors No.4 and No.9 after their differentiation into 
cells  of  endodermal  lineage  using  the  Protocol  8.  Cell  nuclei  counterstained  with  DAPI. 
Magnification 200x.
Appendix 23
Expression of PDX1 in ASCs of the donors No.4 and No.9 after their differentiation into cells 
of  endodermal  lineage  using  the  Protocol  5.  Cell  nuclei  counterstained  with  DAPI. 
Magnification 200x.
Appendix 24
Expression of PDX1 in ASCs of the donors No.4 and No.9 after their differentiation into cells 
of  endodermal  lineage  using  the  Protocol  6.  Cell  nuclei  counterstained  with  DAPI. 
Magnification 200x.
Appendix 25
Expression of PDX1 in ASCs of the donors No.4 and No.9 after their differentiation into cells 
of  endodermal  lineage  using  the  Protocol  7.  Cell  nuclei  counterstained  with  DAPI. 
Magnification 200x.
Appendix 26
Expression of PDX1 in ASCs of the donors No.4 and No.9 after their differentiation into cells 
of  endodermal  lineage  using  the  Protocol  8.  Cell  nuclei  counterstained  with  DAPI. 
Magnification 200x.
Appendix 27
Detection  of  INS,  C-PEPT, GCG  and  SST  in  cryosections  of  mouse  pancreas  (islets  of 
Langerhans). Cell nuclei counterstained with DAPI. Magnification 400x.
 
